Sepsis

On this page

Quick Reference

RxDrug of choiceNorepinephrine (first-line vasopressor for septic shock, initiate early if MAP <65 mmHg after fluids)

AltAlternativesVasopressin (0.03 U/min) as second-line; epinephrine as third-line; hydrocortisone 200 mg/day IV for refractory shock

⊘AvoidHydroxyethyl starches, activated protein C (drotrecogin alfa), low-dose dopamine, vitamin C/thiamine/hydrocortisone combination, non-dihydropyridine CCBs, and supranormal oxygen delivery targets

DxTest of choiceSerum lactate (initial and serial clearance); blood cultures (two sets before antibiotics); procalcitonin for de-escalation guidance

ScKey scoreSOFA score (≥2 increase defines sepsis; trajectory over 48-72h predicts mortality); qSOFA (≥2 for rapid bedside screening in non-ICU settings)

→When to referRefractory shock (norepinephrine >0.5 µg/kg/min), need for source control (surgery/IR), ECMO consideration, goals-of-care discussions with multiple poor prognostic factors

Early recognition (qSOFA), 1-hour bundle (antibiotics, balanced crystalloids, norepinephrine), source control within 12 hours, and ABCDEF bundle for post-resuscitation care are the pillars of sepsis management.

Sepsis is a medical emergency defined by life-threatening organ dysfunction due to a dysregulated host response to infection. The key to survival is early recognition using qSOFA, immediate broad-spectrum antibiotics within 1 hour, aggressive fluid resuscitation with balanced crystalloids, and early vasopressor support with norepinephrine targeting MAP ≥65 mmHg. Source control must be achieved within 12 hours. The ABCDEF bundle guides post-resuscitation care: light sedation, daily awakening and breathing trials, delirium monitoring, early mobilization, and family engagement. Despite advances, mortality remains high (~20% for sepsis, >40% for septic shock). Long-term complications include ICU-acquired weakness, cognitive impairment, and post-intensive care syndrome, requiring structured follow-up.

Overview and Recommendations

Background

•Sepsis is life-threatening organ dysfunction from a dysregulated host response to infection, defined by Sepsis-3 as an acute increase in SOFA score ≥ 2 points. Septic shock requires vasopressors to maintain MAP ≥ 65 mmHg and lactate > 2 mmol/L after adequate fluids, with hospital mortality > 40%.
•It affects approximately 49 million people annually worldwide, causing 11 million deaths. Hospital-treated incidence is 189 per 100,000 person-years, with mortality of 26.7% for all sepsis and 41.9% for ICU-treated cases. Incidence is rising due to aging populations and improved recognition.
•Pathophysiology begins with pathogen recognition via Toll-like receptors, triggering a cytokine storm (TNF-α, IL-1, IL-6) that causes vasodilation, capillary leak, and microcirculatory failure. Endothelial activation leads to coagulopathy and DIC, while mitochondrial dysfunction (cytopathic hypoxia) impairs oxygen utilization. Later, immune paralysis (lymphocyte apoptosis, reduced HLA-DR) increases vulnerability to secondary infections, driving late mortality.
•Risk factors include extremes of age (neonates, elderly >65 years), immunosuppression (HIV, chemotherapy, transplant), indwelling devices, recent hospitalization, and comorbidities like diabetes and hypertension. One in eight patients with infection and organ failure does not meet SIRS criteria; qSOFA (altered mentation, RR ≥ 22, SBP ≤ 100 mmHg) is a more specific bedside screening tool.
•Sepsis subphenotypes identified by organ dysfunction trajectory, rapidly worsening, delayed worsening, rapidly improving, and delayed improving, carry distinct mortality risks. Molecular phenotyping (hyperinflammatory vs. hypoinflammatory) may guide future therapy but current management remains standardized.

Evaluation

•Suspect sepsis in any patient with infection plus altered mentation, tachypnea, or hypotension. Calculate qSOFA: 1 point each for GCS < 15, RR ≥ 22, SBP ≤ 100 mmHg. A score ≥ 2 should trigger immediate escalation of care.
•Measure serum lactate immediately. A level > 2 mmol/L indicates tissue hypoperfusion; > 4 mmol/L defines severe shock and mandates urgent resuscitation. Repeat lactate at 2-4 hours; failure to clear (decrease < 10% or persistent elevation) is associated with higher mortality.
•Obtain two sets of blood cultures (aerobic and anaerobic) before initiating antibiotics. Do not delay antibiotics more than 45 minutes if cultures are difficult to obtain. Collect other cultures (urine, sputum, wound, CSF) based on suspected source.
•Assess organ dysfunction using the SOFA score (or quick bedside assessment: MAP, PaO₂/FiO₂, creatinine, bilirubin, platelets, GCS). An increase ≥ 2 points from baseline confirms sepsis.
•Order chest radiograph for pneumonia; CT abdomen/pelvis with IV contrast if intra-abdominal source suspected; bedside ultrasound for cholecystitis, hydronephrosis, or abscess.
•Consider echocardiography if hemodynamic instability persists despite fluids and vasopressors, to rule out right ventricular dysfunction (present in ~50% of septic patients, associated with 3-fold higher 28-day mortality) or endocarditis.
•Check procalcitonin (PCT) to support bacterial etiology and guide antibiotic de-escalation. Serial PCT with drop > 80% from peak or to ≤ 0.5 µg/L suggests stopping antibiotics. CRP is less specific but can be used if PCT unavailable.
•In refractory septic shock, assess for critical illness-related corticosteroid insufficiency (CIRCI) with random cortisol < 10 µg/dL or delta < 9 µg/dL after cosyntropin stimulation.
•Evaluate for DIC with platelet count, PT/PTT, fibrinogen, D-dimer. Purpura fulminans (sudden extensive purpuric lesions) signals meningococcemia or pneumococcal sepsis and requires immediate aggressive management.
•Reassess fluid responsiveness after initial bolus using dynamic measures (passive leg raise, pulse pressure variation) before administering additional fluids. A positive passive leg raise test predicts response to further boluses.

Management

•Initiate the 1-hour sepsis bundle immediately upon recognition of hypotension (MAP < 65 mmHg) or lactate ≥ 4 mmol/L: measure lactate, obtain blood cultures, start broad-spectrum antibiotics, begin 30 mL/kg crystalloid bolus, and start norepinephrine if MAP < 65 persists.
•Administer 30 mL/kg of balanced crystalloids (e.g., lactated Ringer's) within the first 3 hours. Balanced crystalloids reduce mortality compared to 0.9% saline in sepsis (NNT = 20). Avoid hydroxyethyl starches (increase mortality and need for RRT).
•Start norepinephrine as first-line vasopressor if MAP < 65 mmHg persists after initial fluid bolus. Target MAP 65-70 mmHg. Early norepinephrine (within 1-2 hours) improves shock control at 6 hours and reduces cardiogenic pulmonary edema and new-onset arrhythmias.
•If norepinephrine exceeds 0.25-0.5 µg/kg/min, add vasopressin 0.03 U/min. Vasopressin spares norepinephrine but has no proven mortality benefit. Consider epinephrine as third-line agent.
•For refractory shock despite norepinephrine and vasopressin, add hydrocortisone 50 mg IV every 6 hours (200 mg/day). This accelerates shock reversal but does not improve survival and may increase superinfection. Avoid vitamin C/thiamine/hydrocortisone combination (no benefit; vitamin C alone may cause harm).
•Choose empiric antibiotics based on suspected source, local epidemiology, immune status, and prior antibiotic exposure. For septic shock with high mortality risk (>25%), consider combination therapy (e.g., antipseudomonal beta-lactam plus aminoglycoside or fluoroquinolone). De-escalate using cultures and PCT.
•Achieve source control within 12 hours of diagnosis: drainage of abscesses, debridement of necrotic tissue, removal of infected catheters, surgical intervention for intra-abdominal infections. Failure to control source is an independent risk factor for mortality.
•Provide lung-protective ventilation for ARDS: tidal volume 6 mL/kg predicted body weight, plateau pressure ≤ 30 cm H₂O, SpO₂ 92-96%. Use high-flow nasal cannula after extubation to reduce reintubation.
•Implement the ABCDEF bundle: Assess and treat pain, daily spontaneous awakening and breathing trials, analgesia-first sedation (target RASS 0 to -2), delirium monitoring (CAM-ICU or ICDSC), early mobility and exercise, and family engagement. Each element reduces mortality and delirium.
•For delirium, avoid benzodiazepines. Use dexmedetomidine or propofol for sedation. Haloperidol (1-2 mg IV q6-8h) may be used for incident delirium with QTc monitoring.
•Provide VTE prophylaxis with LMWH (e.g., enoxaparin 40 mg subcutaneously daily) or unfractionated heparin (5000 U subcutaneously twice daily). In high-risk patients (e.g., COVID-19 with coagulopathy), consider therapeutic-dose enoxaparin with caution for bleeding.
•Start stress ulcer prophylaxis with a PPI (e.g., pantoprazole 40 mg IV daily) in mechanically ventilated patients. Discontinue when oral intake resumes and no longer ventilated.
•Initiate enteral nutrition within 48 hours of ICU admission if hemodynamically stable. Avoid overfeeding. Immunonutrition with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants may reduce mortality but evidence is limited.
•Monitor for ICU-acquired weakness using MRC sum score (score < 35 defines paresis). Begin early physical and occupational therapy as soon as hemodynamically stable.
•Do not use: supranormal oxygen delivery goals, activated protein C (drotrecogin alfa, withdrawn), low-dose dopamine for renal protection, or routine albumin (no survival benefit). Do not delay antibiotics to obtain cultures; the 1-hour window is critical.
•Refer to intensivist for any sepsis with organ dysfunction. Consult surgery or interventional radiology for source control. Consider ECMO for refractory shock in selected patients. Involve palliative care when multiple poor prognostic factors are present (advanced cancer, frailty, high lactate, persistent organ failure).
•Discharge criteria: resolution of organ dysfunction (SOFA improving), stable hemodynamics off vasopressors for ≥ 24 hours, no ongoing infection, adequate oral intake, and plan for post-ICU follow-up to screen for PICS at 2-4 weeks using validated tools (MoCA, HADS, IES-R, 6-minute walk test).

Board Review — High Yield

•qSOFA, Bedside score: altered mentation, RR≥22, SBP≤100; score ≥2 identifies high-risk patients with poor outcomes.
•Sepsis-3 definition, Organ dysfunction = acute increase in SOFA ≥2 points; septic shock = vasopressor requirement + lactate >2 mmol/L after fluids.
•1-hour bundle, Measure lactate, obtain blood cultures, give broad-spectrum antibiotics, start 30 mL/kg crystalloid, begin norepinephrine if MAP<65.
•Balanced crystalloids, Associated with lower 30-day mortality vs saline in sepsis (SMART trial; NNT=20).
•Norepinephrine first-line, Target MAP 65-70 mmHg; early use improves shock control and reduces complications.
•Source control within 12 hours, Independent predictor of survival; failure increases mortality (OR 2.1).
•ABCDEF bundle, Each component reduces mortality and delirium: Assess pain, SAT/SBT, choice of sedation, delirium monitoring, early mobility, family engagement.
•Procalcitonin-guided de-escalation, Reduces antibiotic duration by ~1 day without increasing mortality; stop when PCT drops >80% or ≤0.5 µg/L.
•Corticosteroids, Consider in refractory shock; faster reversal but no survival benefit; avoid in SRS2 endotype (increased mortality).
•Post-ICU syndrome (PICS), Screen at 2-4 weeks post-discharge for cognitive, physical, and mental health impairments using MoCA, HADS, IES-R, 6-minute walk.

Deep Dive — Evidence Details

Definition, Classification & Shock-Physiology Spine

▸Sepsis is defined by life-threatening organ dysfunction (SOFA ≥2) due to a dysregulated host response; the term 'severe sepsis' is obsolete.
▸Septic shock requires vasopressors to maintain MAP ≥65 mm Hg plus lactate >2 mmol/L after adequate fluid resuscitation; mortality exceeds 40%.
▸Classification into distributive, hypovolemic, cardiogenic, or obstructive shock guides initial resuscitation priorities.

HY High Yield: Septic shock is defined by the triad of vasopressor requirement (MAP ≥65 mm Hg), lactate >2 mmol/L, and exclusion of hypovolemia, this combination identifies patients with >40% hospital mortality [17,41].

Sepsis is a potentially life-threatening condition that arises when the body's dysregulated response to infection causes injury to its own tissues and organs. — Sepsis — Sepsis is a potentially life-threatening condition that arises when the body's dysregulated response to infection causes injury to its own tissues and...Wikipedia ↗

Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection ^[41]^A1c. The term replaces older constructs such as "septicemia" and "systemic inflammatory response syndrome (SIRS) with infection"; "severe sepsis" is now recognized as redundant and should be abandoned ^[41]^A1c.

Sepsis and Septic Shock Definitions

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) operationalized sepsis as an acute increase in the Sequential [Sepsis-related] Organ Failure Assessment ( ) score of ≥2 points attributable to infection, which is associated with an in-hospital mortality risk exceeding 10% ^[41]^A1c^[43]^B2b. For rapid bedside screening in non-ICU settings, the quick SOFA ( ) score assigns 1 point each for altered mentation, respiratory rate ≥22/min, and systolic blood pressure ≤100 mm Hg; a score ≥2 identifies patients likely to have poor outcomes ^[43]^B2b.

Septic shock is a subset of sepsis with profound circulatory, cellular, and metabolic abnormalities. Clinically, it is defined by a vasopressor requirement to maintain mean arterial pressure (MAP) ≥65 mm Hg and serum lactate >2 mmol/L after adequate fluid resuscitation, a combination carrying a hospital mortality rate >40% ^[17]^A1c^[41]^A1c. The term "refractory septic shock" has been further refined by an SCCM/ESICM consensus: persistent lactate elevation and/or prolonged capillary refill time in a patient who is fluid-unresponsive and requires norepinephrine equivalents >0.5 µg/kg/min, with consideration of critical care ultrasound to exclude mixed shock ^[24]^D5.

Classification of Shock Types

Septic shock is a form of distributive shock (vasodilatory, with low systemic vascular resistance). The four-shock classification spine governs initial resuscitation decisions:

Type	Key hemodynamic feature	Typical initial intervention
Distributive	Low SVR, normal or high CO	Norepinephrine, fluids
Hypovolemic	Low preload, low CO	Crystalloid resuscitation
Cardiogenic	Low CO, high filling pressures	Inotrope, cause-directed therapy
Obstructive	Impaired diastolic filling (e.g., tamponade, PE)	Relieve obstruction

Sepsis-related organ dysfunction, most commonly affecting the respiratory, cardiovascular, renal, coagulation, and neurologic systems, is quantified by the SOFA score (or the Phoenix Sepsis Score in children, which uses a ≥2-point threshold based on respiratory, cardiovascular, coagulation, and neurologic subscores) ^[42]^A1c^[44]^B2b.

Clinical Significance

Sepsis was declared a global health priority by the World Health Assembly in 2017 ^[40]^D5. It remains the leading cause of death from infection, with an estimated 11 million sepsis-related deaths annually worldwide. The standardized definitions above provide the framework for every downstream decision, from recognition and resuscitation to source control and organ support. The pathobiology that underlies the dysregulated host response is explored in the next section.

Pearl: Classification into distributive, hypovolemic, cardiogenic, or obstructive shock guides initial resuscitation priorities.

Pathophysiology & Mechanism

▸Sepsis is a dysregulated host response, not simply overwhelming inflammation; the initial hyperinflammatory phase is followed by immunosuppression in many patients.
▸Endothelial dysfunction and microcirculatory failure are central to organ dysfunction, often persisting despite normalized macrocirculation.
▸Mitochondrial inhibition (cytopathic hypoxia) explains why cells cannot use oxygen even when delivery is adequate, driving lactate elevation and organ failure.

HY High Yield: Mitochondrial dysfunction is the final common pathway of sepsis-induced organ failure: despite adequate oxygen delivery, cells cannot produce ATP, leading to organ dysfunction independent of ischemia.

Building on the conceptual framework of sepsis as a dysregulated host response, the pathophysiologic cascade begins the moment a pathogen breaches host barriers. Pattern recognition receptors (PRRs), Toll-like receptors (TLRs), NOD-like receptors, and RIG-I-like receptors, on innate immune cells, endothelium, and epithelium recognize pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) ^[66]^D5. This triggers intracellular signaling via NF-κB, MAP kinases, and inflammasome activation, driving release of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8) and upregulation of adhesion molecules ^[66]^D5^[71]^D5. The initial cytokine storm produces the classic features of systemic inflammation: fever, vasodilation, and capillary leak.

Endothelial Activation and Microcirculatory Failure

Endothelial cells are not passive bystanders. Activated endothelium expresses tissue factor, initiating coagulation, and upregulates adhesion molecules (ICAM-1, VCAM-1, E-selectin) that recruit neutrophils and platelets ^[71]^D5^[78]^D5. Neutrophil infiltration into remote organs is driven by CCR2, which is induced on circulating neutrophils in a TLR/NF-κB-dependent manner; CCR2 blockade protects mice from multiple organ dysfunction ^[78]^D5. Simultaneously, endothelial glycocalyx degradation and intercellular junction disruption increase microvascular permeability, leading to tissue edema and impaired oxygen diffusion ^[71]^D5. The result is a profound microcirculatory derangement, heterogeneous flow, shunting, and areas of no-reflow, that persists even when macrocirculatory parameters (blood pressure, cardiac output) appear normal ^[59]^B2b^[75]^B2b. Sublingual microcirculatory alterations correlate poorly with central-to-toe temperature gradient, illustrating the dissociation between systemic and microvascular compartments ^[59]^B2b.

Coagulopathy and Complement Dysregulation

Tissue factor exposure and endothelial injury activate the extrinsic coagulation pathway, generating thrombin and depleting natural anticoagulants (protein C, antithrombin). Simultaneously, the complement cascade (C3a, C5a) amplifies inflammation and neutrophil activation ^[71]^D5. The net effect is a consumptive coagulopathy that ranges from subclinical thrombocytopenia to overt disseminated intravascular coagulation (DIC), further compromising organ perfusion ^[71]^D5^[92]^D5.

Mitochondrial Dysfunction and Cytopathic Hypoxia

Despite adequate , cells cannot use it. Sepsis suppresses mitochondrial respiration through inhibition of complexes I and IV, uncoupling of oxidative phosphorylation, and depletion of ATP ^[66]^D5^[97]^D5. Hypoxia-inducible factor-1α (HIF-1α) is stabilized, driving a shift toward glycolysis and upregulating genes that promote inflammation, angiogenesis, and metabolic reprogramming ^[97]^D5. This “cytopathic hypoxia” underlies the failure of lactate clearance and the dissociation between oxygen supply and demand.

Immune Paralysis and Persistent Inflammation

After the initial hyperinflammatory phase, many patients transition to an immunosuppressive state marked by lymphocyte apoptosis, expansion of myeloid-derived suppressor cells, reduced monocyte HLA-DR expression, and impaired T-cell function ^[79]^D5. Norepinephrine, the first-line vasopressor, may exacerbate this immunoparalysis through β2-adrenergic suppression of TNF-α and IL-12 production ^[80]^D5. The resulting vulnerability to secondary infections drives late mortality ^[79]^D5. Sepsis subphenotypes, defined by trajectory of organ dysfunction, reflect distinct underlying pathophysiologies: a rapidly worsening phenotype with acidosis and visceral organ failure carries the highest mortality, while an improving phenotype with vasopressor-responsive shock has a far better prognosis ^[91]^B3b.

Pearl: The transition from hyperinflammation to immunosuppression means that late mortality is often due to secondary infections, not the initial insult, consider immunostimulatory strategies (e.g., GM-CSF, IL-7) in patients with persistent lymphopenia or low monocyte HLA-DR ^[79]^D5.

Epidemiology, Etiology & Risk Factors

▸Hospital-treated sepsis incidence is 189 per 100,000 person-years, with 26.7% mortality; ICU-treated sepsis mortality is 41.9%.
▸Hospital-acquired sepsis accounts for 23.6% of cases and carries 52.3% mortality in the ICU.
▸One in eight patients with infection and organ failure does not meet SIRS criteria, yet has similar mortality.

HY High Yield: SIRS criteria miss ~12% of patients with infection and organ failure, do not rely on SIRS for sepsis screening [39].

The pathophysiologic cascade described above translates into a substantial global burden of sepsis, with an estimated 189 hospital-treated cases per 100,000 person-years (95% CI 133-267) ^[111]^B2a. ICU-treated sepsis incidence is 58 per 100,000 person-years (95% CI 42-81) ^[111]^B2a. Mortality among hospital-treated sepsis patients is 26.7% (95% CI 22.9-30.7), rising to 41.9% (95% CI 36.2-47.7) for those requiring ICU admission ^[111]^B2a. Hospital-acquired sepsis accounts for 23.6% of all cases, and ICU-acquired sepsis carries a mortality of 52.3% ^[112]^B2a. Temporal trends show a +46% increase in hospital-treated sepsis incidence after 2008, likely reflecting improved recognition and aging populations ^[111]^B2a.

Demographic and Geographic Distribution

Sepsis affects all ages, but extremes, neonates and adults >65 years, bear the highest burden. The pediatric point prevalence of severe sepsis is 8.2% in ICU settings, with hospital mortality 25% ^[28]^B2c. In adults, the median age at presentation is approximately 60 years, with a slight male predominance ^[111]^B2a^[125]^B2b. Geographically, low- and middle-income countries (LMICs) harbor the greatest burden, though precise incidence data remain scarce for most LMICs ^[111]^B2a. Seasonal variation is pronounced, driven by winter respiratory viruses, influenza A (H3N2) is associated with high ICU admission rates and can trigger bacterial superinfection in 30-50% of cases ^[159]^D5.

Risk Factors

Risk Factor	Odds Ratio / Relative Risk	Evidence Level
Total parenteral nutrition	OR 4.6 (95% CI 3.3-6.3)	Meta-analysis ^[129]^A1a
Age >65 years	HR 2.0 (95% CI 1.53-2.60)	Cohort ^[139]^B2b
Sepsis severity (septic shock vs sepsis)	Cumulative risk of AF: 40% vs 10%	Cohort ^[128]^B2b

Comorbidities are underreported: only 35.4% of sepsis RCTs report baseline comorbidity data, with diabetes (86.1% of those trials) and (65.1%) most common ^[33]^A1a. Importantly, one in eight patients with infection and organ failure does not meet two SIRS criteria, yet carries similar mortality, SIRS-based screening misses these patients ^[39]^B2b.

Special Populations

In allogeneic hematopoietic stem-cell transplant recipients admitted to the ICU with sepsis, 90-day mortality is 48%, rising to 100% with four or more risk factors (age >56, time from transplant 30-90 days, corticosteroid-refractory GVHD, vasopressors, mechanical ventilation) ^[139]^B2b. Pediatric severe sepsis shows similar mortality to adults (25%), with 67% having multiorgan dysfunction at recognition ^[28]^B2c.

Pearl: One in eight patients with infection and organ failure does not meet SIRS criteria, do not rely on SIRS for sepsis screening; use or a low threshold for lactate and organ dysfunction assessment ^[39]^B2b.

Clinical Presentation

▸Severe sepsis is present at ED arrival in 71% of patients with community-acquired pneumonia; it is not a delayed event [182].
▸Capillary refill time >3 seconds and a mottling score ≥2 are powerful bedside predictors of mortality, independent of blood pressure [189].
▸Purpura fulminans carries a 41% mortality and 28% limb amputation risk; the most common causes are N. meningitidis and S. pneumoniae [163].

HY High Yield: In the elderly, delirium or tachypnea may be the only sign of sepsis. Always check a capillary refill time and calculate a qSOFA score.

! Warning: Hypothermia (<36°C) in sepsis is an ominous sign associated with higher mortality, do not be reassured by the absence of fever.

The patient with sepsis arrives through a spectrum of acuity, from the alert but tachypneic older adult to the obtunded, hypotensive individual in extremis. The clinical presentation reflects the underlying infection, the host's inflammatory response, and the degree of organ dysfunction, all of which evolve over hours. Recognizing this syndrome at the bedside is the first step toward timely resuscitation.

Presenting Symptoms and Time Course

Most patients report a febrile illness with rigors, myalgias, and malaise. The inciting infection often declares itself: cough and purulent sputum (pneumonia), dysuria or flank pain (urinary tract), abdominal pain and distension (intra-abdominal), or headache and neck stiffness (meningitis). In the PORT study of community-acquired pneumonia, severe sepsis was present at emergency department arrival in 71% of cases, it is not a delayed event ^[182]^B3b. Symptoms progress rapidly; the median time from triage to septic shock is 11.2 hours in patients with a positive score, compared with 26 hours in those with only SIRS criteria ^[181]^B3b. A history of recent hospitalization, indwelling catheters, or immunocompromising conditions (e.g., HIV, malignancy, chemotherapy) should be sought immediately ^[173]^D5^[195]^B3b.

Vital Signs and Hemodynamic Examination

Fever (temperature >38.3°C) is classic but hypothermia (<36°C) is an ominous sign, especially in older or immunocompromised patients and carries a higher mortality. Tachycardia is nearly universal. Tachypnea (respiratory rate >22 breaths/min) often precedes overt hypoxemia and is a sensitive early sign of the increased metabolic demand of sepsis. Hypotension (systolic blood pressure <90 mmHg or mean arterial pressure <65 mmHg) defines septic shock when it persists after adequate fluid resuscitation, but cryptic shock, normal blood pressure with elevated lactate and tissue hypoperfusion, is equally dangerous ^[179]^C4. The capillary refill time (CRT) at the fingertip or sternum, assessed at presentation, predicts 24-hour mortality with an area under the curve of 0.829 ^[189]^B2b. A CRT >3 seconds indicates peripheral hypoperfusion and portends a worse outcome even when the blood pressure is preserved. The mottling score, graded from 0 (no mottling) to 5 (extensive, extending beyond the knee), correlates with 7- and 28-day mortality (AUC 0.732 and 0.749, respectively) ^[189]^B2b.

Physical Examination by System

Skin: Warm, flushed skin in early vasodilatory shock gives way to cool, clammy, mottled extremities as perfusion fails. The most dramatic cutaneous sign is purpura fulminans, sudden, extensive, painful purpuric lesions that indicate disseminated intravascular coagulation and microvascular thrombosis. In a multicenter French cohort, purpura fulminans carried a hospital mortality of 41.2% and led to limb amputation in 28.3% of survivors; the most common causative organisms were Neisseria meningitidis (63.7%) and Streptococcus pneumoniae (21.9%) ^[163]^B3b. Petechiae, especially in a dependent distribution, should raise concern for meningococcemia.

Mental Status: Altered mentation, confusion, agitation, lethargy, or coma, is a hallmark of sepsis-associated encephalopathy. It arises from a combination of cerebral hypoperfusion, neuroinflammation, and metabolic derangement. The absence of fever does not rule out sepsis; elderly patients often present with delirium as the sole manifestation.

Respiratory: Tachypnea, use of accessory muscles, and crackles on auscultation suggest pneumonia as the source. However, even with a non-pulmonary source, sepsis frequently triggers acute respiratory distress syndrome (ARDS), which develops in 41% of critically ill septic patients in some cohorts ^[172]^B2b^[183]^B2b. Early recognition of hypoxemia (SpO2 <90% on room air) and increased work of breathing triggers escalation of respiratory support.

Cardiovascular: A hyperdynamic precordium, bounding pulses, and wide pulse pressure characterize early vasodilatory shock. As myocardial depression progresses, the pulse pressure narrows, heart sounds become muffled, and jugular venous distension may appear from fluid overload or right ventricular dysfunction.

Phenotypic Variants by Infection Source

Source	Key Clinical Features	Frequency (UK cohort, n=426,812) ^[178]^B3b
Respiratory	Cough, sputum, pleuritic chest pain, crackles, hypoxemia	60.9%
Genitourinary	Dysuria, flank pain, pyuria, costovertebral angle tenderness	11.5%
	Abdominal pain, distension, vomiting, diarrhea, peritonitis	10.3%
Skin/soft tissue	, abscess, , purpura	Variable
Central nervous system	Headache, neck stiffness, photophobia, altered mental status	Variable
Catheter-related	Indwelling line, portal for bacteremia, no obvious focal source	Variable

Source-specific clues guide initial imaging and antibiotic selection. For example, in the UK cohort, respiratory infections predominated, and genitourinary sepsis increased over time from 2.0% (1988-1990) to 13.4% (2017-2019) ^[178]^B3b.

Red Flags

Certain exam findings demand immediate, aggressive action:

Respiratory distress: Tachypnea >30 breaths/min, accessory muscle use, or SpO2 <90% on room air, consider impending intubation.
Hypotension refractory to initial fluid bolus: Persistent MAP <65 mmHg after 30 mL/kg crystalloid indicates septic shock and need for vasopressors.
Altered mental status: New-onset confusion or coma, especially in the elderly.
Purpura fulminans or extensive petechiae: Signals meningococcemia or pneumococcal sepsis with high risk of amputation and death ^[163]^B3b.
Autonomic instability: Extremes of heart rate (>130 or <50 bpm), irregular rhythm, or labile blood pressure.

Atypical Presentations

Sepsis can present without fever, particularly in older adults, those on corticosteroids, or patients with renal failure. Isolated delirium, unexplained tachypnea, or new-onset may be the only clues. Hypothermia (<36°C) is a particularly dangerous variant, associated with higher mortality (odds ratio approximately 2.0 in several cohorts). Patients with indwelling catheters or devices may have no localizing signs; the infection source is only discovered after imaging. In resource-limited settings, the absence of typical signs does not lower suspicion; qSOFA ≥2 (altered mental status, respiratory rate ≥22, systolic blood pressure ≤100 mmHg) has superior discrimination for excess mortality compared with SIRS criteria (AUROC 0.70 vs 0.59) ^[185]^B3b.

Pearl: The most common pitfall is dismissing an elderly patient with confusion and tachypnea as "altered mental status of unknown etiology", check a capillary refill time and a respiratory rate; a CRT >3 seconds or a qSOFA ≥2 should immediately trigger sepsis evaluation and resuscitation regardless of blood pressure or temperature.

Diagnosis & Workup (Hemodynamic & Bedside-First)

▸Sepsis is a clinical diagnosis defined by infection + acute organ dysfunction (SOFA score increase ≥2).
▸qSOFA (≥2) is a rapid bedside tool with high specificity (97.3%) for predicting poor outcomes; it does not replace SOFA for ICU patients.
▸An elevated lactate (>2 mmol/L) and failure to clear lactate by ≥10% over 2-6 hours identify ongoing tissue hypoperfusion and should drive resuscitation.

Dx Diagnostic Essentials: The gold standard for sepsis diagnosis is the clinical constellation of suspected or documented infection plus an acute increase in SOFA score of ≥2 points [41]. No single test replaces this bedside judgment.

HY High Yield: Blood cultures drawn after antibiotics reduce yield by up to 50%. Draw them before antibiotics, but never delay antibiotics by more than 45 minutes for culture acquisition [215].

Once clinical suspicion of sepsis is raised - triggered by infection plus vitals or altered mentation - the diagnosis must be confirmed and the source identified within a narrow therapeutic window. Sepsis is a clinical diagnosis: no single laboratory test or imaging study "rules it in." The clinician's task is to rapidly assess organ dysfunction, initiate resuscitation, obtain cultures, and locate the infection, all in parallel.

Clinical Diagnosis (Sepsis-3 Criteria)

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) define sepsis as life-threatening organ dysfunction caused by a dysregulated host response to infection ^[41]^A1c. For clinical operationalization, organ dysfunction is represented by an increase in the Sequential [Sepsis-related] Organ Failure Assessment ( ) score of ≥2 points, which is associated with in-hospital mortality >10% ^[41]^A1c. In out-of-hospital, emergency department, or general ward settings, the quick SOFA ( ) score - two of: altered mental status, respiratory rate ≥22/min, systolic blood pressure ≤100 mm Hg - rapidly identifies patients with suspected infection who are likely to have poor outcomes ^[41]^A1c. A meta-analysis of 229,480 patients found that qSOFA has better specificity (97.3%) for predicting in-hospital mortality than SIRS criteria, although SIRS has higher sensitivity for sepsis diagnosis ^[206]^A1a. Among 184,875 patients admitted to ICUs with suspected infection, SOFA score demonstrated significantly greater discrimination for in-hospital mortality (AUROC 0.753) than either SIRS (0.589) or qSOFA (0.607) ^[230]^B2b. Septic shock is defined by a vasopressor requirement to maintain MAP ≥65 mm Hg and serum lactate >2 mmol/L after adequate fluid resuscitation, a combination carrying hospital mortality >40% ^[17]^A1c.

Laboratory Studies

Test	Finding	Timing	Sensitivity/Specificity
Serum lactate	>2 mmol/L marks tissue hypoperfusion; >4 mmol/L indicates severe shock	At presentation, repeat at 2-4 h	Decreasing lactate over 6-24 h consistently associated with lower mortality ^[135]^B2a
Blood cultures	Two sets (aerobic + anaerobic) before	Before antimicrobial therapy ^[215]^D5	Positive in ~30-40% of sepsis cases; yield drops after antibiotics
Procalcitonin (PCT)	Elevated in bacterial infection	Admission, serial for de-escalation	AUROC ~0.75 for infection ^[233]^B2b; PCT-guided therapy reduces antibiotic duration by ~1.28 days without increasing mortality ^[51]^A1a
C-reactive protein (CRP)	Elevated in inflammation	Admission	AUROC 0.77 for infection ^[233]^B2b; less specific than PCT
	Leukocytosis or leukopenia, thrombocytopenia	Admission	Non-specific
Lactate clearance	<10% decrease over 2-6 h suggests ongoing hypoperfusion	Serial q2-4h	Noninferior to ScvO₂ ≥70% as resuscitation goal (mortality 17% vs 23%) ^[203]^A1b

Biomarker panels. The PMN CD64 index, combined with PCT and sTREM-1, creates a "bioscore" that outperforms any single marker for diagnosing sepsis in critically ill patients (AUROC 0.82-0.89 in validation) ^[219]^B2b. The SeptiCyte LAB host-response assay (4-gene signature) discriminates sepsis from non-infectious SIRS with AUROC 0.82-0.89 ^[224]^B2b. Novel biomarkers such as pancreatic stone protein (PSP) and interleukin-40 (IL-40) show promise for early risk stratification but are not yet incorporated into routine practice ^[233]^B2b^[242]^B2b.

End-organ dysfunction. Check serum creatinine (AKI), bilirubin (hepatic dysfunction), platelet count (DIC), and arterial blood gas (PaO₂/FiO₂ for ARDS). The Endothelial Activation and Stress Index (EASIX) - calculated as lactate dehydrogenase (U/L) × creatinine (mg/dL) / platelet count (10⁹/L) - is independently associated with 30-day mortality in critically ill patients with diabetes (HR 1.20 per log2 unit) ^[232]^B3b.

Adrenal insufficiency. In patients with septic shock refractory to fluids and moderate-to-high dose vasopressors, consider (CIRCI). A random plasma cortisol <10 µg/dL or a delta cortisol <9 µg/dL after cosyntropin 250 µg suggests CIRCI ^[211]^A1c^[221]^B2b.

Imaging

Imaging should be performed promptly to identify the source of infection ^[5]^A1c. Chest radiograph is the first-line test for pneumonia. CT of the abdomen/pelvis with IV contrast is indicated when intra-abdominal infection is suspected (e.g., biliary, , abscess). Ultrasound (bedside or formal) can rapidly assess for cholecystitis, hydronephrosis, or abscess. Echocardiography (transthoracic or transesophageal) is indicated when endocarditis is suspected or when hemodynamic instability persists despite adequate volume and vasopressors ^[144]^B2b. Right ventricular dysfunction (FAC <35% or TAPSE <1.6 cm) is present in nearly half of septic patients and is associated with >3-fold higher 28-day mortality ^[144]^B2b.

Diagnostic Algorithm (Time-Critical)

Step 1: Suspect sepsis. In any patient with infection ± fever, tachycardia, tachypnea, or altered mentation, calculate qSOFA. If ≥2, proceed.

Step 2: Assess organ dysfunction. Obtain SOFA score (or a quick bedside assessment: MAP, lactate, creatinine, bilirubin, platelets, PaO₂/FiO₂, ). An increase ≥2 points defines sepsis.

Step 3: Draw blood cultures and lactate. Two sets before antibiotics (do not delay antibiotics by more than 45 min if cultures are difficult) ^[215]^D5.

Step 4: Initiate resuscitation. Start 30 mL/kg crystalloid bolus, measure lactate, and begin serial lactate monitoring ^[5]^A1c. Early norepinephrine (within 1-2 h of hypotension) increases shock control at 6 h from 48.4% to 76.1% compared with standard care ^[196]^A1b.

Step 5: Identify source. Chest X-ray, CT, or ultrasound as guided by history and exam. Obtain relevant cultures (urine, sputum, wound, CSF if indicated).

Step 6: Reassess. After initial fluids and vasopressors, reassess perfusion (lactate clearance, capillary refill time, urine output). If shock persists, consider intensive monitoring (arterial line, central venous access, echocardiography) and adjunctive therapies (vasopressin, corticosteroids).

Pearl: The diagnosis of sepsis is a clinical judgment that must be made within minutes, not hours. qSOFA ≥2 should trigger immediate escalation; lactate >2 mmol/L confirms tissue hypoperfusion and mandates urgent resuscitation. Time to effective antibiotics is the strongest modifiable predictor of mortality - each hour delay increases risk of death by 4% ^[227]^B2b.

Severity Scoring & Risk Stratification (ICU Scores)

▸The full SOFA score is the standard for ICU severity stratification, with AUROC 0.753 for in-hospital mortality, outperforming qSOFA and SIRS.
▸Delta SOFA (trajectory) is more strongly associated with mortality than fixed-day SOFA, explaining 32% of treatment effect on mortality in meta-regression.
▸SOFA-2 improves discrimination (AUROC 0.746 vs 0.679) and identifies a higher-risk subgroup not captured by SOFA-1, with a hazard ratio of 3.52 for in-hospital mortality.
▸Dynamic organ dysfunction trajectories and molecular phenotypes (hyperinflammatory/hypoinflammatory) enable precision risk stratification and differential treatment response prediction.

HY High Yield: qSOFA is designed for non-ICU triage; do not use it to rule out sepsis in the ICU, where full SOFA remains the standard.

The Sequential Organ Failure Assessment ( ) score is the cornerstone of sepsis severity stratification, as codified in the Sepsis-3 definition. Once organ dysfunction is identified, the SOFA score quantifies the degree of failure across six systems (respiratory, coagulation, hepatic, cardiovascular, renal, and neurologic) and provides a validated estimate of in-hospital mortality risk. For non-ICU settings, the quick SOFA ( ) score, assigning 1 point each for systolic hypotension ≤100 mm Hg, tachypnea ≥22/min, or altered mentation, offers a bedside tool to identify patients at high risk of poor outcomes. In the original Sepsis-3 validation cohort, qSOFA demonstrated an area under the receiver operating characteristic curve (AUROC) of 0.81 for in-hospital mortality among non-ICU patients with suspected infection ^[43]^B2b. In ICU patients, the full SOFA score outperforms qSOFA and systemic inflammatory response syndrome (SIRS) criteria. In a validation study of 184,875 patients admitted to Australian and New Zealand ICUs, SOFA had an AUROC of 0.753 for in-hospital mortality, compared with 0.607 for qSOFA and 0.589 for SIRS ^[230]^B2b.

Delta SOFA and Trajectory

Importantly, the trajectory of SOFA over time (Delta SOFA) carries greater prognostic weight than a single static score. A meta-regression of 87 randomized trials found that treatment effects on Delta SOFA were significantly associated with mortality (slope 0.70, 95% CI 0.26-1.14; R² 32%), whereas fixed-day SOFA showed no significant association (R² 3%) ^[262]^A1a. This supports the use of Delta SOFA as a surrogate endpoint in clinical trials. Beyond static scores, dynamic organ dysfunction trajectories define distinct subphenotypes. Using 72-hour SOFA trajectories, four subphenotypes were identified: Rapidly Worsening (13.1% of patients, in-hospital mortality 28.3%), Delayed Worsening (20.5%), Rapidly Improving (41.3%, mortality 5.5%), and Delayed Improving (25.1%) ^[91]^B3b. The Rapidly Worsening group had the highest mortality despite a lower initial SOFA, highlighting the critical importance of trajectory. Similarly, blood pressure response index (BPRI) trajectories in septic shock identified six hemodynamic phenotypes with ICU mortality ranging from 21.9% to 54.5% ^[25]^B3b.

SOFA-2 Update

The updated SOFA-2 score, released in 2025, incorporates modern ICU practices such as high-flow nasal oxygen and updated renal criteria. In a multicenter cohort of 74,615 patients, diagnostic concordance between SOFA-1 and SOFA-2 was 89.62%, but SOFA-2 uniquely identified an additional 6.84% of patients as septic, including a cohort with substantial mortality (9.23%) ^[269]^B2b. SOFA-2 also achieved earlier diagnosis in 23.12% of cases versus 15.64% with SOFA-1 ^[269]^B2b. In a separate Chinese cohort of 24,510 patients, SOFA-2 demonstrated superior discrimination for in-hospital mortality (AUROC 0.746 vs 0.679 for SOFA-1) ^[284]^B3b. Patients identified only by SOFA-2 had a hazard ratio of 3.52 for in-hospital mortality compared with those negative by both scores ^[284]^B3b. In pneumonia-associated sepsis, a composite model incorporating SOFA-2 with key clinical variables improved the day-1 AUC to 0.87, with an optimal risk-stratification cutoff of >11 ^[270]^B2b.

Additional Prognostic Scores and Molecular Phenotypes

The Acute Physiology and Chronic Health Evaluation (APACHE) II and IV scores provide complementary prognostic information by incorporating age, chronic health status, and acute physiologic derangements (mean 20.3 in the A2B trial ^[119]^A1b). Frailty, assessed by the Clinical Frailty Scale, is independently associated with increased mortality and disability after critical illness ^[272]^B2b. Molecular phenotyping adds another layer of risk stratification. The hyperinflammatory and hypoinflammatory phenotypes, identified by latent class analysis, have distinct biomarker signatures and differential treatment responses ^[138]^B2b^[217]^B3b. Transition from hyperinflammatory to hypoinflammatory over the first few days is associated with improved survival ^[138]^B2b. In pediatric sepsis-associated acute kidney injury, subphenotypes pSAKI-1 and pSAKI-2 showed differential responses to corticosteroids, with pSAKI-1 patients experiencing harm (mortality 10% vs 3.7% in propensity-matched analysis, P = 0.008) ^[266]^B2b.

Score	Setting	Components	AUROC for In-Hospital Mortality	Key Strengths
SOFA (full)	ICU	6 organ systems, 0-24	0.753 ^[230]^B2b	Standard for Sepsis-3 definition, widely validated
qSOFA	Non-ICU	3 clinical variables, 0-3	0.81 (non-ICU) ^[43]^B2b	Rapid bedside triage without labs
SOFA-2	ICU	Updated SOFA with modern thresholds	0.746 ^[284]^B3b	Improved discrimination, earlier diagnosis
APACHE II/IV	ICU	12+ physiologic variables + chronic health	0.638 (APACHE II) ^[277]^B2b	Comprehensive risk adjustment for research

Risk stratification in sepsis is evolving from a single static score to a multidimensional assessment incorporating trajectory, hemodynamic response, and molecular endotypes. These tools guide prognostic discussions, inform escalation decisions, and enable enrichment for clinical trials, leading directly into the acute resuscitative interventions that must follow.

Pearl: The trajectory of SOFA (Delta SOFA) over the first 48-72 hours is a stronger predictor of mortality than any single static score, and should guide both prognostic discussions and trial enrichment strategies.

Acute Resuscitation & Time-Critical Management

▸The 1-hour sepsis bundle (lactate, blood cultures, antibiotics, 30 mL/kg crystalloid, vasopressors) is the cornerstone of time-critical management.
▸Balanced crystalloids (e.g., lactated Ringer's) are preferred over 0.9% saline; hydroxyethyl starches are contraindicated.
▸Norepinephrine is the first-line vasopressor; target MAP 65-70 mm Hg; add vasopressin rather than escalating norepinephrine dose above 0.25-0.50 µg/kg/min.

Rx Drug of Choice: Norepinephrine is the first-line vasopressor for septic shock (SSC strong recommendation, moderate-quality evidence) [2]. Start at 5-10 µg/min IV and titrate to MAP ≥65 mm Hg.

! Warning: Do NOT use hydroxyethyl starch (HES) solutions in sepsis; they increase mortality and acute kidney injury risk [307, 201]. Do NOT use high-dose vitamin C (50 mg/kg IV every 6 h); it increases the risk of death or persistent organ dysfunction (RR 1.21, 95% CI 1.04-1.40) [200].

Once a patient with sepsis-induced hypotension (mean arterial pressure [MAP] <65 mm Hg) or a serum lactate ≥4 mmol/L is identified, the clock starts. The 1-hour sepsis bundle, lactate measurement, blood cultures, broad-spectrum , crystalloid fluid (30 mL/kg), and vasopressors if needed, must be initiated immediately. A recent stepped-wedge cluster trial (872 patients) found that bundle implementation shortened median time to antibiotics from 113 to 40 minutes (difference -73 min, 95% CI -93 to -53) but did not significantly reduce in-hospital mortality (12.1% vs 12.6%; aRR 0.81, 95% CI 0.48-1.39) ^[251]^A1b (1b). Despite this, the Surviving Sepsis Campaign (SSC) continues to recommend the 1-hour bundle as a best practice statement, because every hour delay in antibiotic administration increases risk-adjusted mortality (OR 1.04 per hour, 95% CI 1.02-1.05) ^[227]^B2b (2b).

Step 1: Initial Fluid Resuscitation

Administer 30 mL/kg of intravenous crystalloids within the first 3 hours for patients with hypotension or lactate ≥4 mmol/L ^[5]^A1c (1c). The ESICM 2024 guideline gives a conditional recommendation for balanced crystalloids over isotonic saline in sepsis (low certainty of evidence) ^[288]^A1c (1c). In the SMART secondary analysis of 1,641 septic patients, balanced crystalloids reduced 30-day in-hospital mortality from 31.2% to 26.3% (aOR 0.74, 95% CI 0.59-0.93; NNT = 20) and major adverse kidney events (35.4% vs 40.1%; aOR 0.78, 95% CI 0.63-0.97) ^[11]^B3b (3b). A secondary analysis of the CLOVERS trial (1,563 patients) found that lactated Ringer's (vs 0.9% saline) for initial resuscitation was associated with lower 90-day mortality (12.2% vs 15.9%; aHR 0.71, 95% CI 0.51-0.99) ^[290]^B2b (2b). Do not use hydroxyethyl starches: they increase the risk of death (RR 1.17, 95% CI 1.01-1.36) and renal-replacement therapy (RR 1.35, 95% CI 1.01-1.80) ^[307]^A1b (1b).

Step 2: Vasopressor Initiation

If MAP remains <65 mm Hg after initial fluid bolus, start norepinephrine as the first-line vasopressor ^[2]^A1c (1c). The CENSER trial (310 patients) showed that early norepinephrine (median 93 min vs 192 min) increased shock control by 6 hours (76.1% vs 48.4%; NNT = 4) and reduced cardiogenic pulmonary edema (14.4% vs 27.7%) and new-onset arrhythmia (11% vs 20%) ^[196]^A1b (1b). Target a MAP of 65-70 mm Hg; the SEPSISPAM trial (776 patients) found no difference in 28-day mortality between a high target (80-85 mm Hg) and a low target (65-70 mm Hg) (36.6% vs 34.0%; HR 1.07, 95% CI 0.84-1.38), and the high-target group had more ^[305]^A1b (1b). For patients on norepinephrine who remain hypotensive, add vasopressin (0.03 U/min) rather than escalating norepinephrine beyond 0.25-0.50 µg/kg/min ^[2]^A1c (1c). Vasopressin spares norepinephrine but has not shown a mortality benefit in large trials ^[55]^D5 (5).

Step 3: Monitoring and Titration

Reassess fluid responsiveness using dynamic measures (passive leg raise, pulse pressure variation) before further boluses after the initial 30 mL/kg ^[300]^A1b (1b). The ESICM 2025 guideline recommends individualized fluid volume in the optimization phase, with no strong recommendation for restrictive vs liberal strategies ^[289]^A1c (1c). The CLOVERS trial (1,563 patients) found no difference in 90-day mortality between a restrictive fluid strategy (prioritizing vasopressors) and a liberal strategy (14.0% vs 14.9%; P = 0.61) ^[304]^A1b (1b). However, in patients with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m²), the restrictive strategy was associated with lower mortality (21.7% vs 39.4%; HR 0.50, 95% CI 0.29-0.85; NNT = 6) ^[315]^B2b (2b).

Step 4: Adjunctive Therapies in Refractory Shock

For patients who remain hypotensive despite norepinephrine and vasopressin, consider 200 mg/day IV (50 mg every 6 hours) ^[2]^A1c (1c). The CORTICUS trial (499 patients) showed faster shock reversal but no survival benefit (28-day mortality 34.3% vs 31.5%; P = 0.51) and more superinfection ^[306]^A1b (1b). The SSC/SCCM 2017 guideline recommends corticosteroids in septic shock not responsive to fluids and moderate- to high-dose vasopressors (conditional, low-quality evidence) ^[211]^A1c (1c). Do not use vitamin C, thiamine, and hydrocortisone (the "VICTAS" regimen), the VITAMINS trial (216 patients) showed no difference in vasopressor-free days (median difference -0.6 h, 95% CI -8.3 to 7.2) ^[16]^A1b (1b), and the LOVIT trial (872 patients) found that vitamin C alone increased the risk of death or persistent organ dysfunction (44.5% vs 38.5%; RR 1.21, 95% CI 1.04-1.40) ^[200]^A1b (1b).

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Balanced crystalloids vs saline as first-line fluid	ESICM 2024, conditional recommendation for balanced crystalloids in sepsis (low certainty) ^[288]^A1c	SSC 2016, recommends crystalloids, but does not specify balanced vs saline ^[2]^A1c	Moderate	Use balanced crystalloids, especially in patients with high chloride levels or pre-existing kidney injury.

Pearl: Initiate the 1-hour bundle immediately upon recognition of sepsis-induced hypotension or lactate ≥4 mmol/L: measure lactate, obtain blood cultures, administer broad-spectrum antibiotics, start 30 mL/kg balanced crystalloids, and begin norepinephrine if MAP <65 mm Hg persists.

Vasopressor Dosing in Septic Shock

Drug	Starting dose	Titration	Max dose	Key monitoring
Norepinephrine	5-10 µg/min IV	Increase by 1-5 µg/min every 5 min	100 µg/min (rarely needed)	MAP, heart rate, arrhythmia
Vasopressin	0.03 U/min IV (fixed dose)	Not titrated	0.03 U/min	Observe for ischemia; discontinue if no norepinephrine-sparing effect
Epinephrine	5-10 µg/min IV	Increase by 1-5 µg/min every 5 min	100 µg/min	Monitor lactate, cardiac ischemia, hyperglycemia
Phenylephrine	5-10 µg/min IV	Increase by 1-5 µg/min every 5 min	100 µg/min	Use only when norepinephrine is contraindicated (e.g., tachyarrhythmia)

Definitive Therapy & Source Control of the Inciting Insult

▸Source control within 12 hours and antibiotics within 1 hour are the two most critical interventions for sepsis.
▸Procalcitonin-guided antibiotic de-escalation safely reduces treatment duration and may lower mortality.
▸Combination antibiotic therapy is beneficial only in high-risk patients with septic shock; it is harmful in low-risk patients.

HY High Yield: The 1-hour antibiotic administration and 12-hour source control targets are the most actionable interventions to reduce mortality in septic shock.

With initial resuscitation underway, the next priority is definitive control of the infection source and initiation of appropriate antimicrobial therapy. This section addresses the cause-directed track of sepsis , distinct from the organ-support strategies covered subsequently.

Step 1: Source Control

Identify and control the infectious source as soon as possible. The Surviving Sepsis Campaign guidelines recommend source control with attention to the balance of risks and benefits of the chosen method within 12 hours of diagnosis (grade 1C) ^[1]^A1c. Source control failure, defined as need for surgical revision or persistent inflammation, is an independent risk factor for mortality in intra-abdominal infections (OR 2.1) ^[126]^B2b. For catheter-related infections, ethanol lock does not reduce infections compared to saline (HR 1.55) ^[342]^A1b; catheter removal is preferred when feasible.

Step 2: Antimicrobial Therapy - Timing

Administer broad-spectrum antimicrobials within 1 hour of recognition of septic shock (grade 1B) and within 1 hour of recognition of severe sepsis without shock (grade 1C) ^[1]^A1c. In a retrospective analysis of the Surviving Sepsis Campaign database (N=17,990), each hour delay in antibiotic administration was associated with a linear increase in in-hospital mortality (adjusted OR per hour delay 1.10) ^[318]^B3b.

Step 3: Antimicrobial Selection - Empiric Regimen

Choose empiric therapy based on local , suspected source, immune status, prior antibiotic exposure, and documented colonization with multidrug-resistant organisms ^[215]^D5^[363]^D5. For patients with septic shock and a high risk of death (monotherapy mortality >25%), combination antibiotic therapy improves survival (OR 0.51, 95% CI 0.41-0.64; I²=8.6%) ^[347]^B2a. In low-risk patients (mortality ≤15%), combination therapy is harmful (OR 1.53) ^[347]^B2a. For patients with severe sepsis without shock, monotherapy is appropriate unless there is a high suspicion of resistant pathogens.

Step 4: De-escalation and Duration of Therapy

Reassess antimicrobial therapy daily for de-escalation (grade 1B) ^[1]^A1c. Procalcitonin-guided algorithms reduce antibiotic duration without increasing mortality: in a network meta-analysis (N=5023), PCT-guided strategies shortened treatment by -1.89 days (95% CI -2.30 to -1.47) and lowered mortality (-27 per 1000; 95% CI -45 to -7) ^[109]^A1a. The ADAPT-Sepsis trial (N=2760) confirmed that daily PCT-guided protocols reduce antibiotic duration compared to standard care (mean difference -0.88 days; 95%) while maintaining noninferiority for 28-day mortality (absolute difference 1.57%; 95% CI -2.18 to 5.32) ^[117]^A1b. CRP-guided protocols did not reduce duration ^[117]^A1b. Cessation is recommended when PCT drops >80% from peak or to ≤0.5 μg/L, or when serial CRP trends show sustained decline. Duration of therapy is typically 5-8 days for most infections, with longer courses reserved for slow clinical response, undrainable foci, or specific pathogens ^[215]^D5^[363]^D5.

Step 5: Antifungal Therapy

Empirical antifungal therapy should not be routinely administered in non-neutropenic critically ill patients. The EMPIRICUS trial (N=260) showed that empirical micafungin (100 mg daily for 14 days) did not improve fungal infection-free survival at day 28 compared to placebo (HR 1.35), despite reducing new invasive fungal infections (3% vs 12%, p=0.008) ^[123]^A1b. Antifungal therapy should be reserved for patients with proven or highly probable invasive candidiasis based on risk factors, colonization indices, and biomarkers (e.g., β-D-glucan >280 pg/mL) ^[368]^B2b.

Step 6: Optimizing Antimicrobial Delivery

For β-lactam , continuous infusion compared to intermittent bolus did not achieve statistical significance for 90-day mortality in the BLING III trial (N=7031): 24.9% vs 26.8% (OR 0.91, 95% CI 0.81-1.01) ^[118]^A1b. However, continuous infusion was associated with higher clinical cure rates (55.7% vs 50.0%; absolute difference 5.7%, 95% CI 2.4-9.1%) ^[118]^A1b. Personalized dosing using decision support systems (e.g., AutoKinetics) improved pharmacokinetic target attainment for (69% vs 3%; OR 62.5) ^[357]^A1b and may be considered for selected antibiotics, especially in patients with altered pharmacokinetics (e.g., renal impairment, obesity).

What NOT to Do

Do not delay source control beyond 12 hours when feasible ^[1]^A1c.
Do not use combination antibiotic therapy in low-risk patients without septic shock ^[347]^B2a.
Do not routinely administer empirical antifungal therapy in non-neutropenic patients with sepsis ^[123]^A1b.
Do not rely on CRP guidance alone to shorten antibiotic duration; it is ineffective ^[117]^A1b.

Pearl: Source control within 12 hours and appropriate broad-spectrum antibiotics within 1 hour are the two most modifiable determinants of survival in septic shock; daily procalcitonin-driven de-escalation safely reduces antibiotic exposure by 1-2 days ^[109]^A1a^[117]^A1b.

Key Recommendations for Definitive Therapy and Source Control

Recommendation	Strength of Evidence	Key Trials
Source control within 12 hours	Grade 1C (SSC)	SSC guidelines ^[1]^A1c; AbSeS cohort ^[126]^B2b
Antibiotics within 1 hour (septic shock)	Grade 1B (SSC)	SSC guidelines ^[1]^A1c; Ferrer et al. ^[318]^B3b
Combination therapy for high-risk septic shock	Meta-analysis (OR 0.51)	Kumar et al. ^[347]^B2a
PCT-guided de-escalation (shortens duration, reduces mortality)	Multiple RCTs, meta-analysis	ADAPT-Sepsis ^[117]^A1b; Kubo et al. ^[109]^A1a
Continuous infusion β-lactam (no mortality benefit, higher clinical cure)	RCT (N=7031)	BLING III ^[118]^A1b
Empirical micafungin not recommended	RCT (N=260)	EMPIRICUS ^[123]^A1b

History and Evolution of Treatment

▸The 2001 Rivers EGDT trial was overturned by three multicenter trials, leading the 2016 SSC to downgrade mandatory EGDT.
▸Balanced crystalloids are preferred over saline, and initial fluid volume is limited to up to 30 mL/kg, with individualized optimization afterward.
▸Many adjunctive therapies (activated protein C, esomeprazole, iloprost, acetaminophen) failed in phase 3, while precision immunotherapy (anakinra/interferon-γ) shows promise in selected phenotypes.

HY High Yield: The history of EGDT illustrates the danger of implementing a single-center protocol without multicenter confirmation. Current guidelines prioritize time-to-antibiotics and individualized fluid and vasopressor management over rigid targets.

Once source control is addressed, the evolution of sepsis over the past two decades has been defined by landmark trials that reshaped resuscitation, antimicrobial therapy, and adjunctive strategies.

Early Goal-Directed Therapy and Resuscitation

The 2001 Rivers trial reported a 16% absolute mortality reduction (30.5% vs. 46.5%) with a 6-hour protocol of early goal-directed therapy (EGDT) targeting central venous oxygen saturation, lactate, and base deficit ^[392]^A1b. This single-center result became the cornerstone of the 2004 Surviving Sepsis Campaign (SSC) guidelines ^[376]^A1c. However, subsequent multicenter trials, ProCESS, ARISE, and ProMISe, failed to replicate the benefit, and the 2016 SSC guidelines downgraded EGDT from a strong to a weak recommendation, shifting emphasis to rapid recognition and a 1-hour bundle ^[2]^A1c^[3]^A1c. A 2023 stepped-wedge trial of the 1-hour bundle in 23 emergency departments showed no significant mortality difference (12.1% vs. 12.6%) despite faster and fluids ^[251]^A1b.

Fluid Resuscitation: From Crystalloid vs. Colloid to Balanced vs. Saline and Restrictive vs. Liberal

The ALBIOS trial (2014) found no survival benefit from adding 20% albumin to crystalloids in severe sepsis (28-day mortality 31.8% vs. 32.0%) ^[393]^A1b. The SMART trial (2019) demonstrated that balanced crystalloids reduced 30-day in-hospital mortality compared with saline among medical ICU patients with sepsis (26.3% vs. 31.2%; aOR 0.74) ^[11]^B3b. A secondary analysis of the CLOVERS trial reported a lower hazard of death with lactated Ringer's versus saline (aHR 0.71; 95% CI 0.51-0.99) ^[290]^B2b. The CLOVERS trial itself (2023) found no difference in 90-day mortality between early restrictive and liberal fluid strategies (14.0% vs. 14.9%) ^[304]^A1b, though a prespecified subgroup analysis in patients with advanced chronic kidney disease showed a mortality benefit with the restrictive approach (21.7% vs. 39.4%; HR 0.50) ^[315]^B2b. The 2024 ESICM guideline conditionally recommends balanced crystalloids over saline in sepsis (low certainty) and suggests up to 30 mL/kg of crystalloids in the initial phase, followed by individualized optimization ^[288]^A1c^[289]^A1c.

Vasopressor Therapy

The CENSER trial (2019) found that early low-dose norepinephrine improved shock control by 6 hours (76.1% vs. 48.4%) and reduced cardiogenic pulmonary edema and new-onset arrhythmia, though 28-day mortality did not differ ^[196]^A1b. The SEPSISPAM trial (2014) showed that targeting a MAP of 80-85 mm Hg, compared with 65-70 mm Hg, did not affect mortality but increased the risk of ^[305]^A1b. Norepinephrine has consistently been the first-line vasopressor across all SSC iterations, with vasopressin reserved as a second agent ^[2]^A1c^[376]^A1c. The Landi-SEP trial (2024) demonstrated that the ultra-short-acting β1-blocker landiolol effectively controlled heart rate (39.8% vs. 23.5% achieved the combined endpoint) but did not improve 28-day mortality ^[292]^A1b. Methylene blue, as an early adjunctive therapy, reduced time to vasopressor discontinuation (69 vs. 94 hours) in a 2023 single-center trial ^[314]^A1b.

Adjunctive Therapies: Corticosteroids, Activated Protein C, Vitamin C, and Others

Corticosteroid use was shaped by the CORTICUS trial (2008), which showed no 28-day mortality benefit (34.3% vs. 31.5%) but faster shock reversal and more superinfection ^[306]^A1b. A post-hoc analysis of the VANISH trial identified a transcriptional endotype (SRS2) in which was associated with increased mortality (OR 7.90) ^[297]^B2b. The ImmunoSep trial (2026) used precision immunotherapy guided by macrophage activation-like syndrome or immunoparalysis: anakinra or interferon-γ improved the score by day 9 (35.1% vs. 17.9% achieved a ≥1.4-point decrease) ^[410]^A1b. Activated protein C (drotrecogin alfa) was withdrawn from the market in 2011 after a trial showed increased mortality; it should no longer be used ^[424]^A1a. Vitamin C monotherapy reduced mortality in a meta-analysis of 16 RCTs (RR 0.73, 95% CI 0.60-0.89), but the later C-EASIE trial (2025) found no benefit ^[397]^A1a^[264]^A1b. Multiple other adjunctive agents have failed to improve outcomes in large phase 3 trials: esomeprazole, iloprost, acetaminophen, thrombomodulin, and ilofotase alfa ^[249]^A1b^[58]^A1b^[162]^A1b^[413]^A1b^[8]^A1b.

Antimicrobial Strategies

The 1-hour bundle of blood cultures, lactate measurement, broad-spectrum antibiotics, and fluid administration did not reduce mortality in a 2023 stepped-wedge trial ^[251]^A1b. Procalcitonin-guided therapy safely reduced antibiotic duration compared with standard care (10.7 vs. 9.8 days; noninferior for mortality) in the ADAPT-Sepsis trial (2025) ^[117]^A1b. Continuous infusion of β-lactam antibiotics showed a trend toward lower 90-day mortality (24.9% vs. 26.8%; OR 0.91) in the BLING III trial (2024) ^[118]^A1b. Therapeutic drug monitoring of piperacillin/tazobactam did not improve the SOFA score but increased target attainment ^[382]^A1b.

What Was Abandoned

Several therapies have been abandoned after rigorous testing: EGDT as a mandatory protocol, activated protein C, hetastarch (avoided since 2012 SSC ^[5]^A1c), and low-dose dopamine for renal protection. The 2016 SSC explicitly recommended against supranormal goals ^[2]^A1c. The 2024 ESICM guideline advises against routine albumin use in sepsis (conditional recommendation, moderate certainty) ^[288]^A1c.

Pearl: The history of sepsis therapy is a cautionary tale: single-center results (EGDT) were overturned by multicenter trials, and many promising adjunctive agents failed in phase 3. Current evidence supports balanced crystalloids, norepinephrine, early antibiotics, and individualized care, but not a one-size-fits-all approach.

Landmark Trials That Shaped Sepsis Therapy

Trial	Year	Intervention	Key Finding	Implication
Rivers EGDT ^[392]^A1b	2001	Protocolized resuscitation	16% absolute mortality reduction	Instigated SSC guidelines
ALBIOS ^[393]^A1b	2014	Albumin + crystalloid vs. crystalloid alone	No mortality benefit	Albumin not routine
SMART ^[11]^B3b	2019	Balanced crystalloids vs. saline	Lower mortality (26.3% vs. 31.2%)	Prefer balanced crystalloids
CLOVERS ^[304]^A1b	2023	Restrictive vs. liberal fluid	No overall mortality difference	Individualize fluid strategy
CENSER ^[196]^A1b	2019	Early norepinephrine vs. standard	Improved shock control, no mortality benefit	Earlier vasopressor use
SEPSISPAM ^[305]^A1b	2014	MAP 80-85 vs. 65-70 mm Hg	No mortality difference, more AF in high-target	MAP 65 mm Hg sufficient
CORTICUS ^[306]^A1b	2008	Hydrocortisone vs. placebo	No mortality benefit, faster shock reversal	Corticosteroids not routine
BLING III ^[118]^A1b	2024	Continuous vs. intermittent β-lactam infusion	Trend toward lower mortality (OR 0.91)	Consider continuous infusion
ADAPT-Sepsis ^[117]^A1b	2025	PCT-guided vs. standard care	Reduced antibiotic duration, noninferior mortality	PCT guidance safe

Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets

▸MAP target of 65-70 mm Hg is recommended; higher targets are not beneficial and may cause harm when requiring high-dose norepinephrine.
▸Balanced crystalloids are preferred over saline for fluid resuscitation, associated with lower 30-day mortality in sepsis.
▸Delayed initiation of RRT (after 48 h) is noninferior to early initiation, allowing 38-45% of patients to avoid RRT.
▸Dexmedetomidine and propofol produce similar clinical outcomes for light sedation; dexmedetomidine has no clear mortality benefit but may reduce inflammation.

From the landmark trials that defined early goal-directed therapy and the Surviving Sepsis Campaign bundles, the focus has shifted to a multi-modal, evidence-based approach targeting each failing organ system individually. The following evidence-based targets guide organ support across the ventilatory, hemodynamic, renal, and extracorporeal domains, with sedation and nutrition integrated into the same framework.

Ventilatory Targets

Low tidal volume ventilation (6 mL/kg predicted body weight) is the standard of care, though the ARDSNet protocol is not repeated here ^[311]^A1b. Conservative oxygen therapy (targeting SpO₂ 90-97%) in mechanically ventilated patients with sepsis did not improve 90-day mortality in the ICU-ROX post hoc analysis; point estimates suggested possible harm (36.2% vs 29.2%; adjusted difference 7 percentage points, 95% CI -4.6 to 18.6) ^[462]^B2b. In contrast, a single-center RCT found that hyperoxygenation (targeting PaO₂ 100-150 mm Hg) reduced 28-day mortality from 40.7% to 18.7% (P = 0.005) compared with conservative oxygenation ^[326]^A1b. Current practice maintains SpO₂ 92-96% until further trials clarify the optimal target.

Hemodynamic Targets

A mean arterial pressure (MAP) target of 65-70 mm Hg is recommended based on the SEPSISPAM trial, which showed no mortality benefit from a higher target of 80-85 mm Hg (28-day mortality 36.6% vs 34.0%; HR 1.07, 95% CI 0.84-1.38) ^[305]^A1b. A higher target requiring high norepinephrine doses or failing to resolve skin mottling was associated with increased mortality ^[9]^B3b. In pediatric septic shock, targeting the 5th centile MAP was noninferior to the 50th centile (28-day mortality 16.9% vs 23.2%; risk difference -6.3%, 95% CI -6.9 to 19.2) and reduced vasoactive use ^[338]^A1b. The TARTARE-2S trial tested a tissue-perfusion-guided approach (capillary refill time, lactate, MAP 50-65 mm Hg) against MAP-guided care and found no difference in days alive without vasopressors or lactate normalization ^[104]^A1b.

Fluid resuscitation should use balanced crystalloids. In the SMART secondary analysis of patients with sepsis, balanced crystalloids were associated with lower 30-day in-hospital mortality (26.3% vs 31.2%; aOR 0.74, 95% CI 0.59-0.93) ^[11]^B3b. Albumin added to crystalloids did not improve survival in the ALBIOS trial (28-day mortality 31.8% vs 32.0%; RR 1.00, 95% CI 0.87-1.14) ^[393]^A1b. Dynamic assessment of fluid responsiveness (passive leg raise) reduced positive fluid balance and the need for renal replacement therapy (5.1% vs 17.5%) ^[300]^A1b. Molecular subphenotypes may identify patients who benefit from a restrictive fluid strategy: the SP2 subphenotype (endothelial injury/inflammation) had lower 28-day mortality with restrictive vs liberal fluid (27% vs 41%) ^[295]^B2b.

Renal Support

Renal replacement therapy (RRT) should be initiated with a delayed strategy. In the IDEAL-ICU trial, early RRT (within 12 h of failure stage) did not reduce 90-day mortality compared with a delayed approach (58% vs 54%; P = 0.38); 38% of patients in the delayed group never received RRT ^[15]^A1b. The AKIKI post hoc analysis confirmed that a delayed strategy allowed 45% of patients with septic shock to escape RRT without worsening 60-day mortality ^[12]^B3b. RRT intensity does not need to exceed that of less-intensive regimens: the VA/NIH ATN trial found no difference in 60-day mortality between intensive (CVVHDF 35 mL/kg/h) and less-intensive (20 mL/kg/h) therapy (53.6% vs 51.5%; OR 1.09, 95% CI 0.86-1.40) ^[116]^A1b. Sodium bicarbonate infusion for severe metabolic acidemia (pH ≤7.20) did not reduce day-90 mortality (62.1% vs 61.7%) but reduced the need for RRT (35% vs 50%) ^[120]^A1b.

Extracorporeal Support

Venovenous or venoarterial ECMO is considered for refractory septic shock, particularly in children ^[452]^A1c. In adults with on VA-ECMO, moderate hypothermia (33-34 °C) did not improve 30-day mortality compared with normothermia (42% vs 51%; adjusted OR 0.71, 95% CI 0.45-1.13) ^[469]^A1b. Polymyxin B hemoperfusion for gram-negative abdominal sepsis reduced 28-day mortality from 53% to 32% in the small EUPHAS trial (unadjusted HR 0.43, 95% CI 0.20-0.94) ^[312]^A1b. High-volume hemofiltration (70 mL/kg/h) in burn patients with septic shock and AKI improved hemodynamics but not survival ^[478]^A1b.

Sedation and

Light sedation (target RASS -2 to 0) is recommended. In the MENDS2 trial, dexmedetomidine and propofol produced similar days alive without delirium or coma (adjusted median 10.7 vs 10.8 days; OR 0.96, 95% CI 0.74-1.26) and similar 90-day mortality (38% vs 39%) ^[348]^A1b. The A2B trial found no difference in time to extubation between dexmedetomidine and propofol (subdistribution HR 1.09, 95% CI 0.96-1.25) ^[119]^A1b. Dexmedetomidine reduced CRP and procalcitonin levels in the DESIRE trial sub-analysis ^[471]^B2b but did not improve mortality in the primary trial ^[122]^A1b. The ADRESS pilot showed higher early mortality with dexmedetomidine in refractory shock ^[7]^A1b. Clonidine-based sedation also did not reduce time to extubation compared with propofol ^[119]^A1b.

Nutrition

Early enteral nutrition (within 48 h) in mechanically ventilated patients with circulatory shock was associated with more ICU-free days and vasopressor-free days, although the effect was attenuated after adjustment for illness severity ^[263]^B2b. Immunonutrition with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants reduced 28-day mortality by 19.4% (absolute) and increased ventilator-free days in patients with severe sepsis or septic shock (13.4 vs 5.8 days) ^[458]^A1b. may reduce in neonates (20% vs 47.5%; OR 0.28, 95% CI 0.10-0.75) ^[484]^A1b.

Pearl: The key to organ support in sepsis is not a single target but a coherent bundle: MAP ≥65 mm Hg, balanced crystalloids, low tidal volume ventilation, delayed RRT, and light sedation, each adjusted to the patient's physiological response to avoid harm from overtreatment.

De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)

▸The ABCDEF bundle, implemented with high compliance, reduces mortality, ICU length of stay, and delirium duration in a dose‑response manner [495].
▸Dexmedetomidine does not reduce mortality or ventilator‑free days compared with propofol in sepsis, but it lowers delirium risk in cardiac surgical patients and is associated with higher cerebral oxygen saturation [122][501][503].
▸Post‑intensive care syndrome (PICS) affects >50% of sepsis survivors; screening with validated tools (MoCA, HADS, IES‑R, 6MWT, EQ‑5D‑5L) should begin 2‑4 weeks after discharge [22][487].

HY High Yield: The ABCDEF bundle is recommended in a dose‑response fashion: each additional element implemented reduces mortality and delirium duration. Prioritize SAT/SBT and light sedation (RASS 0 to -2).

After initial organ support stabilizes the patient, the focus shifts to safely withdrawing that support, a process as consequential as the initial resuscitation. The ABCDEF (A2F) bundle operationalizes the 2018 Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption (PADIS) Guidelines and, across over 25,000 patients in nearly 100 institutions, has shown a dose‑response improvement in survival, length of stay, coma and delirium duration, cost, and discharge disposition ^[495]^D5.

Spontaneous Awakening and Breathing Trials

Daily paired spontaneous awakening trials (SATs) and spontaneous breathing trials (SBTs) are the cornerstone of liberation. Among 745 mechanically ventilated patients, 77% were extubated on the day they passed an SBT; independent predictors of same‑day extubation included higher Richmond Agitation‑Sedation Scale (RASS) score (‑2 vs ‑4: odds ratio [OR] 1.83, 95% CI 1.56‑2.14), receipt of sedation the day prior (OR 2.12, 95% CI 1.63‑2.74), and absence of sepsis or septic shock (OR 0.77, 95% CI 0.59‑1.0) ^[504]^B2b. After extubation, high‑flow nasal cannula oxygen therapy reduces reintubation within 72 h in low‑risk patients (4.9% vs 12.2%; absolute difference 7.2%, 95% CI 2.5%‑12.2%; NNT = 14) ^[351]^A1b.

For patients with a tracheostomy, decannulation readiness can be assessed by frequency rather than a 24‑hour capping trial. In a randomized trial of 330 patients, continuous high‑flow oxygen with suctioning‑guided decannulation shortened time to decannulation from 13 days (IQR 11‑14) to 6 days (IQR 5‑7) without increasing decannulation failure ^[115]^A1b.

Sedation and Delirium Control

‑first, light sedation (RASS 0 to ‑2) is the target. compared with did not significantly reduce mortality or ventilator‑free days in a 201‑patient sepsis trial (28‑day mortality 22.8% vs 30.8%; HR 0.69, 95% CI 0.38‑1.22) ^[122]^A1b. A meta‑analysis of 41 trials (N = 3948) found dexmedetomidine reduced the risk of ICU delirium in cardiac surgical patients (risk ratio 0.49, 95% CI 0.29‑0.87; high certainty) but increased bradycardia; it did not shorten ICU length of stay across any subtype ^[501]^A1a. In septic patients, dexmedetomidine sedation was associated with higher mean regional cerebral oxygen saturation (rSO2) compared with propofol, and delirious patients had lower rSO2 than non‑delirious patients ^[503]^A1b.

Delirium should be monitored at least once per shift using a validated tool, the Confusion Assessment Method for the ICU (CAM‑ICU) or the Intensive Care Delirium Screening Checklist (ICDSC) ^[495]^D5. In a study of 1,535 matched assessments, bedside nurse‑documented ICDSC (cutoff ≥4) had moderate agreement with researcher CAM‑ICU (Cohen’s κ = 0.42); a logistic model incorporating ICDSC components and clinical data improved discrimination (AUC 0.87) ^[489]^B2b.

Treatment of incident delirium with (open‑label IV 2 mg three times daily, up to 5 mg three times daily for symptoms) was associated with a dose‑dependent improvement in survival: each additional milligram per day reduced 28‑day mortality (HR 0.93, 95% CI 0.91‑0.95) and 90‑day mortality (HR 0.97, 95% CI 0.96‑0.98) in a post‑hoc analysis of 1,495 patients ^[491]^B2b. However, antipsychotics have not reliably improved brain function in randomized trials, and the primary strategy remains prevention through non‑pharmacological measures ^[495]^D5.

Biomarkers of systemic inflammation and glial activation are linked to delirium duration and severity. Higher quartiles of IL‑6, IL‑8, IL‑10, TNF‑α, CRP, and S100β at delirium onset were associated with fewer delirium‑/coma‑free days and greater delirium severity up to day 8 ^[488]^B2b. Elevated IL‑6 (OR 1.8, 95% CI 1.4‑2.3), IL‑8 (OR 1.3, 95% CI 1.1‑1.5), and TNFR1 (OR 1.3, 95% CI 1.1‑1.6) and lower protein C (OR 0.7, 95% CI 0.6‑0.8) predicted delirium the following day ^[496]^B2b. The monocyte‑to‑lymphocyte ratio (MLR) is independently associated with 28‑day mortality in sepsis‑associated delirium (HR 1.08 per unit, 95% CI 1.02‑1.15) ^[507]^B2b. Potentially modifiable factors for sepsis‑associated encephalopathy include acute renal failure (aOR 1.41), hypoglycemia <3 mmol/L (aOR 2.66), hyperglycemia >10 mmol/L (aOR 1.37), hypercapnia >45 mm Hg (aOR 1.91), and hypernatremia >145 mmol/L (aOR 2.30) ^[267]^B2b. Acute kidney injury stage 2 or 3 is also a risk factor for delirium (OR 1.55 and 2.56, respectively) and coma ^[500]^B2b.

Early Mobilization and ICU‑Acquired Weakness

Early mobilization combined with best evidence‑based ICU practices reduces short‑term weakness ^[237]^D5. ICU‑acquired paresis (ICUAP), defined by a Medical Research Council (MRC) sum score <35, occurred in 33% of patients with systemic inflammatory response syndrome and mechanical ventilation; it was an independent risk factor for death before day 180 (38% vs 77% survival) ^[498]^B2b. The ABCDEF bundle’s mobility component aims to overcome this.

Post‑Intensive Care Syndrome (PICS)

PICS encompasses new or worsening impairments in physical, cognitive, and/or mental health after critical illness. At 3 and 12 months, one or more PICS problems were present in 64% and 56% of survivors, respectively; co‑occurring problems in two or more domains occurred in 25% and 21% ^[487]^B2b. Four phenotypes of sepsis survivors have been identified: no PICS, mild PICS (physical and cognitive), moderate PICS (all domains), and severe PICS (all domains). Physical and cognitive PICS in the mild group improved by 3 months, but moderate and severe disabilities persisted over 1 year ^[490]^B2b.

Screening for PICS should begin 2‑4 weeks after hospital discharge using validated tools: Montreal Cognitive Assessment (cognition), Hospital Anxiety and Depression Scale (mood), Impact of Event Scale‑Revised (PTSD), 6‑minute walk test (physical function), and EuroQol‑5D‑5L (quality of life) ^[22]^A1c. A post‑ICU telehealth model with scheduled visits at 1 and 2 weeks did not show a clear incremental net benefit in a randomized trial of 400 patients, but wide variation was observed ^[106]^A1b.

Long‑term cognitive impairment is common: 79% of mechanically ventilated survivors had impairment at 3 months and 71% at 12 months; delirium duration was an independent predictor (P = 0.02 at 3 months, P = 0.03 at 12 months) ^[492]^B2b. Delirium duration is also associated with white matter disruption on diffusion tensor imaging persisting at 3 months ^[494]^B2b.

Pearl: The ABCDEF bundle, Assess, prevent, and manage pain; Both SAT and SBT; Choice of analgesia and sedation; Delirium monitoring and ; Early mobility and exercise; Family engagement, should be applied in a dose‑response fashion: each additional element implemented reduces mortality and delirium duration ^[495]^D5.

Components of the ABCDEF (A2F) Bundle

Component	Description	Key Evidence
Assess, prevent, and manage pain	Use CPOT or BPS; treat pain before sedation	PADIS guidelines ^[495]^D5
Both SAT and SBT	Daily paired spontaneous awakening and breathing trials	^[504]^B2b
Choice of analgesia and sedation	Analgesia‑first, light sedation (RASS 0 to -2); avoid benzodiazepines	^[122]^A1b^[501]^A1a
Delirium monitoring and management	CAM‑ICU or ICDSC every shift; non‑pharmacological prevention	^[489]^B2b^[495]^D5
Early mobility and exercise	Begin as soon as hemodynamically stable	^[237]^D5
Family engagement	Involve family in care rounds and decision‑making	^[495]^D5

Post‑Intensive Care Syndrome (PICS) Domains and Screening Tools

Domain	Screening Tool	Threshold	Timing
Cognitive	Montreal Cognitive Assessment (MoCA)	<26	2‑4 weeks post‑discharge
Mental health: Anxiety/Depression	Hospital Anxiety and Depression Scale (HADS)	≥8 per subscale	2‑4 weeks post‑discharge
Mental health: PTSD	Impact of Event Scale‑Revised (IES‑R)	≥25	2‑4 weeks post‑discharge
Physical function	6‑minute walk test (6MWT)	Age‑adjusted norms	2‑4 weeks post‑discharge
Health‑related quality of life	EuroQol‑5D‑5L (EQ‑5D‑5L)	Population norms	2‑4 weeks post‑discharge

Source: ^[22]^A1c

Complications and Iatrogenesis

▸ICU-acquired weakness affects 25-60% of sepsis survivors and is preventable by glycemic control, minimal sedation, and early mobilization.
▸ICU-acquired infections carry a 10.9% attributable mortality fraction; bundle compliance (6-hour SEP-1) is associated with survival benefit.
▸Hospital-acquired infections (VAP, BSI, UTI) are halved by adherence to prevention bundles, including silver-coated endotracheal tubes and probiotics in select populations.

HY High Yield: ICU-acquired weakness is the most preventable complication: early mobilization (within 48-72 hours of admission) reduces ventilator days, delirium, and mortality.

The ABCDEF bundle reduces sedation and promotes early rehabilitation, yet surviving sepsis carries a heavy burden of iatrogenic and disease-related complications that demand systematic surveillance. The most common and consequential complications fall into predictable categories, each with evidence-based prevention strategies.

ICU-Acquired Weakness and Respiratory Monitoring

Critical illness polyneuropathy and myopathy, collectively labeled ICU-acquired weakness (ICU-AW), affects limb and respiratory muscles, prolonging mechanical ventilation and increasing mortality ^[110]^D5^[519]^D5. Risk factors include sepsis itself, hyperglycemia, corticosteroids, and prolonged immobilization ^[110]^D5^[519]^D5. Prevention hinges on avoiding hyperglycemia, minimizing sedation, and early mobilization ^[110]^D5. Diaphragm dysfunction, often from ventilator-induced inactivity, further impairs weaning ^[143]^D5. Post-extubation dysphagia independently predicts , occurring in up to 50% of extubated sepsis patients ^[54]^D5. Formal bedside swallowing evaluation before oral intake is mandatory ^[54]^D5.

Autonomic and Complications

Sepsis-induced autonomic dysfunction manifests as , hypotension, ileus, and urinary retention ^[35]^B2c. Fluid balance must be carefully managed because high net fluid balance is an independent risk factor for ARDS (OR 1.3 per SD) ^[531]^B2b. Gastrointestinal failure (feeding intolerance, ileus) is common; synbiotics (Bifidobacterium breve, Lactobacillus casei, galactooligosaccharides) reduced enteritis (6.3% vs 27.0%) and VAP (14.3% vs 48.6%) in a randomized trial ^[355]^A1b.

Venous Thromboembolism Prophylaxis

Pharmacologic prophylaxis with low-molecular-weight (e.g., ) is recommended in the absence of contraindications, combined with mechanical prophylaxis when feasible. Inadequate prophylaxis is associated with a 2- to 3-fold increase in fatal PE ^[35]^B2c.

Pain and Sedation

Pain in sepsis arises from the primary insult, invasive devices, and immobility. -first sedation using or , titrated to the Critical-Care Pain Observation Tool (CPOT), reduces delirium duration ^[110]^D5. Avoid benzodiazepines when possible; they exacerbate ICU-AW and delirium ^[110]^D5.

Hospital-Acquired Infections

ICU-acquired infections occur in 13.5% of sepsis admissions and carry a population attributable mortality fraction of 10.9% by day 60 ^[231]^B2b^[527]^B2b. (VAP) is the most frequent, with and Klebsiella spp. predominating ^[353]^B2b^[528]^B2b. Prevention bundles, -of-bed elevation 30-45°, daily sedation interruption, oral care with chlorhexidine, silver-coated endotracheal tubes (associated with reduced VAP mortality, OR 0.28) ^[530]^B2b, reduce incidence. (lactobacillus-based) lowered VAP in neonates (20% vs 47.5%, OR 0.28) ^[484]^A1b and oral colostrum reduced late-onset sepsis (62.5% vs 93.9%, RR 0.66) in VLBW infants ^[534]^A1b. Bloodstream infections and catheter-associated UTIs are mitigated by strict adherence to insertion and maintenance bundles, daily review of line necessity, and removal of unnecessary catheters ^[362]^D5.

Rehabilitation and Mobilization

Early physical and occupational therapy (initiated during mechanical ventilation, as soon as hemodynamically stable) improves functional outcomes and reduces ICU-AW ^[519]^D5. Neuromuscular electrical stimulation shows inconsistent benefit ^[110]^D5. Mobilization should be systematic, with daily goals for sitting, standing, and walking based on the patient's stability.

Complication	Frequency	Prevention	Management
ICU-acquired weakness	25-60% ^[110]^D5	Glycemic control, sedation minimization, early mobilization	Range-of-motion exercises, neuromuscular stimulation (unclear benefit) ^[110]^D5
Ventilator-associated pneumonia	10-30% ^[353]^B2b	Head-of-bed elevation, subglottic , oral chlorhexidine, silver-coated ETT ^[530]^B2b	Culture-directed , de-escalation ^[375]^D5
ICU-acquired infections (overall)	13.5% ^[231]^B2b	Bundle compliance, infection control ^[538]^B2b	Targeted antimicrobials, source control
Venous thromboembolism	5-20% ^[35]^B2c	Enoxaparin (or unfractionated heparin)	Therapeutic anticoagulation if diagnosed
Pressure injury	5-10% ^[35]^B2c	Turning every 2 hours, pressure-relieving surfaces	Wound care, debridement

Pearl: The most modifiable driver of iatrogenic harm in sepsis is immobility, prevention of ICU-acquired weakness through early mobilization and minimal sedation reduces downstream infection, VTE, and pressure injury more than any single bundle component.

Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)

▸Sepsis-3 categories (infection, sepsis, septic shock) stratify hospital mortality from 13% to 51% [544].
▸In patients with poor prognostic factors (advanced cancer, multiple organ failure, elevated lactate, hyperdynamic LVEF), early goals-of-care discussions are warranted [34][554][549].
▸Brain death determination follows standard neurologic criteria; organ donation should be considered in all patients who progress to brain death.

HY High Yield: Hyperdynamic left ventricular ejection fraction (>70%) in sepsis is independently associated with 90-day mortality (OR 3.90), whereas depressed LVEF is not [549]. This paradoxical finding likely reflects unmitigated vasoplegia rather than cardiac dysfunction.

The complications that follow sepsis, particularly organ failure, ICU-acquired weakness, and cognitive impairment, shape a trajectory that extends far beyond ICU discharge. Prognostication must therefore be integrated into daily care, informing goals-of-care discussions and, when the course is irreversible, end-of-life decisions including brain-death determination and organ donation.

Overall Mortality and Recovery

Hospital mortality tracks closely with Sepsis-3 categories: 13% for infection without organ dysfunction, 20% for sepsis, 39% for cardiovascular dysfunction (vasopressors but lactate ≤ 2 mmol/L), and 51% for septic shock ^[544]^B2b. Among elderly ICU survivors, 6-month post-discharge mortality reaches 27.3% ^[560]^B2b. For patients who develop persistent critical illness (ICU stay ≥ 10-14 days), in-hospital mortality is 27% and 1-year mortality climbs to 45% ^[567]^D5. In special populations, mortality is even higher: 28-day mortality 69.4% in solid tumor patients with septic shock ^[34]^B2b and 90-day mortality 48% in allogeneic hematopoietic stem-cell transplant recipients ^[139]^B2b.

Prognostic Factors

Factor	Favorable	Unfavorable
Sepsis category	Infection only	Septic shock
Lactate	≤ 2 mmol/L	> 2 mmol/L (OR 3.19 per unit in solid tumors)
score	Low (AUC 0.74)	High (independent predictor per point)
Number of organ failures	0-1	≥ 3 (OR 2.87 per additional failure)
Performance status ( )	0-2	3-4 (OR 2.72)
Malignancy	Absent	Metastatic disease (OR 3.17)
Age	< 65 years	≥ 65 years
Frailty	Robust	Skilled-care facility admission
LVEF	Normal (55-70%)	Hyperdynamic (>70%) (OR 3.90)
Diaphragm dysfunction	Ptr,stim ≥ 11 cm H₂O	Ptr,stim < 11 cm H₂O
Biomarker AIM	≤ 543.66 ng/mL	> 543.66 ng/mL (AUC 0.86)
RPR (RDW/platelet)	0.1-0.2	> 0.21 (HR 1.83)
KPC infection	Absent	Present (aOR 1.58)

Validated Prognostic Scores

The SOFA score predicts hospital mortality with an AUC of 0.74, significantly outperforming SIRS criteria (AUC 0.53) ^[544]^B2b. The updated SOFA-2 score shows similar discrimination (AUC 0.736) ^[269]^B2b; a composite model integrating SOFA-2 with clinical variables improves the AUC to 0.87 for 28-day mortality in pneumonia-associated sepsis ^[270]^B2b. The single biomarker AIM (CD5L) achieves an AUC of 0.86, exceeding SOFA, lactate, and procalcitonin ^[558]^B2b.

Long-Term Sequelae

Sepsis survivors frequently develop ICU-acquired weakness (ICUAW), persisting up to 2 years in up to 50% of patients ^[160]^D5. Chronic critical illness is marked by poor functional outcomes, with many survivors requiring long-term care ^[567]^D5. Psychological sequelae, depression, anxiety, post-traumatic stress, are common but not detailed in the cited studies.

Goals of Care and End-of-Life

Early goals-of-care discussions are warranted when multiple poor prognostic factors coexist, especially advanced cancer, poor performance status, elevated lactate, and respiratory failure ^[34]^B2b^[554]^B2b. In patients with , a performance status ≥ 2, stage IV disease, and organ failure number predict 6-month mortality of 72% ^[554]^B2b.

Brain-death determination follows standard neurologic criteria: absence of consciousness, brainstem reflexes, and respiratory drive, with apnea testing and ancillary studies (e.g., cerebral blood flow imaging) as needed. Organ donation should be considered in all patients who progress to brain death, and donation after circulatory death (DCD) may be an option when life-sustaining therapy is withdrawn per the patient's or surrogate's wishes. No sepsis-specific modifications exist; standard protocols apply.

Pearl: When a septic patient with a hyperdynamic left ventricle (LVEF > 70%) and rising lactate reaches Day 3, the 90-day mortality exceeds 50%, a threshold that should prompt a structured goals-of-care conversation ^[549]^B2b.

Special Populations

▸Pediatric sepsis requires age-adjusted vital signs and weight-based dosing; children >12 years with community-acquired sepsis can be managed in adult ICUs but complex conditions need PICUs [574].
▸Pregnancy alters sepsis physiology and drug pharmacokinetics; avoid teratogenic antibiotics but treat aggressively; corticosteroids for term C-section reduce neonatal respiratory morbidity [580].
▸Elderly patients often present with delirium and have high frailty prevalence; frailty independently predicts mortality and disability [272]; avoid unnecessary sedative prescriptions at discharge [568].
▸Immunocompromised patients (especially allogeneic HSCT recipients) have higher mortality and require broader empiric antimicrobial coverage for opportunistic infections [139, 362].

The unique physiology of special populations forces diagnostic vigilance and treatment modifications that differ from the general sepsis patient. Each group demands an individualized approach to recognition, resuscitation, and drug selection.

Pediatrics

Children with sepsis often present with subtle signs: tachycardia, hypothermia, or altered mental status may be the only clues. Age-adjusted vital signs and weight-based dosing are critical. In public health emergencies, children >12 years with community-acquired sepsis can be managed in adult ICUs, but those with complex pediatric-specific disorders (e.g., congenital heart disease, metabolic syndromes) are best served in PICUs ^[574]^D5. Developmental impact of critical illness includes cognitive impairment and functional disability, which may affect long-term school performance and quality of life.

Pregnancy

Pregnancy-induced physiologic changes, increased cardiac output, decreased vascular resistance, and altered hepatic/renal clearance, shift drug pharmacokinetics and organ-support targets. Pregnancy is an independent risk factor for ARDS in influenza ^[159]^D5. Avoid tetracyclines and aminoglycosides when possible, but treat sepsis aggressively; most beta-lactams and macrolides are safe. For meconium-stained amniotic fluid, prophylactic reduce (RR 0.36, 95% CI 0.21-0.62) but not neonatal sepsis ^[582]^A1a. In preterm prelabour rupture of membranes (PPROM), early birth does not reduce neonatal sepsis and increases neonatal death (RR 2.55, 95% CI 1.17-5.56) ^[579]^A1a. For term elective cesarean section, prophylactic corticosteroids reduce neonatal respiratory distress syndrome (RR 0.48, 95% CI 0.27-0.87) ^[580]^A1a. Delivery planning should involve a multidisciplinary team; is generally safe with standard antibiotics.

Elderly

Atypical presentations, delirium, hypothermia, falls, are common in older adults. Frailty, measured by the Clinical Frailty Scale (CFS), is prevalent even in those <65 years and independently predicts mortality (P=0.01 at 3 months, P<0.001 at 12 months) and disability ^[272]^B2b. Pre-ICU resilience is associated with lower post-ICU mortality (aHR 0.81, 95% CI 0.70-0.94) and greater functional independence ^[573]^B2b. After ICU discharge, 1 in 15 -naive older adults receive a new sedative prescription, and half of those become persistent users ^[568]^B2b. Avoid benzodiazepines; consider dexmedetomidine or propofol with careful titration. Lower MAP targets (60-65 mmHg) may be tolerated in frail elderly, though evidence is limited ^[104]^A1b. Adjust drug doses for renal function and reduced volume of distribution.

Immunocompromised

This group includes HIV, solid organ transplant, hematologic malignancy, and biologic therapy recipients. The incidence of ICU-acquired infections, especially and bloodstream infections, is higher, and fungal and viral pathogens (Pneumocystis jirovecii, CMV, Aspergillus) must be considered ^[362]^D5. Allogeneic hematopoietic stem-cell transplantation (HSCT) recipients have ICU mortality of 26% and 90-day mortality of 48%; independent risk factors include age >56 years, time from HSCT 30-90 days, corticosteroid-refractory graft-versus-host disease, need for vasopressors (OR 1.9, 95% CI 1.42-2.55), and mechanical ventilation (OR 3.1) ^[139]^B2b. Empiric antibiotics should cover resistant gram-negative and gram-positive organisms, and antifungal or antiviral therapy may be needed. Source control is paramount; lower threshold for ICU admission and early diagnostic procedures (bronchoscopy, CSF analysis) are warranted.

Pearl: In special populations, the 'one-size-fits-all' sepsis approach fails, frailty, altered drug handling, and atypical presentations demand individualized diagnostic thresholds and treatment targets.

Prevention, Screening and Post-ICU Surveillance

▸Early VTE prophylaxis with LMWH or unfractionated heparin reduces mortality in sepsis; omission within 24 hours increases hospital mortality (adjusted OR 1.22) [561].
▸Post-ICU PICS screening should begin 2-4 weeks after discharge using validated tools (MoCA, HADS, IES-R, 6MWT, EQ-5D-5L) [22].
▸Sepsis survivors have distinct recovery trajectories; older age, frailty, and lower education predict persistent impairment [510, 590].

HY High Yield: In sepsis survivors, the FROG-ICU study identified a high-risk subtype (48% of patients) with sustained organ dysfunction at ICU discharge, associated with 34% one-year mortality (adjusted HR 1.74) [590].

Following the acute phase, the focus shifts to preventing complications and optimizing long-term recovery. This section consolidates ICU prophylaxis, post-discharge surveillance, and strategies to prevent recurrence.

ICU Prophylaxis Bundle

Venous thromboembolism (VTE) prophylaxis is a cornerstone of sepsis care. The Surviving Sepsis Campaign recommends pharmacologic prophylaxis with low-molecular-weight (LMWH) or unfractionated heparin unless contraindicated ^[1]^A1c. Omission of thromboprophylaxis within the first 24 hours of ICU admission is associated with increased hospital mortality, particularly in sepsis (attributable mortality 8.0%, 95%), with an adjusted odds ratio of 1.22 (95% CI 1.15-1.30) ^[561]^B2b. Sepsis itself is an independent risk factor for VTE (adjusted OR 1.41), and lack of prophylaxis increases risk further (adjusted OR 1.80) ^[253]^A1a. In high-risk patients with and sepsis-induced coagulopathy, therapeutic-dose (1 mg/kg subcutaneous twice daily) reduced thromboembolism compared to standard prophylaxis (10.9% vs 29.0%; RR 0.37, 95% CI 0.21-0.66) but with a trend toward more major bleeding (4.7% vs 1.6%) ^[584]^A1b. Patient-specific factors (history of VTE, obesity, active malignancy, , mechanical ventilation) further stratify risk ^[253]^A1a.

Stress ulcer prophylaxis (SUP) with proton pump inhibitors (PPIs) is routinely used in mechanically ventilated patients. However, recent evidence questions the need for continued SUP beyond ICU stay; cessation during transitions of care may reduce harm without increasing bleeding ^[537]^A1a. High-dose esomeprazole (80 mg bolus followed by 12 mg/h for 72 h) is under investigation for anti-inflammatory effects in sepsis, but this is not yet standard ^[587]^D5.

Delirium prevention is another key component. In critically ill patients with high predicted risk of delirium (≥50%), haloperidol prophylaxis (1 mg/8 h) reduced delirium incidence (65% vs 75%, P=0.01) and increased delirium-free days (median 20 vs 13 days, P=0.003), with a trend toward reduced 28-day mortality (HR 0.80, 95% CI 0.66-0.98) ^[583]^C4. QTc prolongation occurred in 9 of 177 patients, requiring monitoring ^[583]^C4.

Cytomegalovirus (CMV) reactivation is common in CMV-seropositive sepsis patients. Ganciclovir prophylaxis (5 mg/kg IV twice daily for 5 days, then daily until discharge) reduced CMV reactivation (12% vs 39%; absolute risk difference -27%, 95% CI -40 to -14) and increased ventilator-free days (median 23 vs 20 days) but did not improve IL-6 levels, mortality, or ICU length of stay ^[470]^A1b. Routine CMV prophylaxis is not guideline-recommended but may be considered in select high-risk patients.

Post-ICU Surveillance and Screening

Post-intensive care syndrome (PICS), comprising physical, cognitive, and mental health impairments, affects over half of sepsis survivors. At 3 months, 64% have at least one PICS problem; 25% have problems in two or more domains ^[487]^B2b. The Society of Critical Care Medicine consensus recommends serial assessments beginning 2-4 weeks after hospital discharge, using the Montreal Cognitive Assessment (cognitive), Hospital Anxiety and Depression Scale (mental health), Impact of Event Scale-Revised (PTSD, score ≥25 indicates impairment), 6-minute walk test, and EuroQol-5D-5L (quality of life) ^[22]^A1c. Screening should be prioritized for high-risk patients, those with pre-ICU frailty, prolonged delirium, or sepsis ^[22]^A1c^[487]^B2b.

Sepsis survivors have distinct recovery trajectories. Older age, lower education, and higher comorbidity burden predict persistent physical impairment ^[510]^B2b. A latent class analysis identified two subtypes at ICU discharge: subtype B (48% of patients) with sustained organ dysfunction and inflammation had one-year mortality of 34% vs 16% (adjusted HR 1.74) ^[590]^B2b. Four phenotypes of functional decline have been described: no PICS, mild PICS, moderate PICS, and severe PICS, with severe PICS showing persistent disability and worsening survival over 12 months ^[490]^B2b.

Persistent pain is common: 47.7% of ICU survivors report significant pain at 3 months, with risk factors including female sex, prior antidepressant use, prone positioning, and pain at ICU discharge ^[589]^B2b. Neuropathic pain was present in 8.7% of these patients ^[589]^B2b. ICU-acquired weakness (ICUAW) affects many survivors; rehabilitation should be reassessed and tailored to the patient's condition ^[237]^D5.

Prevention of Recurrence

Secondary prevention focuses on managing underlying comorbidities and avoiding recurrent infections. In patients with sepsis due to a known focus, source control was recommended within 12 hours ^[1]^A1c. For recurrent sepsis, a thorough evaluation for occult infections, immunodeficiencies, or indwelling devices is warranted. The relationship between post-sepsis syndrome, Long-COVID, and PICS is overlapping; survivors of COVID-19 sepsis may have more severe consequences than those with milder COVID-19 ^[509]^D5.

Patient Education and Vaccination

Education should address the high risk of readmission, functional decline, and the importance of follow-up. Vaccination against influenza, pneumococcus, and COVID-19 is recommended for sepsis survivors, as they are at increased risk for subsequent infections. The specific timing, generally 3-6 months after acute illness, balances immune response with risk of recurrence. No high-quality trials directly address vaccination timing in sepsis, but expert consensus suggests deferring until clinical stability is achieved.

Pearl: Begin post-ICU PICS screening within 2-4 weeks of discharge using the Montreal Cognitive Assessment, Hospital Anxiety and Depression Scale, and Impact of Event Scale-Revised, prioritizing patients with pre-ICU frailty, prolonged delirium, or sepsis ^[22]^A1c; individualized VTE prophylaxis based on risk factors (history of VTE, obesity, central venous catheter, mechanical ventilation) reduces mortality ^[253]^A1a^[561]^B2b.

References

[1]
Dellinger RP, Levy MM, Rhodes A et al.. “Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012.” Critical care medicine (2013). PMID: 23353941 ↗
L1GUIDELINECited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation), Prevention, Screening and Post-ICU Surveillance
[2]
Rhodes A, Evans LE, Alhazzani W et al.. “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.” Critical care medicine (2017). PMID: 28098591 ↗
L1GUIDELINECited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[3]
Rhodes A, Evans LE, Alhazzani W et al.. “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.” Intensive care medicine (2017). PMID: 28101605 ↗
L1GUIDELINECited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[4]
Weiss SL, Peters MJ, Alhazzani W et al.. “Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children.” Intensive care medicine (2020). PMID: 32030529 ↗
L1GUIDELINECited in: Definition, Classification & Shock-Physiology Spine, Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[5]
Dellinger RP, Levy MM, Rhodes A et al.. “Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.” Intensive care medicine (2013). PMID: 23361625 ↗
L1GUIDELINECited in: Definition, Classification & Shock-Physiology Spine, Clinical Presentation, Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[6]
Annane D, Pastores SM, Rochwerg B et al.. “Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017.” Intensive care medicine (2017). PMID: 28940011 ↗
L1GUIDELINECited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First)
[7]
Dargent A, Bourredjem A, Jacquier M et al.. “Dexmedetomidine to Reduce Vasopressor Resistance in Refractory Septic Shock: α2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS): A Double-Blind Randomized Controlled Pilot Trial.” Critical care medicine (2025). PMID: 40019329 ↗
L1RCTCited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
[8]
Pickkers P, Angus DC, Bass K et al.. “Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL).” Intensive care medicine (2024). PMID: 38172296 ↗
L1RCTCited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Special Populations
[9]
Pirracchio R, Fong N, Legrand M. “Heterogeneity in the response to a high vs low mean arterial pressure target in patients with septic shock a post hoc analysis of a randomized controlled trial.” Intensive care medicine (2025). PMID: 40960603 ↗
L3RCTCited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First), Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[10]
Coz Yataco AO, Soghier I, Hébert PC et al.. “Red Blood Cell Transfusion in Critically Ill Adults: An American College of Chest Physicians Clinical Practice Guideline.” Chest (2024). PMID: 39341492 ↗
L1GUIDELINECited in: Definition, Classification & Shock-Physiology Spine, History and Evolution of Treatment, Complications & Iatrogenesis
[11]
Brown RM, Wang L, Coston TD et al.. “Balanced Crystalloids versus Saline in Sepsis. A Secondary Analysis of the SMART Clinical Trial.” American journal of respiratory and critical care medicine (2019). PMID: 31454263 ↗
L3RCTCited in: Definition, Classification & Shock-Physiology Spine, Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[12]
Gaudry S, Hajage D, Schortgen F et al.. “Timing of Renal Support and Outcome of Septic Shock and Acute Respiratory Distress Syndrome. A Post Hoc Analysis of the AKIKI Randomized Clinical Trial.” American journal of respiratory and critical care medicine (2018). PMID: 29351007 ↗
L3RCTCited in: Definition, Classification & Shock-Physiology Spine, Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
[13]
Weiss SL, Peters MJ, Oczkowski SJW et al.. “Surviving Sepsis Campaign International Guidelines for the Management of Sepsis and Septic Shock in Children 2026.” Intensive care medicine (2026). PMID: 41870559 ↗
L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine
[14]
Menon K, Schlapbach LJ, Akech S et al.. “Criteria for Pediatric Sepsis-A Systematic Review and Meta-Analysis by the Pediatric Sepsis Definition Taskforce.” Critical care medicine (2022). PMID: 34612847 ↗
L3SR_OBSCited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First)
[15]
Barbar SD, Clere-Jehl R, Bourredjem A et al.. “Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis.” The New England journal of medicine (2018). PMID: 30304656 ↗
L1RCTCited in: Definition, Classification & Shock-Physiology Spine, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[16]
Fujii T, Luethi N, Young PJ et al.. “Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial.” JAMA (2020). PMID: 31950979 ↗
L1RCTCited in: Definition, Classification & Shock-Physiology Spine, Acute Resuscitation & Time-Critical Management
[17]
Shankar-Hari M, Phillips GS, Levy ML et al.. “Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).” JAMA (2016). PMID: 26903336 ↗
L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
[18]
Annane D, Bellissant E, Bollaert PE et al.. “Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review.” JAMA (2009). PMID: 19509383 ↗
L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine
[19]
Wirz Y, Meier MA, Bouadma L et al.. “Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials.” Critical care (London, England) (2018). PMID: 30111341 ↗
L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors, Severity Scoring & Risk Stratification (ICU Scores)
[20]
Papp M, Kiss N, Baka M et al.. “Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival-a systematic review and meta-analysis.” Critical care (London, England) (2023). PMID: 37833778 ↗
L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors
[21]
Raschke RA, Garcia-Orr R. “Hemophagocytic lymphohistiocytosis: a potentially underrecognized association with systemic inflammatory response syndrome, severe sepsis, and septic shock in adults.” Chest (2011). PMID: 21737492 ↗
L4CASE_REPORTCited in: Definition, Classification & Shock-Physiology Spine
[22]
Mikkelsen ME, Still M, Anderson BJ et al.. “Society of Critical Care Medicine's International Consensus Conference on Prediction and Identification of Long-Term Impairments After Critical Illness.” Critical care medicine (2020). PMID: 32947467 ↗
L1REVIEW_NARRATIVECited in: Definition, Classification & Shock-Physiology Spine, Severity Scoring & Risk Stratification (ICU Scores), De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS), Prevention, Screening and Post-ICU Surveillance
[23]
Mira JC, Gentile LF, Mathias BJ et al.. “Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome.” Critical care medicine (2017). PMID: 27632674 ↗
L5OTHERCited in: Definition, Classification & Shock-Physiology Spine
[24]
Leone M, Myatra SN, Dugar S et al.. “Clinical Criteria for the Definition of Refractory Septic Shock: A Joint Delphi Consensus from the Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM).” Critical care medicine (2026). PMID: 41873857 ↗
L5OTHERCited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First)
[25]
Shen Y, Zhang W, Lin K et al.. “Blood pressure response index trajectories identify distinct hemodynamic phenotypes and predict mortality in septic shock: a two-database retrospective cohort study.” Critical care (London, England) (2026). PMID: 42057084 ↗
L3COHORTCited in: Definition, Classification & Shock-Physiology Spine, Severity Scoring & Risk Stratification (ICU Scores), Acute Resuscitation & Time-Critical Management
[26]
Song MJ, Jang Y, Legrand M et al.. “Epidemiology of sepsis-associated acute kidney injury in critically ill patients: a multicenter, prospective, observational cohort study in South Korea.” Critical care (London, England) (2024). PMID: 39581988 ↗
L2COHORTCited in: Definition, Classification & Shock-Physiology Spine
[27]
Gordon AC, Alipanah-Lechner N, Bos LD et al.. “From ICU Syndromes to ICU Subphenotypes: Consensus Report and Recommendations for Developing Precision Medicine in the ICU.” American journal of respiratory and critical care medicine (2024). PMID: 38687499 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Shock-Physiology Spine, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[28]
Weiss SL, Fitzgerald JC, Pappachan J et al.. “Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study.” American journal of respiratory and critical care medicine (2015). PMID: 25734408 ↗
L2OTHERCited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors
[29]
Ranzani OT, Prina E, Menéndez R et al.. “New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study.” American journal of respiratory and critical care medicine (2017). PMID: 28613918 ↗
L2OTHERCited in: Definition, Classification & Shock-Physiology Spine
[30]
Muszynski JA, Nofziger R, Moore-Clingenpeel M et al.. “Early Immune Function and Duration of Organ Dysfunction in Critically III Children with Sepsis.” American journal of respiratory and critical care medicine (2018). PMID: 29470918 ↗
L2OTHERCited in: Definition, Classification & Shock-Physiology Spine
[31]
Wong HR, Cvijanovich NZ, Anas N et al.. “Improved Risk Stratification in Pediatric Septic Shock Using Both Protein and mRNA Biomarkers. PERSEVERE-XP.” American journal of respiratory and critical care medicine (2017). PMID: 28324661 ↗
L2OTHERCited in: Definition, Classification & Shock-Physiology Spine, Pathophysiology & Mechanism
[32]
Weiss SL, Peters MJ, Oczkowski SJW et al.. “Surviving Sepsis Campaign International Guidelines for the Management of Sepsis and Septic Shock in Children 2026.” Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies (2026). PMID: 41869844 ↗
L1GUIDELINECited in: Definition, Classification & Shock-Physiology Spine, Acute Resuscitation & Time-Critical Management
[33]
Radulescu SM, Prizeman-Green S, Seth S et al.. “Prevalence and representation of comorbidities and multimorbidity in randomised controlled trials in sepsis or septic shock: a systematic review.” Critical care (London, England) (2026). PMID: 42092974 ↗
L1SR_MA_RCTCited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors
[34]
Cuenca JA, Manjappachar NK, Ramírez CM et al.. “Outcomes and Predictors of 28-Day Mortality in Patients With Solid Tumors and Septic Shock Defined by Third International Consensus Definitions for Sepsis and Septic Shock Criteria.” Chest (2022). PMID: 35644244 ↗
L2OTHERCited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First), Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[35]
Lilly CM, Swami S, Liu X et al.. “Five-Year Trends of Critical Care Practice and Outcomes.” Chest (2017). PMID: 28800866 ↗
L2OTHERCited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First), Severity Scoring & Risk Stratification (ICU Scores), Definitive Therapy & Source Control of the Inciting Insult, Complications & Iatrogenesis
[36]
Fang X, Wang Z, Yang J et al.. “Clinical Evaluation of Sepsis-1 and Sepsis-3 in the ICU.” Chest (2017). PMID: 28711593 ↗
L2OTHERCited in: Definition, Classification & Shock-Physiology Spine
[37]
Otero RM, Nguyen HB, Huang DT et al.. “Early goal-directed therapy in severe sepsis and septic shock revisited: concepts, controversies, and contemporary findings.” Chest (2006). PMID: 17099041 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Shock-Physiology Spine, Clinical Presentation, Acute Resuscitation & Time-Critical Management
[38]
Simpson SQ. “SIRS in the Time of Sepsis-3.” Chest (2017). PMID: 29037526 ↗
L5OTHERCited in: Definition, Classification & Shock-Physiology Spine
[39]
Kaukonen KM, Bailey M, Pilcher D et al.. “Systemic inflammatory response syndrome criteria in defining severe sepsis.” The New England journal of medicine (2015). PMID: 25776936 ↗
L2OTHERCited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors, Special Populations
[40]
Cecconi M, Evans L, Levy M et al.. “Sepsis and septic shock.” Lancet (London, England) (2018). PMID: 29937192 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First)
[41]
Singer M, Deutschman CS, Seymour CW et al.. “The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).” JAMA (2016). PMID: 26903338 ↗
L1OTHERCited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
[42]
Schlapbach LJ, Watson RS, Sorce LR et al.. “International Consensus Criteria for Pediatric Sepsis and Septic Shock.” JAMA (2024). PMID: 38245889 ↗
L1OTHERCited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First)
[43]
Seymour CW, Liu VX, Iwashyna TJ et al.. “Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).” JAMA (2016). PMID: 26903335 ↗
L2OTHERCited in: Definition, Classification & Shock-Physiology Spine, Severity Scoring & Risk Stratification (ICU Scores)
[44]
Sanchez-Pinto LN, Bennett TD, DeWitt PE et al.. “Development and Validation of the Phoenix Criteria for Pediatric Sepsis and Septic Shock.” JAMA (2024). PMID: 38245897 ↗
L2OTHERCited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First)
[45]
Papp M, Turan C, Kiss N et al.. “KInetics of Procalcitonin to Reduce Unnecessary aNtibiotic use (KIPRUN): protocol for a multicentre, randomised, superiority trial to compare the efficacy and safety of procalcitonin kinetics-guided and absolute procalcitonin value-guided antibiotic initiation in critically ill patients.” BMJ open (2026). PMID: 42128499 ↗
L5TRIAL_NONRANDOMCited in: Definition, Classification & Shock-Physiology Spine
[46]
González-Seguel F, Summers LA, Fresenko LE et al.. “Trajectories of Recovery after ACutE and cRitical illness (TRACER): a prospective observational study protocol.” BMJ open (2025). PMID: 41263932 ↗
L5TRIAL_NONRANDOMCited in: Definition, Classification & Shock-Physiology Spine, De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS), Prevention, Screening and Post-ICU Surveillance
[47]
Keshavarz Z, Zand F, Asmarian N et al.. “Predictive variables for early detection of sepsis in adults admitted to intensive care units: protocol for a systematic review.” BMJ open (2026). PMID: 42303390 ↗
L5SR_OBSCited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors, Clinical Presentation
[48]
Fu S, Li F, Qian SY. “Artificial intelligence in pediatric intensive care units: current applications in sepsis management.” World journal of pediatrics : WJP (2026). PMID: 42265523 ↗
L2SR_OBSCited in: Definition, Classification & Shock-Physiology Spine, Severity Scoring & Risk Stratification (ICU Scores)
[49]
Joffe A, Anton N, Lequier L et al.. “Nutritional support for critically ill children.” The Cochrane database of systematic reviews (2016). PMID: 27230550 ↗
L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors
[50]
Joffe A, Anton N, Lequier L et al.. “Nutritional support for critically ill children.” The Cochrane database of systematic reviews (2009). PMID: 19370617 ↗
L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine
[51]
Andriolo BN, Andriolo RB, Salomão R et al.. “Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock.” The Cochrane database of systematic reviews (2017). PMID: 28099689 ↗
L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine, Diagnosis & Workup (Hemodynamic & Bedside-First), Definitive Therapy & Source Control of the Inciting Insult
[52]
Lewis SR, Schofield-Robinson OJ, Alderson P et al.. “Enteral versus parenteral nutrition and enteral versus a combination of enteral and parenteral nutrition for adults in the intensive care unit.” The Cochrane database of systematic reviews (2018). PMID: 29883514 ↗
L1SR_OBSCited in: Definition, Classification & Shock-Physiology Spine
[53]
Warttig S, Alderson P, Evans DJ et al.. “Automated monitoring compared to standard care for the early detection of sepsis in critically ill patients.” The Cochrane database of systematic reviews (2018). PMID: 29938790 ↗
L2SR_OBSCited in: Definition, Classification & Shock-Physiology Spine, Definitive Therapy & Source Control of the Inciting Insult
[54]
Zuercher P, Moret CS, Dziewas R et al.. “Dysphagia in the intensive care unit: epidemiology, mechanisms, and clinical management.” Critical care (London, England) (2019). PMID: 30922363 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Shock-Physiology Spine, Epidemiology, Etiology & Risk Factors, Complications & Iatrogenesis
[55]
Lajoye Q, Orieux A, Boyer A et al.. “Vasopressin and its analogues in patients with septic shock: holy Grail or unfulfilled promise?” Critical care (London, England) (2025). PMID: 40731360 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Shock-Physiology Spine, Acute Resuscitation & Time-Critical Management
[56]
Takkavatakarn K, Oh W, Chan L et al.. “Machine learning derived serum creatinine trajectories in acute kidney injury in critically ill patients with sepsis.” Critical care (London, England) (2024). PMID: 38730421 ↗
L2OTHERCited in: Definition, Classification & Shock-Physiology Spine, Special Populations
[57]
de Oliveira CF, de Oliveira DS, Gottschald AF et al.. “ACCM/PALS haemodynamic support guidelines for paediatric septic shock: an outcomes comparison with and without monitoring central venous oxygen saturation.” Intensive care medicine (2008). PMID: 18369591 ↗
L2RCTCited in: Pathophysiology & Mechanism
[58]
Legrand M, Jullien E, Kimmoun A et al.. “Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion: A Double-Blind, Randomized Controlled Trial.” American journal of respiratory and critical care medicine (2025). PMID: 40387381 ↗
L1RCTCited in: Pathophysiology & Mechanism, Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[59]
Boerma EC, Kuiper MA, Kingma WP et al.. “Disparity between skin perfusion and sublingual microcirculatory alterations in severe sepsis and septic shock: a prospective observational study.” Intensive care medicine (2008). PMID: 18317733 ↗
L2TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism
[60]
Guinot PG, Evezard C, Nguyen M et al.. “Treatment of Acute Circulatory Failure Based on Carbon Dioxide-Oxygen (CO2-O2) Derived Indices: The Lactel Randomized Multicenter Study.” Chest (2024). PMID: 39615831 ↗
L1RCTCited in: Pathophysiology & Mechanism, Diagnosis & Workup (Hemodynamic & Bedside-First), Definitive Therapy & Source Control of the Inciting Insult, Special Populations
[61]
Patel JJ, Willoughby R, Peterson J et al.. “High-Dose IV Hydroxocobalamin (Vitamin B12) in Septic Shock: A Double-Blind, Allocation-Concealed, Placebo-Controlled Single-Center Pilot Randomized Controlled Trial (The Intravenous Hydroxocobalamin in Septic Shock Trial).” Chest (2022). PMID: 36174744 ↗
L1RCTCited in: Pathophysiology & Mechanism, Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[62]
Biesalski HK, McGregor GP. “Antioxidant therapy in critical care--is the microcirculation the primary target?” Critical care medicine (2007). PMID: 17713412 ↗
L5SR_OBSCited in: Pathophysiology & Mechanism
[63]
De Backer D, Deutschman CS, Hellman J et al.. “Surviving Sepsis Campaign Research Priorities 2023.” Critical care medicine (2024). PMID: 38240508 ↗
L5OTHERCited in: Pathophysiology & Mechanism, Acute Resuscitation & Time-Critical Management
[64]
Beesley SJ, Weber G, Sarge T et al.. “Septic Cardiomyopathy.” Critical care medicine (2018). PMID: 29227368 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[65]
Bronicki RA, Tume S, Gomez H et al.. “Application of Cardiovascular Physiology to the Critically Ill Patient.” Critical care medicine (2023). PMID: 38126845 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[66]
Abraham E, Singer M. “Mechanisms of sepsis-induced organ dysfunction.” Critical care medicine (2007). PMID: 17948334 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[67]
Rudiger A. “Beta-block the septic heart.” Critical care medicine (2010). PMID: 21164404 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[68]
Takahashi N, Campbell KR, Nakada TA et al.. “Decreased Clearance of Low-Density Lipoprotein Cholesterol is Causally Associated With Increased Mortality of Septic Shock.” Critical care medicine (2025). PMID: 40758386 ↗
L2OTHERCited in: Pathophysiology & Mechanism
[69]
DeMerle KM, Angus DC, Baillie JK et al.. “Sepsis Subclasses: A Framework for Development and Interpretation.” Critical care medicine (2021). PMID: 33591001 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[70]
Barrett LK, Singer M, Clapp LH. “Vasopressin: mechanisms of action on the vasculature in health and in septic shock.” Critical care medicine (2007). PMID: 17133186 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[71]
Girardis M, David S, Ferrer R et al.. “Understanding, assessing and treating immune, endothelial and haemostasis dysfunctions in bacterial sepsis.” Intensive care medicine (2024). PMID: 39222142 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[72]
Annane D, Pastores SM, Arlt W et al.. “Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM).” Intensive care medicine (2017). PMID: 28940017 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[73]
Andreis DT, Singer M. “Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum.” Intensive care medicine (2016). PMID: 26873833 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[74]
Singh S, Evans TW. “Organ dysfunction during sepsis.” Intensive care medicine (2006). PMID: 16474954 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[75]
Karvunidis T, Chvojka J, Lysak D et al.. “Septic shock and chemotherapy-induced cytopenia: effects on microcirculation.” Intensive care medicine (2012). PMID: 22584795 ↗
L2OTHERCited in: Pathophysiology & Mechanism
[76]
Lange M, Ertmer C, Westphal M. “Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis.” Intensive care medicine (2007). PMID: 18066524 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[77]
Cribbs SK, Sutcliffe DJ, Taylor WR et al.. “Circulating endothelial progenitor cells inversely associate with organ dysfunction in sepsis.” Intensive care medicine (2012). PMID: 22331369 ↗
L2OTHERCited in: Pathophysiology & Mechanism
[78]
Souto FO, Alves-Filho JC, Turato WM et al.. “Essential role of CCR2 in neutrophil tissue infiltration and multiple organ dysfunction in sepsis.” American journal of respiratory and critical care medicine (2010). PMID: 20732989 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[79]
Leentjens J, Kox M, van der Hoeven JG et al.. “Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change?” American journal of respiratory and critical care medicine (2013). PMID: 23590272 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[80]
Stolk RF, van der Poll T, Angus DC et al.. “Potentially Inadvertent Immunomodulation: Norepinephrine Use in Sepsis.” American journal of respiratory and critical care medicine (2016). PMID: 27398737 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[81]
Kapoor A, Shintani Y, Collino M et al.. “Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock.” American journal of respiratory and critical care medicine (2010). PMID: 20693380 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[82]
Chaudhuri D, Herritt B, Lewis K et al.. “Dosing Fluids in Early Septic Shock.” Chest (2020). PMID: 33058814 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
[83]
Hollenberg SM. “Vasopressor support in septic shock.” Chest (2007). PMID: 17998371 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Acute Resuscitation & Time-Critical Management
[84]
Zorowitz RD. “ICU-Acquired Weakness: A Rehabilitation Perspective of Diagnosis, Treatment, and Functional Management.” Chest (2016). PMID: 27312737 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup (Hemodynamic & Bedside-First)
[85]
Ferhat Y, Serkan Y, Ulaş Öİ et al.. “Peripheral Perfusion vs Standard Management in Sepsis/Septic Shock: A Prospective Randomized ED Study.” The American journal of emergency medicine (2025). PMID: 41033063 ↗
L1RCTCited in: Pathophysiology & Mechanism
[86]
Cusack RAF, Rodríguez A, Cantan B et al.. “Microcirculation properties of 20 % albumin in sepsis; a randomised controlled trial.” Journal of critical care (2025). PMID: 40020556 ↗
L1RCTCited in: Pathophysiology & Mechanism
[87]
Lord JM, Midwinter MJ, Chen YF et al.. “The systemic immune response to trauma: an overview of pathophysiology and treatment.” Lancet (London, England) (2014). PMID: 25390327 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[88]
Li H, Liu L, Zhang D et al.. “SARS-CoV-2 and viral sepsis: observations and hypotheses.” Lancet (London, England) (2020). PMID: 32311318 ↗
L5OTHERCited in: Pathophysiology & Mechanism, Clinical Presentation
[89]
Vignon P, Léger J, Evrard B et al.. “Adjunctive dobutamine in patients with septic cardiomyopathy and tissue hypoperfusion: a blinded randomised controlled multicentre trial study protocol of the ADAPT-dobutamine trial.” BMJ open (2025). PMID: 40588393 ↗
L5TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism
[90]
Zhang X, Zhang H, Jin R et al.. “Assessment of Sublingual Microcirculation to Evaluate the Efficacy of Resuscitation Therapy in Septic Shock Patients: A Cohort Study.” Shock (Augusta, Ga.) (2025). PMID: 41031817 ↗
L2COHORTCited in: Pathophysiology & Mechanism
[91]
Xu Z, Mao C, Su C et al.. “Sepsis subphenotyping based on organ dysfunction trajectory.” Critical care (London, England) (2022). PMID: 35786445 ↗
L3OTHERCited in: Pathophysiology & Mechanism, Severity Scoring & Risk Stratification (ICU Scores), Acute Resuscitation & Time-Critical Management
[92]
Kellum JA, Ronco C. “The role of endotoxin in septic shock.” Critical care (London, England) (2023). PMID: 37858258 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup (Hemodynamic & Bedside-First)
[93]
Levy B, Fritz C, Tahon E et al.. “Vasoplegia treatments: the past, the present, and the future.” Critical care (London, England) (2018). PMID: 29486781 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Acute Resuscitation & Time-Critical Management
[94]
Oudemans-van Straaten HM, Spoelstra-de Man AM, de Waard MC. “Vitamin C revisited.” Critical care (London, England) (2014). PMID: 25185110 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Acute Resuscitation & Time-Critical Management
[95]
Atreya MR, Huang M, Moore AR et al.. “Identification and transcriptomic assessment of latent profile pediatric septic shock phenotypes.” Critical care (London, England) (2024). PMID: 39014377 ↗
L2OTHERCited in: Pathophysiology & Mechanism
[96]
Atreya MR, Cvijanovich NZ, Fitzgerald JC et al.. “Prognostic and predictive value of endothelial dysfunction biomarkers in sepsis-associated acute kidney injury: risk-stratified analysis from a prospective observational cohort of pediatric septic shock.” Critical care (London, England) (2023). PMID: 37400882 ↗
L2OTHERCited in: Pathophysiology & Mechanism
[97]
Ruan H, Zhang Q, Zhang YP et al.. “Unraveling the role of HIF-1α in sepsis: from pathophysiology to potential therapeutics-a narrative review.” Critical care (London, England) (2024). PMID: 38539163 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[98]
Garcia B, Su F, Manicone F et al.. “Angiotensin 1-7 in an experimental septic shock model.” Critical care (London, England) (2023). PMID: 36915144 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[99]
Picod A, Azibani F, Harjola VP et al.. “Targeting high circulating dipeptidyl peptidase 3 in circulatory failure.” Critical care (London, England) (2025). PMID: 40745610 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[100]
Tiao J, Bakamutumaho B, Owor N et al.. “Associations between Organ Dysfunction Scoring Systems and Dysregulated Host Responses in Adults with Severe Infection in Uganda: A Prospective Cohort Study.” The American journal of tropical medicine and hygiene (2025). PMID: 40262570 ↗
L2COHORTCited in: Pathophysiology & Mechanism
[101]
Li X, Lin Y, Wang W et al.. “Dynamic left ventricular outflow tract obstruction in critical illness: etiology-driven management and the role of bedside transthoracic echocardiography.” Critical care (London, England) (2025). PMID: 41316420 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism
[102]
Rodhouse C, Bertram Wiggins W, Michael Z et al.. “Optimization of Preclinical Rodent Research Models of Human Shock: Part 2 Trauma, Burn, and the Gut Microbiome.” Shock (Augusta, Ga.) (2026). PMID: 42376926 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[103]
Chen JJ, Lai PC, Lee TH et al.. “Blood Purification for Adult Patients With Severe Infection or Sepsis/Septic Shock: A Network Meta-Analysis of Randomized Controlled Trials.” Critical care medicine (2023). PMID: 37470680 ↗
L1SR_MA_RCTCited in: Epidemiology, Etiology & Risk Factors, Special Populations
[104]
Pettilä V, Pfortmüller CA, Perner A et al.. “Targeted Tissue Perfusion Versus Macrocirculatory-Guided Standard Care in Patients With Septic Shock: A Randomized Clinical Trial-The TARTARE-2S Trial.” Critical care medicine (2025). PMID: 41105050 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
[105]
Myburgh JA, Higgins A, Jovanovska A et al.. “A comparison of epinephrine and norepinephrine in critically ill patients.” Intensive care medicine (2008). PMID: 18654759 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
[106]
Bakhru RN, Flores L, Cain JM et al.. “A Randomized Controlled Trial of a Post-ICU Telehealth Care Model (WFIT).” American journal of respiratory and critical care medicine (2025). PMID: 40532205 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS), Special Populations, Prevention, Screening and Post-ICU Surveillance
[107]
Meduri GU, Golden E, Freire AX et al.. “Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial.” Chest (2007). PMID: 17426195 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[108]
Messmer AS, Zingg C, Müller M et al.. “Fluid Overload and Mortality in Adult Critical Care Patients-A Systematic Review and Meta-Analysis of Observational Studies.” Critical care medicine (2020). PMID: 33009098 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[109]
Kubo K, Sakuraya M, Sugimoto H et al.. “Benefits and Harms of Procalcitonin- or C-Reactive Protein-Guided Antimicrobial Discontinuation in Critically Ill Adults With Sepsis: A Systematic Review and Network Meta-Analysis.” Critical care medicine (2024). PMID: 38949476 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult
[110]
Vanhorebeek I, Latronico N, Van den Berghe G. “ICU-acquired weakness.” Intensive care medicine (2020). PMID: 32076765 ↗
L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Complications & Iatrogenesis
[111]
Fleischmann-Struzek C, Mellhammar L, Rose N et al.. “Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis.” Intensive care medicine (2020). PMID: 32572531 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[112]
Markwart R, Saito H, Harder T et al.. “Epidemiology and burden of sepsis acquired in hospitals and intensive care units: a systematic review and meta-analysis.” Intensive care medicine (2020). PMID: 32591853 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications & Iatrogenesis
[113]
Peake SL, Delaney A, Bailey M et al.. “Goal-directed resuscitation for patients with early septic shock.” The New England journal of medicine (2014). PMID: 25272316 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, Special Populations
[114]
Maitland K, Kiguli S, Opoka RO et al.. “Mortality after fluid bolus in African children with severe infection.” The New England journal of medicine (2011). PMID: 21615299 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult
[115]
Hernández Martínez G, Rodriguez ML, Vaquero MC et al.. “High-Flow Oxygen with Capping or Suctioning for Tracheostomy Decannulation.” The New England journal of medicine (2020). PMID: 32905673 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[116]
Palevsky PM, Zhang JH, O'Connor TZ et al.. “Intensity of renal support in critically ill patients with acute kidney injury.” The New England journal of medicine (2008). PMID: 18492867 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
[117]
Dark P, Hossain A, McAuley DF et al.. “Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical Trial.” JAMA (2025). PMID: 39652885 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Special Populations
[118]
Dulhunty JM, Brett SJ, De Waele JJ et al.. “Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial.” JAMA (2024). PMID: 38864155 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Special Populations
[119]
Walsh TS, Parker RA, Aitken LM et al.. “Dexmedetomidine- or Clonidine-Based Sedation Compared With Propofol in Critically Ill Patients: The A2B Randomized Clinical Trial.” JAMA (2025). PMID: 40388916 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity Scoring & Risk Stratification (ICU Scores), Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
[120]
Jung B, Jabaudon M, De Jong A et al.. “Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury: The BICARICU-2 Randomized Clinical Trial.” JAMA (2025). PMID: 41159812 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
[121]
Hernández G, Vaquero C, Colinas L et al.. “Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation on Reintubation and Postextubation Respiratory Failure in High-Risk Patients: A Randomized Clinical Trial.” JAMA (2016). PMID: 27706464 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
[122]
Kawazoe Y, Miyamoto K, Morimoto T et al.. “Effect of Dexmedetomidine on Mortality and Ventilator-Free Days in Patients Requiring Mechanical Ventilation With Sepsis: A Randomized Clinical Trial.” JAMA (2017). PMID: 28322414 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[123]
Timsit JF, Azoulay E, Schwebel C et al.. “Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.” JAMA (2016). PMID: 27706483 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity Scoring & Risk Stratification (ICU Scores), Definitive Therapy & Source Control of the Inciting Insult, Complications & Iatrogenesis
[124]
Sevransky JE, Rothman RE, Hager DN et al.. “Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial.” JAMA (2021). PMID: 33620405 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult
[125]
Wetterslev M, Hylander Møller M, Granholm A et al.. “Atrial Fibrillation (AFIB) in the ICU: Incidence, Risk Factors, and Outcomes: The International AFIB-ICU Cohort Study.” Critical care medicine (2023). PMID: 37078722 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
[126]
Blot S, Antonelli M, Arvaniti K et al.. “Epidemiology of intra-abdominal infection and sepsis in critically ill patients: "AbSeS", a multinational observational cohort study and ESICM Trials Group Project.” Intensive care medicine (2019). PMID: 31664501 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, Special Populations
[127]
Miano TA, Hennessy S, Yang W et al.. “Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study.” Intensive care medicine (2022). PMID: 35833959 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Special Populations
[128]
Klein Klouwenberg PM, Frencken JF, Kuipers S et al.. “Incidence, Predictors, and Outcomes of New-Onset Atrial Fibrillation in Critically Ill Patients with Sepsis. A Cohort Study.” American journal of respiratory and critical care medicine (2017). PMID: 27467907 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[129]
Thomas-Rüddel DO, Schlattmann P, Pletz M et al.. “Risk Factors for Invasive Candida Infection in Critically Ill Patients: A Systematic Review and Meta-analysis.” Chest (2021). PMID: 34673022 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[130]
Pepper DJ, Sun J, Rhee C et al.. “Procalcitonin-Guided Antibiotic Discontinuation and Mortality in Critically Ill Adults: A Systematic Review and Meta-analysis.” Chest (2019). PMID: 30772386 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[131]
Hui P, Cook DJ, Lim W et al.. “The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review.” Chest (2010). PMID: 21071526 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[132]
Jaber S, Paugam C, Futier E et al.. “Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial.” Lancet (London, England) (2018). PMID: 29910040 ↗
L1TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors
[133]
Chu DK, Kim LH, Young PJ et al.. “Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis.” Lancet (London, England) (2018). PMID: 29726345 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Special Populations
[134]
Legrand M, Bagshaw SM, Bhatraju PK et al.. “Sepsis-associated acute kidney injury: recent advances in enrichment strategies, sub-phenotyping and clinical trials.” Critical care (London, England) (2024). PMID: 38515121 ↗
L5TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Special Populations
[135]
Vincent JL, Quintairos E Silva A, Couto L et al.. “The value of blood lactate kinetics in critically ill patients: a systematic review.” Critical care (London, England) (2016). PMID: 27520452 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First)
[136]
Li X, Liu C, Mao Z et al.. “Timing of renal replacement therapy initiation for acute kidney injury in critically ill patients: a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis.” Critical care (London, England) (2021). PMID: 33407756 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation), Special Populations
[137]
Spottiswoode N, Neyton LP, Mick E et al.. “Host-Microbe Multiomic Profiling Predicts Mortality in Sepsis.” American journal of respiratory and critical care medicine (2026). PMID: 40788839 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations
[138]
van Amstel RBE, Bartek B, Vlaar APJ et al.. “Temporal Transitions of the Hyperinflammatory and Hypoinflammatory Phenotypes in Critical Illness.” American journal of respiratory and critical care medicine (2025). PMID: 39642348 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Severity Scoring & Risk Stratification (ICU Scores), Special Populations
[139]
Lafarge A, Dupont T, Canet E et al.. “Outcomes in Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients.” American journal of respiratory and critical care medicine (2024). PMID: 39018219 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation), Special Populations
[140]
Chouchane O, Schuurman AR, Reijnders TDY et al.. “The Plasma Lipidomic Landscape in Patients with Sepsis due to Community-acquired Pneumonia.” American journal of respiratory and critical care medicine (2024). PMID: 38240721 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors
[141]
Anesi GL, Liu VX, Chowdhury M et al.. “Association of ICU Admission and Outcomes in Sepsis and Acute Respiratory Failure.” American journal of respiratory and critical care medicine (2022). PMID: 34818130 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[142]
Lac J, Han S, Ahmad M et al.. “Low-dose corticosteroids in severe pulmonary infection: a meta-analysis of randomised controlled trials.” BMJ open respiratory research (2026). PMID: 42425738 ↗
L1SR_MA_RCTCited in: Epidemiology, Etiology & Risk Factors
[143]
Supinski GS, Morris PE, Dhar S et al.. “Diaphragm Dysfunction in Critical Illness.” Chest (2017). PMID: 28887062 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup (Hemodynamic & Bedside-First), Complications & Iatrogenesis
[144]
Lanspa MJ, Cirulis MM, Wiley BM et al.. “Right Ventricular Dysfunction in Early Sepsis and Septic Shock.” Chest (2020). PMID: 33068615 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Hemodynamic & Bedside-First), Severity Scoring & Risk Stratification (ICU Scores), Acute Resuscitation & Time-Critical Management
[145]
Marik PE, Khangoora V, Rivera R et al.. “Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study.” Chest (2016). PMID: 27940189 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Acute Resuscitation & Time-Critical Management, Special Populations
[146]
Zuercher P, Schenk NV, Moret C et al.. “Risk Factors for Dysphagia in ICU Patients After Invasive Mechanical Ventilation.” Chest (2020). PMID: 32525018 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations
[147]
Walsh TS, Parker RA, Aitken LM et al.. “Alpha2 agonists for sedation to produce better outcomes for adults with critical illness: a synopsis of the A2B RCT with cost-effectiveness and process evaluation.” Health technology assessment (Winchester, England) (2026). PMID: 42384077 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
[148]
Othman MI, Nashwan AJ, Singh K et al.. “Unraveling the link: A systematic review and meta analysis of acute respiratory distress syndrome and delirium.” Respiratory medicine (2026). PMID: 42320602 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[149]
Krishnegowda VK, Ramaswamy VV, Bandiya P et al.. “Prognosis of neonates receiving invasive mechanical ventilation in low-resource settings: a systematic review and prognostic meta-analysis.” European journal of pediatrics (2026). PMID: 42096067 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[150]
Yang S, Ma L, Zeng J et al.. “Trajectory models of serum creatinine and 28-day mortality in critically ill patients with sepsis complicated by type 2 diabetes mellitus: a cohort study.” Frontiers in endocrinology (2026). PMID: 42416900 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Special Populations
[151]
Li L, Chen H, Liu Y et al.. “Early versus delayed enteral nutrition in patients with sepsis: a propensity score-matched cohort study at a tertiary hospital in Hebei, China.” BMJ open (2026). PMID: 42336791 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Special Populations
[152]
Lewis SR, Pritchard MW, Evans DJ et al.. “Colloids versus crystalloids for fluid resuscitation in critically ill people.” The Cochrane database of systematic reviews (2018). PMID: 30073665 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[153]
Borthwick EM, Hill CJ, Rabindranath KS et al.. “High-volume haemofiltration for sepsis in adults.” The Cochrane database of systematic reviews (2017). PMID: 28141912 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[154]
Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J et al.. “Corticosteroids as adjunctive therapy in the treatment of influenza.” The Cochrane database of systematic reviews (2016). PMID: 26950335 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[155]
Ni hIci T, Boardman HM, Baig K et al.. “Mechanical assist devices for acute cardiogenic shock.” The Cochrane database of systematic reviews (2020). PMID: 32496607 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity Scoring & Risk Stratification (ICU Scores), Acute Resuscitation & Time-Critical Management
[156]
Cabano R, Al-Abdallat H, Hamamreh R et al.. “Acupuncture for procedural pain in newborn infants.” The Cochrane database of systematic reviews (2025). PMID: 40260830 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[157]
Klitgaard TL, Schjørring OL, Nielsen FM et al.. “Higher versus lower fractions of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit.” The Cochrane database of systematic reviews (2023). PMID: 37700687 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[158]
Borthwick EM, Hill CJ, Rabindranath KS et al.. “High-volume haemofiltration for sepsis.” The Cochrane database of systematic reviews (2013). PMID: 23440825 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Definitive Therapy & Source Control of the Inciting Insult
[159]
Kalil AC, Thomas PG. “Influenza virus-related critical illness: pathophysiology and epidemiology.” Critical care (London, England) (2019). PMID: 31324202 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Special Populations
[160]
Hermans G, Van den Berghe G. “Clinical review: intensive care unit acquired weakness.” Critical care (London, England) (2015). PMID: 26242743 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup (Hemodynamic & Bedside-First), Severity Scoring & Risk Stratification (ICU Scores), History and Evolution of Treatment, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[161]
Rivers EP, Kruse JA, Jacobsen G et al.. “The influence of early hemodynamic optimization on biomarker patterns of severe sepsis and septic shock.” Critical care medicine (2007). PMID: 17855815 ↗
L1RCTCited in: Clinical Presentation
[162]
Ware LB, Files DC, Fowler A et al.. “Acetaminophen for Prevention and Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis: The ASTER Randomized Clinical Trial.” JAMA (2024). PMID: 38762798 ↗
L1RCTCited in: Clinical Presentation, Severity Scoring & Risk Stratification (ICU Scores), Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
[163]
Contou D, Sonneville R, Canoui-Poitrine F et al.. “Clinical spectrum and short-term outcome of adult patients with purpura fulminans: a French multicenter retrospective cohort study.” Intensive care medicine (2018). PMID: 30128591 ↗
L3COHORTCited in: Clinical Presentation
[164]
Wang X, Li ZY, Zeng L et al.. “Neutrophil CD64 expression as a diagnostic marker for sepsis in adult patients: a meta-analysis.” Critical care (London, England) (2015). PMID: 26059345 ↗
L1SR_OBSCited in: Clinical Presentation
[165]
Soto GJ, Martin GS, Gong MN. “Healthcare disparities in critical illness.” Critical care medicine (2013). PMID: 24121467 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[166]
Dellinger RP, Levy MM, Carlet JM et al.. “Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.” Critical care medicine (2008). PMID: 18158437 ↗
L1OTHERCited in: Clinical Presentation
[167]
Crouser ED, Parrillo JE, Seymour CW et al.. “Monocyte Distribution Width: A Novel Indicator of Sepsis-2 and Sepsis-3 in High-Risk Emergency Department Patients.” Critical care medicine (2019). PMID: 31107278 ↗
L2OTHERCited in: Clinical Presentation
[168]
Usher MG, Tourani R, Webber B et al.. “Patient Heterogeneity and the J-Curve Relationship Between Time-to-Antibiotics and the Outcomes of Patients Admitted With Bacterial Infection.” Critical care medicine (2022). PMID: 34974496 ↗
L3OTHERCited in: Clinical Presentation
[169]
Binnie A, Walsh CJ, Hu P et al.. “Epigenetic Profiling in Severe Sepsis: A Pilot Study of DNA Methylation Profiles in Critical Illness.” Critical care medicine (2020). PMID: 31939781 ↗
L3OTHERCited in: Clinical Presentation
[170]
Wong HR, Cvijanovich N, Allen GL et al.. “Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum.” Critical care medicine (2009). PMID: 19325468 ↗
L2OTHERCited in: Clinical Presentation
[171]
Helms J, Iba T, Connors JM et al.. “How to manage coagulopathies in critically ill patients.” Intensive care medicine (2023). PMID: 36808215 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[172]
Reilly JP, Zhao Z, Shashaty MGS et al.. “Exposure to ambient air pollutants and acute respiratory distress syndrome risk in sepsis.” Intensive care medicine (2023). PMID: 37470831 ↗
L2OTHERCited in: Clinical Presentation
[173]
Barbier F, Mer M, Szychowiak P et al.. “Management of HIV-infected patients in the intensive care unit.” Intensive care medicine (2020). PMID: 32016535 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[174]
Lukaszewski RA, Jones HE, Gersuk VH et al.. “Presymptomatic diagnosis of postoperative infection and sepsis using gene expression signatures.” Intensive care medicine (2022). PMID: 35831640 ↗
L2OTHERCited in: Clinical Presentation
[175]
Dellinger RP, Levy MM, Carlet JM et al.. “Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.” Intensive care medicine (2007). PMID: 18058085 ↗
L1OTHERCited in: Clinical Presentation
[176]
Klein Klouwenberg PMC, Spitoni C, van der Poll T et al.. “Predicting the clinical trajectory in critically ill patients with sepsis: a cohort study.” Critical care (London, England) (2019). PMID: 31831072 ↗
L2COHORTCited in: Clinical Presentation
[177]
Shashaty MGS, Reilly JP, Faust HE et al.. “Plasma receptor interacting protein kinase-3 levels are associated with acute respiratory distress syndrome in sepsis and trauma: a cohort study.” Critical care (London, England) (2019). PMID: 31253195 ↗
L2COHORTCited in: Clinical Presentation
[178]
Prescott HC, Harrison DA, Rowan KM et al.. “Temporal Trends in Mortality of Critically Ill Patients with Sepsis in the United Kingdom, 1988-2019.” American journal of respiratory and critical care medicine (2024). PMID: 38259190 ↗
L3OTHERCited in: Clinical Presentation
[179]
Angus DC. “Management of sepsis: a 47-year-old woman with an indwelling intravenous catheter and sepsis.” JAMA (2011). PMID: 21467273 ↗
L4CASE_REPORTCited in: Clinical Presentation
[180]
Azoulay É, de Castro N, Barbier F. “Critically Ill Patients With HIV: 40 Years Later.” Chest (2019). PMID: 31421114 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Special Populations
[181]
Bisarya R, Song X, Salle J et al.. “Antibiotic Timing and Progression to Septic Shock Among Patients in the ED With Suspected Infection.” Chest (2021). PMID: 34186038 ↗
L3OTHERCited in: Clinical Presentation
[182]
Dremsizov T, Clermont G, Kellum JA et al.. “Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course?” Chest (2006). PMID: 16608946 ↗
L3OTHERCited in: Clinical Presentation
[183]
Faust HE, Reilly JP, Anderson BJ et al.. “Plasma Mitochondrial DNA Levels Are Associated With ARDS in Trauma and Sepsis Patients.” Chest (2019). PMID: 31622590 ↗
L2OTHERCited in: Clinical Presentation
[184]
Ziegler TR. “Parenteral nutrition in the critically ill patient.” The New England journal of medicine (2009). PMID: 19741230 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Special Populations
[185]
Rudd KE, Seymour CW, Aluisio AR et al.. “Association of the Quick Sequential (Sepsis-Related) Organ Failure Assessment (qSOFA) Score With Excess Hospital Mortality in Adults With Suspected Infection in Low- and Middle-Income Countries.” JAMA (2018). PMID: 29800114 ↗
L3OTHERCited in: Clinical Presentation
[186]
Bernard A, Serna-Higuita LM, Althaus K et al.. “Diminished plasma levels of GPIb-α predict mortality in a prospective ARDS cohort.” Frontiers in medicine (2026). PMID: 42110435 ↗
L2TRIAL_NONRANDOMCited in: Clinical Presentation
[187]
Imamura M, Duggan SN, Vadiveloo T et al.. “Clinical utility of biomarkers for outcomes prediction in adults with suspected sepsis presenting to the emergency department: a synthesis of current evidence.” Health technology assessment (Winchester, England) (2026). PMID: 41912331 ↗
L5SR_OBSCited in: Clinical Presentation
[188]
Angriman F, Angeloni NA, Tanenbaum B et al.. “Clinical characteristics and outcomes of critically ill adult patients admitted with traumatic brain injury: a cohort study.” Canadian journal of anaesthesia = Journal canadien d'anesthesie (2025). PMID: 41430511 ↗
L3COHORTCited in: Clinical Presentation, Prevention, Screening and Post-ICU Surveillance
[189]
Guarino M, Maroncelli G, Perna B et al.. “Comparison of four noninvasive tools for predicting sepsis and septic shock mortality: a prospective cohort study.” Clinical and experimental emergency medicine (2025). PMID: 41327979 ↗
L2COHORTCited in: Clinical Presentation
[190]
Coston TD, Wright SW, Hantrakun V et al.. “Pre-Referral Antibiotics and Mortality Among Adults With Sepsis in Southeast Asia: A Secondary Analysis of a Prospective Cohort Study.” Critical care medicine (2025). PMID: 41196125 ↗
L3COHORTCited in: Clinical Presentation
[191]
Siddiqui S, Razzak J. “Early versus late pre-intensive care unit admission broad spectrum antibiotics for severe sepsis in adults.” The Cochrane database of systematic reviews (2010). PMID: 20927754 ↗
L1SR_OBSCited in: Clinical Presentation
[192]
. “36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016.” Critical care (London, England) (2016). PMID: 27885969 ↗
L5OTHERCited in: Clinical Presentation
[193]
Leite GGF, de Brabander J, Michels EHA et al.. “Monocyte state 1 (MS1) cells in critically ill patients with sepsis or non-infectious conditions: association with disease course and host response.” Critical care (London, England) (2024). PMID: 38504349 ↗
L3OTHERCited in: Clinical Presentation
[194]
Buckel M, Maclean P, Knight JC et al.. “Extending the 'host response' paradigm from sepsis to cardiogenic shock: evidence, limitations and opportunities.” Critical care (London, England) (2023). PMID: 38012789 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[195]
Geng H, Sun W, Shen Q et al.. “Clinical features analysis for complications in infants with late-onset Group B streptococcal sepsis: a retrospective case-control study.” Frontiers in medicine (2025). PMID: 41322235 ↗
L3CASE_CONTROLCited in: Clinical Presentation
[196]
Permpikul C, Tongyoo S, Viarasilpa T et al.. “Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER). A Randomized Trial.” American journal of respiratory and critical care medicine (2019). PMID: 30704260 ↗
L1RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[197]
Shankar-Hari M, Culshaw N, Post B et al.. “Endogenous IgG hypogammaglobulinaemia in critically ill adults with sepsis: systematic review and meta-analysis.” Intensive care medicine (2015). PMID: 25971390 ↗
L1SR_OBSCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[198]
Bassetti M, Garnacho-Montero J, Calandra T et al.. “Intensive care medicine research agenda on invasive fungal infection in critically ill patients.” Intensive care medicine (2017). PMID: 28255613 ↗
L5SR_OBSCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[199]
Thiele H, Zeymer U, Neumann FJ et al.. “Intraaortic balloon support for myocardial infarction with cardiogenic shock.” The New England journal of medicine (2012). PMID: 22920912 ↗
L1RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), History and Evolution of Treatment
[200]
Lamontagne F, Masse MH, Menard J et al.. “Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit.” The New England journal of medicine (2022). PMID: 35704292 ↗
L1RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[201]
Brunkhorst FM, Engel C, Bloos F et al.. “Intensive insulin therapy and pentastarch resuscitation in severe sepsis.” The New England journal of medicine (2008). PMID: 18184958 ↗
L1RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
[202]
Annane D, Siami S, Jaber S et al.. “Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial.” JAMA (2013). PMID: 24108515 ↗
L1RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[203]
Jones AE, Shapiro NI, Trzeciak S et al.. “Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial.” JAMA (2010). PMID: 20179283 ↗
L1RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[204]
Pickkers P, Mehta RL, Murray PT et al.. “Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury: A Randomized Clinical Trial.” JAMA (2018). PMID: 30357272 ↗
L1RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[205]
Munshi L, Dumas G, Rochwerg B et al.. “Long-term survival and functional outcomes of critically ill patients with hematologic malignancies: a Canadian multicenter prospective study.” Intensive care medicine (2024). PMID: 38466402 ↗
L2COHORTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Severity Scoring & Risk Stratification (ICU Scores)
[206]
Serafim R, Gomes JA, Salluh J et al.. “A Comparison of the Quick-SOFA and Systemic Inflammatory Response Syndrome Criteria for the Diagnosis of Sepsis and Prediction of Mortality: A Systematic Review and Meta-Analysis.” Chest (2017). PMID: 29289687 ↗
L1SR_OBSCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[207]
Bréchot N, Hajage D, Kimmoun A et al.. “Venoarterial extracorporeal membrane oxygenation to rescue sepsis-induced cardiogenic shock: a retrospective, multicentre, international cohort study.” Lancet (London, England) (2020). PMID: 32828186 ↗
L2COHORTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[208]
Xie J, Wang H, Kang Y et al.. “The Epidemiology of Sepsis in Chinese ICUs: A National Cross-Sectional Survey.” Critical care medicine (2020). PMID: 31804299 ↗
L2OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Special Populations
[209]
Binnie A, Tsang JLY, Hu P et al.. “Epigenetics of Sepsis.” Critical care medicine (2020). PMID: 32167492 ↗
L5OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[210]
Sacha GL, Lam SW, Wang L et al.. “Association of Catecholamine Dose, Lactate, and Shock Duration at Vasopressin Initiation With Mortality in Patients With Septic Shock.” Critical care medicine (2022). PMID: 34582425 ↗
L3OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
[211]
Annane D, Pastores SM, Rochwerg B et al.. “Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017.” Critical care medicine (2017). PMID: 28938253 ↗
L1OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
[212]
Terrasini N, Lionetti V. “Exosomes in Critical Illness.” Critical care medicine (2017). PMID: 28328650 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[213]
Iacobone E, Bailly-Salin J, Polito A et al.. “Sepsis-associated encephalopathy and its differential diagnosis.” Critical care medicine (2009). PMID: 20046118 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[214]
Delaney A, Borges-Sa M, Chew MS et al.. “Current standard of care for septic shock.” Intensive care medicine (2025). PMID: 41359028 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
[215]
Timsit JF, Ruppé E, Barbier F et al.. “Bloodstream infections in critically ill patients: an expert statement.” Intensive care medicine (2020). PMID: 32047941 ↗
L5OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Definitive Therapy & Source Control of the Inciting Insult
[216]
Martin-Loeches I, Antonelli M, Cuenca-Estrella M et al.. “ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients.” Intensive care medicine (2019). PMID: 30911804 ↗
L5OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[217]
Neyton LPA, Sinha P, Sarma A et al.. “Host and Microbe Blood Metagenomics Reveals Key Pathways Characterizing Critical Illness Phenotypes.” American journal of respiratory and critical care medicine (2024). PMID: 38190719 ↗
L3OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Severity Scoring & Risk Stratification (ICU Scores)
[218]
Dres M, Mancebo J, Curley GF. “Update in Critical Care 2015.” American journal of respiratory and critical care medicine (2016). PMID: 27367886 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Complications & Iatrogenesis
[219]
Gibot S, Béné MC, Noel R et al.. “Combination biomarkers to diagnose sepsis in the critically ill patient.” American journal of respiratory and critical care medicine (2012). PMID: 22538802 ↗
L2OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[220]
Goligher EC, Douflé G, Fan E. “Update in Mechanical Ventilation, Sedation, and Outcomes 2014.” American journal of respiratory and critical care medicine (2015). PMID: 26075422 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[221]
Annane D, Maxime V, Ibrahim F et al.. “Diagnosis of adrenal insufficiency in severe sepsis and septic shock.” American journal of respiratory and critical care medicine (2006). PMID: 16973979 ↗
L2OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[222]
Dépret F, Hollinger A, Cariou A et al.. “Incidence and Outcome of Subclinical Acute Kidney Injury Using penKid in Critically Ill Patients.” American journal of respiratory and critical care medicine (2020). PMID: 32516543 ↗
L2OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[223]
Langley RJ, Tipper JL, Bruse S et al.. “Integrative "omic" analysis of experimental bacteremia identifies a metabolic signature that distinguishes human sepsis from systemic inflammatory response syndromes.” American journal of respiratory and critical care medicine (2014). PMID: 25054455 ↗
L4OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[224]
Miller RR, Lopansri BK, Burke JP et al.. “Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU.” American journal of respiratory and critical care medicine (2018). PMID: 29624409 ↗
L2OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Severity Scoring & Risk Stratification (ICU Scores)
[225]
Marik PE. “Critical illness-related corticosteroid insufficiency.” Chest (2009). PMID: 19136406 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[226]
Wheeler AP. “Recent developments in the diagnosis and management of severe sepsis.” Chest (2007). PMID: 18079230 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
[227]
Seymour CW, Gesten F, Prescott HC et al.. “Time to Treatment and Mortality during Mandated Emergency Care for Sepsis.” The New England journal of medicine (2017). PMID: 28528569 ↗
L2OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
[228]
Feng F, Chen Y, Cai H et al.. “Comparing the efficacy of fospropofol with propofol and midazolam for goal-directed sedation in critically ill patients: a prospective, open-label, pilot, randomized controlled trial.” BMC anesthesiology (2026). PMID: 41654755 ↗
L1RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[229]
Zampieri FG, Bagshaw SM, Semler MW. “Fluid Therapy for Critically Ill Adults With Sepsis: A Review.” JAMA (2023). PMID: 37314271 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management
[230]
Raith EP, Udy AA, Bailey M et al.. “Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Score for In-Hospital Mortality Among Adults With Suspected Infection Admitted to the Intensive Care Unit.” JAMA (2017). PMID: 28114553 ↗
L2OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Severity Scoring & Risk Stratification (ICU Scores)
[231]
van Vught LA, Klein Klouwenberg PM, Spitoni C et al.. “Incidence, Risk Factors, and Attributable Mortality of Secondary Infections in the Intensive Care Unit After Admission for Sepsis.” JAMA (2016). PMID: 26975785 ↗
L2OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Severity Scoring & Risk Stratification (ICU Scores), Complications & Iatrogenesis
[232]
Ding R, Su R, Deng Y et al.. “Association between endothelial activation and stress index and mortality in critically ill patients with diabetes mellitus: a retrospective cohort study.” BMC endocrine disorders (2026). PMID: 42092874 ↗
L3COHORTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Special Populations
[233]
Jaiswal V, Krishnareddy K, Nihalani S et al.. “Comparison of serial pancreatic stone protein, C-reactive protein and procalcitonin for the diagnosis of infection and sepsis in critically Ill patients: a multicentre prospective study.” BMC anesthesiology (2026). PMID: 42069535 ↗
L2COHORTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Severity Scoring & Risk Stratification (ICU Scores)
[234]
Li J, Deng Y, Huang Y et al.. “Association of Shenfu injection with reduced 28-day mortality in critically ill patients with sepsis: a retrospective propensity score-matched cohort study.” BMC infectious diseases (2026). PMID: 41673625 ↗
L3COHORTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[235]
Molano Franco D, Arevalo-Rodriguez I, Roqué I Figuls M et al.. “Plasma interleukin-6 concentration for the diagnosis of sepsis in critically ill adults.” The Cochrane database of systematic reviews (2019). PMID: 31038735 ↗
L2SR_OBSCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[236]
Kuriyama A, Heels-Ansdell D, Fernando SM et al.. “Pantoprazole Use in Invasively Ventilated Patients With Septic Shock: A Protocol and Statistical Analysis Plan.” Acta anaesthesiologica Scandinavica (2026). PMID: 42186360 ↗
L5TRIAL_NONRANDOMCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[237]
Latronico N, Rasulo FA, Eikermann M et al.. “Illness Weakness, Polyneuropathy and Myopathy: Diagnosis, treatment, and long-term outcomes.” Critical care (London, England) (2023). PMID: 37957759 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First), History and Evolution of Treatment, De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS), Prevention, Screening and Post-ICU Surveillance
[238]
Barichello T, Generoso JS, Singer M et al.. “Biomarkers for sepsis: more than just fever and leukocytosis-a narrative review.” Critical care (London, England) (2022). PMID: 34991675 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[239]
Nates JL, Pène F, Darmon M et al.. “Septic shock in the immunocompromised cancer patient: a narrative review.” Critical care (London, England) (2024). PMID: 39215292 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[240]
Bitar R, Khan UM, Rosenthal ES. “Utility and rationale for continuous EEG monitoring: a primer for the general intensivist.” Critical care (London, England) (2024). PMID: 39014421 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Complications & Iatrogenesis
[241]
White KC, Costa-Pinto R, Blank S et al.. “Effect of early adjunctive vasopressin initiation for septic shock patients: a target trial emulation.” Critical care (London, England) (2025). PMID: 40355911 ↗
L2OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First), Acute Resuscitation & Time-Critical Management, Special Populations
[242]
Cai S, Li X, Zhang C et al.. “Inhibition of Interleukin-40 prevents multi-organ damage during sepsis by blocking NETosis.” Critical care (London, England) (2025). PMID: 39819454 ↗
L2OTHERCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[243]
Candel FJ, Salavert M, Cantón R et al.. “The role of rapid multiplex molecular syndromic panels in the clinical management of infections in critically ill patients: an experts-opinion document.” Critical care (London, England) (2024). PMID: 39736683 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[244]
Jiang H, Xie Z, Xiang J et al.. “Diagnostic Value of End-Tidal Carbon Dioxide Combined With Lactate for Early Detection of Sepsis in Prehospital Patients: A Prospective Cohort Study.” Medical science monitor : international medical journal of experimental and clinical research (2026). PMID: 41973647 ↗
L2COHORTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[245]
De Silva S, Charles-Nelson A, McQuilten Z et al.. “The association between a sepsis diagnosis, demographic factors, and health-related quality of life in survivors at 180 days following critical illness.” Australian critical care : official journal of the Confederation of Australian Critical Care Nurses (2026). PMID: 42139834 ↗
L2RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[246]
van de Sand L, Dubler S, Bertram S et al.. “Landouzy sepsis in a young adult with multiorgan failure: successful ECMO-assisted management using an individualized antituberculous regimen.” BMC infectious diseases (2026). PMID: 41987072 ↗
L4CASE_REPORTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[247]
Huang P, He SS, Feng S et al.. “Efficacy and Safety of Shenfu Injection in Patients with Septic Shock: A Randomized Controlled Open-Label Trial with Network Pharmacology-Based Mechanistic Insights.” Chinese journal of integrative medicine (2026). PMID: 41870792 ↗
L1RCTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[248]
Dahiya A, Goel S, Saha A et al.. “Transient antenatal Bartter syndrome type 5 presenting as shock and metabolic acidosis in a preterm neonate.” Pediatric nephrology (Berlin, Germany) (2026). PMID: 41711945 ↗
L4CASE_REPORTCited in: Diagnosis & Workup (Hemodynamic & Bedside-First)
[249]
Monti G, Carta S, Kotani Y et al.. “A Multinational Randomized Trial of Mega-Dose Esomeprazole as Anti-Inflammatory Agent in Sepsis.” Critical care medicine (2025). PMID: 40439536 ↗
L1RCTCited in: Severity Scoring & Risk Stratification (ICU Scores), Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Special Populations
[250]
Almeida TML, Freitas FGR, Figueiredo RC et al.. “Acetylsalicylic Acid Treatment in Patients With Sepsis and Septic Shock: A Phase 2, Placebo-Controlled, Randomized Clinical Trial.” Critical care medicine (2025). PMID: 39982179 ↗
L1RCTCited in: Severity Scoring & Risk Stratification (ICU Scores), Definitive Therapy & Source Control of the Inciting Insult
[251]
Freund Y, Cancella de Abreu M, Lebal S et al.. “Effect of the 1-h bundle on mortality in patients with suspected sepsis in the emergency department: a stepped wedge cluster randomized clinical trial.” Intensive care medicine (2024). PMID: 38913098 ↗
L1RCTCited in: Severity Scoring & Risk Stratification (ICU Scores), Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
[252]
Oeyen SG, Vandijck DM, Benoit DD et al.. “Quality of life after intensive care: a systematic review of the literature.” Critical care medicine (2010). PMID: 20838335 ↗
L2SR_OBSCited in: Severity Scoring & Risk Stratification (ICU Scores), Complications & Iatrogenesis
[253]
Tran A, Fernando SM, Rochwerg B et al.. “Prognostic Factors Associated With Development of Venous Thromboembolism in Critically Ill Patients-A Systematic Review and Meta-Analysis.” Critical care medicine (2022). PMID: 34636806 ↗
L1SR_OBSCited in: Severity Scoring & Risk Stratification (ICU Scores), Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation), Prevention, Screening and Post-ICU Surveillance
[254]
Busch LM, Sun J, Eichacker PQ et al.. “Inhibitory Immune Checkpoint Molecule Expression in Clinical Sepsis Studies: A Systematic Review.” Critical care medicine (2020). PMID: 32706554 ↗
L2SR_OBSCited in: Severity Scoring & Risk Stratification (ICU Scores)
[255]
Stevens RD, Dowdy DW, Michaels RK et al.. “Neuromuscular dysfunction acquired in critical illness: a systematic review.” Intensive care medicine (2007). PMID: 17639340 ↗
L2SR_OBSCited in: Severity Scoring & Risk Stratification (ICU Scores)
[256]
Søvik S, Isachsen MS, Nordhuus KM et al.. “Acute kidney injury in trauma patients admitted to the ICU: a systematic review and meta-analysis.” Intensive care medicine (2019). PMID: 30725141 ↗
L1SR_OBSCited in: Severity Scoring & Risk Stratification (ICU Scores)
[257]
Jabre P, Combes X, Lapostolle F et al.. “Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial.” Lancet (London, England) (2009). PMID: 19573904 ↗
L1RCTCited in: Severity Scoring & Risk Stratification (ICU Scores), Definitive Therapy & Source Control of the Inciting Insult, Special Populations
[258]
Ng PY, Ng AK, Ip A et al.. “Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study.” Critical care medicine (2023). PMID: 37026864 ↗
L2COHORTCited in: Severity Scoring & Risk Stratification (ICU Scores)
[259]
Peters-Sengers H, Butler JM, Uhel F et al.. “Source-specific host response and outcomes in critically ill patients with sepsis: a prospective cohort study.” Intensive care medicine (2021). PMID: 34902047 ↗
L2COHORTCited in: Severity Scoring & Risk Stratification (ICU Scores)
[260]
Higgins AM, Neto AS, Bailey M et al.. “Predictors of death and new disability after critical illness: a multicentre prospective cohort study.” Intensive care medicine (2021). PMID: 34089063 ↗
L2COHORTCited in: Severity Scoring & Risk Stratification (ICU Scores)
[261]
Timsit JF, Schwebel C, Styfalova L et al.. “Impact of bronchial colonization with Candida spp. on the risk of bacterial ventilator-associated pneumonia in the ICU: the FUNGIBACT prospective cohort study.” Intensive care medicine (2019). PMID: 31020361 ↗
L2COHORTCited in: Severity Scoring & Risk Stratification (ICU Scores), Complications & Iatrogenesis
[262]
de Grooth HJ, Geenen IL, Girbes AR et al.. “SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis.” Critical care (London, England) (2017). PMID: 28231816 ↗
L1SR_MA_RCTCited in: Severity Scoring & Risk Stratification (ICU Scores)
[263]
Ortiz-Reyes L, Patel JJ, Jiang X et al.. “Early versus delayed enteral nutrition in mechanically ventilated patients with circulatory shock: a nested cohort analysis of an international multicenter, pragmatic clinical trial.” Critical care (London, England) (2022). PMID: 35681220 ↗
L2RCTCited in: Severity Scoring & Risk Stratification (ICU Scores), Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[264]
Vandervelden S, Cortens B, Fieuws S et al.. “Early administration of vitamin C in patients with sepsis or septic shock in emergency departments: a multicenter, double-blind, randomized controlled trial: the C-EASIE trial.” Critical care (London, England) (2025). PMID: 40269974 ↗
L1RCTCited in: Severity Scoring & Risk Stratification (ICU Scores), Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
[265]
Morgan RW, Reeder RW, Carcillo JA et al.. “Outcomes, Characteristics, and Physiology of In-Hospital Cardiac Arrest in Children With Sepsis.” Critical care medicine (2025). PMID: 40558671 ↗
L2OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
[266]
Stanski NL, Zhang B, Ouyang J et al.. “External Validation, Molecular Signatures, and Therapeutic Relevance of Pediatric Sepsis-Associated Acute Kidney Injury Subphenotypes.” Critical care medicine (2026). PMID: 42159375 ↗
L2OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
[267]
Sonneville R, de Montmollin E, Poujade J et al.. “Potentially modifiable factors contributing to sepsis-associated encephalopathy.” Intensive care medicine (2017). PMID: 28466149 ↗
L2OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores), De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[268]
Halvorsen P, Marks-Hultström M, Wallin E et al.. “Health-related quality of life and functional recovery after intensive care for sepsis in a national cohort.” Intensive care medicine (2025). PMID: 40549021 ↗
L2OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
[269]
Zhu H, Li P, Wang B et al.. “Impact of the updated SOFA-2 score on sepsis diagnosis and prognosis: a retrospective multicenter cohort study.” Critical care (London, England) (2026). PMID: 42092945 ↗
L2COHORTCited in: Severity Scoring & Risk Stratification (ICU Scores), Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation), Special Populations
[270]
Wei S, Wang T, Li C et al.. “SOFA-2 score predicts mortality in pneumonia-associated sepsis: a retrospective cohort study.” Critical care (London, England) (2026). PMID: 42045961 ↗
L2COHORTCited in: Severity Scoring & Risk Stratification (ICU Scores), Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[271]
Goligher EC, Dres M, Fan E et al.. “Mechanical Ventilation-induced Diaphragm Atrophy Strongly Impacts Clinical Outcomes.” American journal of respiratory and critical care medicine (2018). PMID: 28930478 ↗
L2OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores), Special Populations
[272]
Brummel NE, Bell SP, Girard TD et al.. “Frailty and Subsequent Disability and Mortality among Patients with Critical Illness.” American journal of respiratory and critical care medicine (2017). PMID: 27922747 ↗
L2OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores), Special Populations
[273]
Li A, Ling L, Qin H et al.. “Epidemiology, Management, and Outcomes of Sepsis in ICUs among Countries of Differing National Wealth across Asia.” American journal of respiratory and critical care medicine (2022). PMID: 35763381 ↗
L2OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
[274]
Miller RR, Dong L, Nelson NC et al.. “Multicenter implementation of a severe sepsis and septic shock treatment bundle.” American journal of respiratory and critical care medicine (2013). PMID: 23631750 ↗
L2OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
[275]
Ginestra JC, Coz Yataco AO, Dugar SP et al.. “Hospital-Onset Sepsis Warrants Expanded Investigation and Consideration as a Unique Clinical Entity.” Chest (2024). PMID: 38246522 ↗
L5REVIEW_NARRATIVECited in: Severity Scoring & Risk Stratification (ICU Scores)
[276]
de Wit M, Jones DG, Sessler CN et al.. “Alcohol-use disorders in the critically ill patient.” Chest (2010). PMID: 20923804 ↗
L5REVIEW_NARRATIVECited in: Severity Scoring & Risk Stratification (ICU Scores)
[277]
Que YA, Guessous I, Dupuis-Lozeron E et al.. “Prognostication of Mortality in Critically Ill Patients With Severe Infections.” Chest (2015). PMID: 26065577 ↗
L2OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
[278]
Williams LS, Walker GR, Loewenherz JW et al.. “Association of Contrast and Acute Kidney Injury in the Critically Ill: A Propensity-Matched Study.” Chest (2019). PMID: 31669231 ↗
L3OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
[279]
Sevransky JE, Martin GS, Mendez-Tellez P et al.. “Pulmonary vs nonpulmonary sepsis and mortality in acute lung injury.” Chest (2008). PMID: 18641112 ↗
L2OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
[280]
Katz JN, Kolappa KP, Becker RC. “Beyond thrombosis: the versatile platelet in critical illness.” Chest (2011). PMID: 21362652 ↗
L5OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
[281]
Vasquez DN, Estenssoro E, Canales HS et al.. “Clinical characteristics and outcomes of obstetric patients requiring ICU admission.” Chest (2007). PMID: 17356085 ↗
L3OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
[282]
Kalimouttou A, Kennedy JN, Feng J et al.. “Optimal Vasopressin Initiation in Septic Shock: The OVISS Reinforcement Learning Study.” JAMA (2025). PMID: 40098600 ↗
L3OTHERCited in: Severity Scoring & Risk Stratification (ICU Scores)
[283]
Huang S, Yu S, Pan B et al.. “Clinical characteristics and 28-day outcomes of sepsis associated with klebsiella pneumoniae carbapenemase-producing Enterobacterales: a single-center retrospective cohort study.” BMC infectious diseases (2026). PMID: 42104317 ↗
L3COHORTCited in: Severity Scoring & Risk Stratification (ICU Scores), Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation), Special Populations
[284]
Liufu R, Fu XY, Shi XQ et al.. “Performance of sequential organ failure assessment 1 versus 2 for sepsis identification in patients with suspected infection: a multicenter retrospective cohort study.” Critical care (London, England) (2026). PMID: 42036712 ↗
L3COHORTCited in: Severity Scoring & Risk Stratification (ICU Scores)
[285]
Hu L, Chen X, Huang X et al.. “The CD4/CD8 ratio as an immune phenotype improves risk stratification for sepsis-associated acute kidney injury: A single-center, multi-ICU Chinese cohort study.” Journal of critical care (2026). PMID: 41985267 ↗
L3COHORTCited in: Severity Scoring & Risk Stratification (ICU Scores)
[286]
Do DK, Rockenschaub P, Boie SD et al.. “The Impact of Evaluation Strategy on Sepsis Prediction Model Performance Metrics in Intensive Care Data: Retrospective Cohort Study.” Journal of medical Internet research (2026). PMID: 41874553 ↗
L3COHORTCited in: Severity Scoring & Risk Stratification (ICU Scores)
[287]
Allingstrup M, Wetterslev J, Ravn FB et al.. “Antithrombin III for critically ill patients.” The Cochrane database of systematic reviews (2016). PMID: 26858174 ↗
L1SR_OBSCited in: Severity Scoring & Risk Stratification (ICU Scores)
[288]
Arabi YM, Belley-Cote E, Carsetti A et al.. “European Society of Intensive Care Medicine clinical practice guideline on fluid therapy in adult critically ill patients. Part 1: the choice of resuscitation fluids.” Intensive care medicine (2024). PMID: 38771364 ↗
L1GUIDELINECited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[289]
Mekontso Dessap A, AlShamsi F, Belletti A et al.. “European Society of Intensive Care Medicine (ESICM) 2025 clinical practice guideline on fluid therapy in adult critically ill patients: part 2-the volume of resuscitation fluids.” Intensive care medicine (2025). PMID: 40163133 ↗
L1GUIDELINECited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[290]
Gelbenegger G, Shapiro NI, Zeitlinger M et al.. “Lactated Ringer's or Normal Saline for Initial Fluid Resuscitation in Sepsis-Induced Hypotension.” Critical care medicine (2025). PMID: 39969246 ↗
L2RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[291]
Gray AJ, Oatey K, Grahamslaw J et al.. “Albumin Versus Balanced Crystalloid for the Early Resuscitation of Sepsis: An Open Parallel-Group Randomized Feasibility Trial- The ABC-Sepsis Trial.” Critical care medicine (2024). PMID: 38912884 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[292]
Rehberg S, Frank S, Černý V et al.. “Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP).” Intensive care medicine (2024). PMID: 39297945 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[293]
Bhavani SV, Semler M, Qian ET et al.. “Development and validation of novel sepsis subphenotypes using trajectories of vital signs.” Intensive care medicine (2022). PMID: 36152041 ↗
L3RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[294]
Jorda A, Gelbenegger G, Shapiro NI et al.. “Effects of an early restrictive versus liberal fluid strategy on long-term patient-centered outcomes in sepsis-induced hypotension: an open-label, randomized controlled trial.” American journal of respiratory and critical care medicine (2026). PMID: 42093058 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management
[295]
Kiernan E, Zelnick LR, Khader A et al.. “Molecular Phenotyping of Sepsis and Differential Response to Fluid Resuscitation.” American journal of respiratory and critical care medicine (2025). PMID: 40668865 ↗
L2RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[296]
Gattinoni L, Vasques F, Camporota L et al.. “Understanding Lactatemia in Human Sepsis. Potential Impact for Early Management.” American journal of respiratory and critical care medicine (2019). PMID: 30985210 ↗
L2RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[297]
Antcliffe DB, Burnham KL, Al-Beidh F et al.. “Transcriptomic Signatures in Sepsis and a Differential Response to Steroids. From the VANISH Randomized Trial.” American journal of respiratory and critical care medicine (2019). PMID: 30365341 ↗
L2RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[298]
Moskowitz A, Berg KM, Grossestreuer AV et al.. “Thiamine for Renal Protection in Septic Shock (TRPSS): A Randomized, Placebo-controlled, Clinical Trial.” American journal of respiratory and critical care medicine (2023). PMID: 37364280 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management
[299]
Zampieri FG, Machado FR, Biondi RS et al.. “Association between Type of Fluid Received Prior to Enrollment, Type of Admission, and Effect of Balanced Crystalloid in Critically Ill Adults: A Secondary Exploratory Analysis of the BaSICS Clinical Trial.” American journal of respiratory and critical care medicine (2022). PMID: 35349397 ↗
L2RCTCited in: Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult
[300]
Douglas IS, Alapat PM, Corl KA et al.. “Fluid Response Evaluation in Sepsis Hypotension and Shock: A Randomized Clinical Trial.” Chest (2020). PMID: 32353418 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[301]
Ezz Al-Regal AR, Ramzy EA, Atia AAA et al.. “Dexmedetomidine for Reducing Mortality in Patients With Septic Shock: A Randomized Controlled Trial (DecatSepsis).” Chest (2024). PMID: 39004217 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[302]
Sehgal IS, Basumatary NM, Dhooria S et al.. “A Randomized Trial of Mycobacterium w in Severe Presumed Gram-Negative Sepsis.” Chest (2021). PMID: 33852919 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[303]
Lissauer D, Gadama L, Waitt C et al.. “A Multicomponent Intervention to Improve Maternal Infection Outcomes.” The New England journal of medicine (2025). PMID: 41259754 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management
[304]
Shapiro NI, Douglas IS, Brower RG et al.. “Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension.” The New England journal of medicine (2023). PMID: 36688507 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[305]
Asfar P, Meziani F, Hamel JF et al.. “High versus low blood-pressure target in patients with septic shock.” The New England journal of medicine (2014). PMID: 24635770 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[306]
Sprung CL, Annane D, Keh D et al.. “Hydrocortisone therapy for patients with septic shock.” The New England journal of medicine (2008). PMID: 18184957 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[307]
Perner A, Haase N, Guttormsen AB et al.. “Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis.” The New England journal of medicine (2012). PMID: 22738085 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[308]
Gendreau S, Frapard T, Carteaux G et al.. “Geo-economic Influence on the Effect of Fluid Volume for Sepsis Resuscitation: A Meta-Analysis.” American journal of respiratory and critical care medicine (2024). PMID: 38259196 ↗
L1SR_OBSCited in: Acute Resuscitation & Time-Critical Management
[309]
Holcomb JB, Tilley BC, Baraniuk S et al.. “Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial.” JAMA (2015). PMID: 25647203 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[310]
Arabi YM, Alsaawi A, Alzahrani M et al.. “Electronic Sepsis Screening Among Patients Admitted to Hospital Wards: A Stepped-Wedge Cluster Randomized Trial.” JAMA (2025). PMID: 39658862 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[311]
Karalapillai D, Weinberg L, Peyton P et al.. “Effect of Intraoperative Low Tidal Volume vs Conventional Tidal Volume on Postoperative Pulmonary Complications in Patients Undergoing Major Surgery: A Randomized Clinical Trial.” JAMA (2020). PMID: 32870298 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[312]
Cruz DN, Antonelli M, Fumagalli R et al.. “Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial.” JAMA (2009). PMID: 19531784 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[313]
Ahn C, Yu G, Shin TG et al.. “Comparison of Early and Late Norepinephrine Administration in Patients With Septic Shock: A Systematic Review and Meta-Analysis.” Chest (2024). PMID: 38972348 ↗
L1SR_OBSCited in: Acute Resuscitation & Time-Critical Management
[314]
Ibarra-Estrada M, Kattan E, Aguilera-González P et al.. “Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial.” Critical care (London, England) (2023). PMID: 36915146 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[315]
Jorda A, Douglas IS, Staudinger T et al.. “Fluid management for sepsis-induced hypotension in patients with advanced chronic kidney disease: a secondary analysis of the CLOVERS trial.” Critical care (London, England) (2024). PMID: 38992663 ↗
L2RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[316]
Yanase F, Spano S, Maeda A et al.. “Mega-dose sodium ascorbate: a pilot, single-dose, physiological effect, double-blind, randomized, controlled trial.” Critical care (London, England) (2023). PMID: 37828547 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management
[317]
Davis AL, Carcillo JA, Aneja RK et al.. “American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock.” Critical care medicine (2017). PMID: 28509730 ↗
L1OTHERCited in: Acute Resuscitation & Time-Critical Management
[318]
Ferrer R, Martin-Loeches I, Phillips G et al.. “Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program.” Critical care medicine (2014). PMID: 24717459 ↗
L3OTHERCited in: Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult
[319]
Kuttab HI, Lykins JD, Hughes MD et al.. “Evaluation and Predictors of Fluid Resuscitation in Patients With Severe Sepsis and Septic Shock.” Critical care medicine (2019). PMID: 31393324 ↗
L3OTHERCited in: Acute Resuscitation & Time-Critical Management
[320]
Bakker J, Kattan E, Annane D et al.. “Current practice and evolving concepts in septic shock resuscitation.” Intensive care medicine (2021). PMID: 34910228 ↗
L5REVIEW_NARRATIVECited in: Acute Resuscitation & Time-Critical Management
[321]
Im Y, Kang D, Ko RE et al.. “Time-to-antibiotics and clinical outcomes in patients with sepsis and septic shock: a prospective nationwide multicenter cohort study.” Critical care (London, England) (2022). PMID: 35027073 ↗
L2COHORTCited in: Acute Resuscitation & Time-Critical Management
[322]
Munroe ES, Hyzy RC, Semler MW et al.. “Evolving Management Practices for Early Sepsis-induced Hypoperfusion: A Narrative Review.” American journal of respiratory and critical care medicine (2023). PMID: 36812500 ↗
L5REVIEW_NARRATIVECited in: Acute Resuscitation & Time-Critical Management
[323]
Byrne L, Obonyo NG, Diab SD et al.. “Unintended Consequences: Fluid Resuscitation Worsens Shock in an Ovine Model of Endotoxemia.” American journal of respiratory and critical care medicine (2018). PMID: 29882682 ↗
L5OTHERCited in: Acute Resuscitation & Time-Critical Management
[324]
Yealy DM, Kellum JA, Huang DT et al.. “A randomized trial of protocol-based care for early septic shock.” The New England journal of medicine (2014). PMID: 24635773 ↗
L1OTHERCited in: Acute Resuscitation & Time-Critical Management
[325]
Boussina A, Allison C, Quintero K et al.. “Medical Record Abstraction for Quality Improvement in Sepsis Care Using Artificial Intelligence: A Cluster Randomized Trial.” JAMA network open (2026). PMID: 42348212 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment
[326]
Chen X, Wen W, Zheng L. “Impact of Oxygen Targets on Sepsis Outcome: A Randomized Controlled Trial.” Shock (Augusta, Ga.) (2026). PMID: 42337386 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[327]
Mehrotra H, Bhattacharjee S, Datta SK et al.. “Endothelium Protective Effect of 5% Human Albumin-Based Fluid Therapy in Perforation Peritonitis Patients Undergoing Emergency Laparotomy: A Randomized Controlled Trial.” The Journal of surgical research (2026). PMID: 42172925 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management
[328]
Cavallin F, Doglioni N, Risso FM et al.. “Drying Very Preterm Infants Before Plastic Wrapping at Birth: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 41774445 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult
[329]
Hilderink BN, van den Brink DP, Kleinveld DJB et al.. “The effect of plasma versus crystalloids on intravascular volume, tissue perfusion and tissue oxygenation: a randomized controlled trial in a human endotoxemia model.” Critical care (London, England) (2026). PMID: 41736143 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management
[330]
Lotz C, Heckelmann J, Lendzian C et al.. “Clinical and Immunologic Effects of Extracorporeal Cytokine Removal in Patients with Septic Shock: A Randomized Controlled Trial.” Shock (Augusta, Ga.) (2026). PMID: 41670614 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management
[331]
Oshima K, Yan B, Tao R et al.. “Plasma chondroitin sulfate predicts the effectiveness of fluid resuscitation strategies in patients with sepsis.” The Journal of clinical investigation (2026). PMID: 41632536 ↗
L2RCTCited in: Acute Resuscitation & Time-Critical Management
[332]
Huo Y, Liu MZ, Zhu RY et al.. “Impact of renal vein doppler ultrasound-guided CVP titration in sepsis: a pilot randomized controlled trial.” Critical care (London, England) (2026). PMID: 41580843 ↗
L1RCTCited in: Acute Resuscitation & Time-Critical Management, Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[333]
Luo JC, Mou T, Li M et al.. “Recombinant human brain natriuretic peptide for the recovery stage of septic shock: an interventional study protocol.” BMJ open (2026). PMID: 42192636 ↗
L4TRIAL_NONRANDOMCited in: Acute Resuscitation & Time-Critical Management
[334]
Li D, Li X, Cui W et al.. “Liberal versus conservative fluid therapy in adults and children with sepsis or septic shock.” The Cochrane database of systematic reviews (2018). PMID: 30536956 ↗
L1SR_OBSCited in: Acute Resuscitation & Time-Critical Management
[335]
Monnet X, Lai C, Teboul JL. “How I personalize fluid therapy in septic shock?” Critical care (London, England) (2023). PMID: 36964573 ↗
L5REVIEW_NARRATIVECited in: Acute Resuscitation & Time-Critical Management
[336]
Iapichino G, Albicini M, Umbrello M et al.. “Tight glycemic control does not affect asymmetric-dimethylarginine in septic patients.” Intensive care medicine (2008). PMID: 18504551 ↗
L1SR_MA_RCTCited in: Definitive Therapy & Source Control of the Inciting Insult
[337]
Iten M, Bachmann K, Jakob SM et al.. “Adjunctive Sedation with Dexmedetomidine for the Prevention of Severe Inflammation and Septic Encephalopathy: A Pilot Randomized Controlled Study.” Critical care medicine (2025). PMID: 40162868 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Special Populations
[338]
Shah S, Kaul A, Shiwarkar G et al.. “Fifth Centile Versus 50th Centile Mean Blood Pressure Targets in Pediatric Septic Shock: A Randomized Controlled Trial.” Critical care medicine (2025). PMID: 40511998 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[339]
Guirgis FW, Black LP, Henson M et al.. “The Lipid Intensive Drug Therapy for Sepsis Phase II Pilot Clinical Trial.” Critical care medicine (2024). PMID: 38488429 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult
[340]
Abdul-Aziz MH, Sulaiman H, Mat-Nor MB et al.. “Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.” Intensive care medicine (2016). PMID: 26754759 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[341]
Kruger P, Bailey M, Bellomo R et al.. “A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis.” American journal of respiratory and critical care medicine (2013). PMID: 23348980 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult
[342]
Souweine B, Lautrette A, Gruson D et al.. “Ethanol lock and risk of hemodialysis catheter infection in critically ill patients. A randomized controlled trial.” American journal of respiratory and critical care medicine (2015). PMID: 25668557 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[343]
Shehabi Y, Sterba M, Garrett PM et al.. “Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial.” American journal of respiratory and critical care medicine (2014). PMID: 25295709 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult
[344]
Nobre V, Harbarth S, Graf JD et al.. “Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial.” American journal of respiratory and critical care medicine (2007). PMID: 18096708 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult
[345]
Jackson KE, Wang L, Casey JD et al.. “Effect of Early Balanced Crystalloids Before ICU Admission on Sepsis Outcomes.” Chest (2020). PMID: 32882244 ↗
L2RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, Special Populations
[346]
Iankova I, Thompson-Leduc P, Kirson NY et al.. “Efficacy and Safety of Procalcitonin Guidance in Patients With Suspected or Confirmed Sepsis: A Systematic Review and Meta-Analysis.” Critical care medicine (2018). PMID: 29271844 ↗
L1SR_OBSCited in: Definitive Therapy & Source Control of the Inciting Insult
[347]
Kumar A, Safdar N, Kethireddy S et al.. “A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study.” Critical care medicine (2010). PMID: 20562695 ↗
L2SR_OBSCited in: Definitive Therapy & Source Control of the Inciting Insult
[348]
Hughes CG, Mailloux PT, Devlin JW et al.. “Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis.” The New England journal of medicine (2021). PMID: 33528922 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[349]
Dorling J, Abbott J, Berrington J et al.. “Controlled Trial of Two Incremental Milk-Feeding Rates in Preterm Infants.” The New England journal of medicine (2019). PMID: 31597020 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult
[350]
Fowler AA, Truwit JD, Hite RD et al.. “Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial.” JAMA (2019). PMID: 31573637 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, Special Populations
[351]
Hernández G, Vaquero C, González P et al.. “Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical Trial.” JAMA (2016). PMID: 26975498 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[352]
Greer DM, Helbok R, Badjatia N et al.. “Fever Prevention in Patients With Acute Vascular Brain Injury: The INTREPID Randomized Clinical Trial.” JAMA (2024). PMID: 39320879 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, Complications & Iatrogenesis, Special Populations
[353]
Martin-Loeches I, Reyes LF, Nseir S et al.. “European Network for ICU-Related Respiratory Infections (ENIRRIs): a multinational, prospective, cohort study of nosocomial LRTI.” Intensive care medicine (2023). PMID: 37812242 ↗
L2COHORTCited in: Definitive Therapy & Source Control of the Inciting Insult, Complications & Iatrogenesis
[354]
De Bruyn L, Téblick A, Van Oudenhove T et al.. “Glucocorticoid treatment increases cholesterol availability during critical illness: effect on adrenal and muscle function.” Critical care (London, England) (2024). PMID: 39238038 ↗
L2RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, Special Populations
[355]
Shimizu K, Yamada T, Ogura H et al.. “Synbiotics modulate gut microbiota and reduce enteritis and ventilator-associated pneumonia in patients with sepsis: a randomized controlled trial.” Critical care (London, England) (2018). PMID: 30261905 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, Complications & Iatrogenesis
[356]
Chappell MC, Schaich CL, Busse LW et al.. “Stronger association of intact angiotensinogen with mortality than lactate or renin in critical illness: post-hoc analysis from the VICTAS trial.” Critical care (London, England) (2024). PMID: 39402593 ↗
L2RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[357]
Roggeveen LF, Guo T, Fleuren LM et al.. “Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trial.” Critical care (London, England) (2022). PMID: 36064438 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult
[358]
Van Nynatten LR, Bokhary D, Wong MYS et al.. “Predictive enrichment using biomarkers in studies of critically-ill patients with sepsis: a systematic review.” Critical care (London, England) (2025). PMID: 41310736 ↗
L2SR_OBSCited in: Definitive Therapy & Source Control of the Inciting Insult
[359]
Prkno A, Wacker C, Brunkhorst FM et al.. “Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock--a systematic review and meta-analysis.” Critical care (London, England) (2013). PMID: 24330744 ↗
L1SR_OBSCited in: Definitive Therapy & Source Control of the Inciting Insult
[360]
Villa G, Di Maggio P, De Gaudio AR et al.. “Effects of continuous renal replacement therapy on linezolid pharmacokinetic/pharmacodynamics: a systematic review.” Critical care (London, England) (2016). PMID: 27863531 ↗
L2SR_OBSCited in: Definitive Therapy & Source Control of the Inciting Insult
[361]
Abdul-Aziz MH, Alffenaar JC, Bassetti M et al.. “Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.” Intensive care medicine (2020). PMID: 32383061 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy & Source Control of the Inciting Insult
[362]
Kreitmann L, Helms J, Martin-Loeches I et al.. “ICU-acquired infections in immunocompromised patients.” Intensive care medicine (2024). PMID: 38197931 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy & Source Control of the Inciting Insult, Complications & Iatrogenesis, Special Populations
[363]
Timsit JF, Bassetti M, Cremer O et al.. “Rationalizing antimicrobial therapy in the ICU: a narrative review.” Intensive care medicine (2019). PMID: 30659311 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy & Source Control of the Inciting Insult
[364]
Martin FP, Poulain C, Mulier JH et al.. “Identification and validation of robust hospital-acquired pneumonia subphenotypes associated with all-cause mortality: a multi-cohort derivation and validation.” Intensive care medicine (2025). PMID: 40261385 ↗
L2OTHERCited in: Definitive Therapy & Source Control of the Inciting Insult, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[365]
Quintin J, Le Thuaut A, Plouvier F et al.. “Characteristics and outcomes of ICU patients with sepsis transmitted by cats and dogs: the PETSEPSIS multicentre retrospective observational cohort study.” Critical care (London, England) (2025). PMID: 40696484 ↗
L2COHORTCited in: Definitive Therapy & Source Control of the Inciting Insult
[366]
Hammond NE, Kumar A, Kaur P et al.. “Estimates of Sepsis Prevalence and Outcomes in Adult Patients in the ICU in India: A Cross-sectional Study.” Chest (2022). PMID: 35092747 ↗
L2OTHERCited in: Definitive Therapy & Source Control of the Inciting Insult
[367]
Faust K, Strecker F, Haug C et al.. “Extended Barrier Precautions vs Hand Hygiene Alone and Neonatal Sepsis in Intensive Care Patients: The BALTIC Cluster-Randomized Clinical Trial.” JAMA network open (2026). PMID: 42138920 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult
[368]
Standl L, Huber T, Bloos F et al.. “Diagnostic performance of β-(1→3)-D-glucan, two Candida antigen, and five anti-Candida antibody assays in ICU patients with sepsis and high risk for invasive candidiasis: a secondary endpoint of the CandiSep randomized clinical trial.” Journal of clinical microbiology (2026). PMID: 42023876 ↗
L2RCTCited in: Definitive Therapy & Source Control of the Inciting Insult
[369]
Jain A, Agarwal N, Anand R et al.. “7-days versus 14-days antibiotic therapy in uncomplicated culture proven neonatal sepsis: a randomized control assessor-blinded trial.” European journal of pediatrics (2026). PMID: 41984236 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult
[370]
Wu Y, Liu S, Shi C et al.. “Continuous versus intermittent vancomycin infusions in critically ill children with gram-positive bacterial infections: a randomized controlled trial.” BMC infectious diseases (2026). PMID: 41715039 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult
[371]
Meng L, Liu J, Wang P et al.. “Risk factors of sepsis-associated encephalopathy in sepsis patients with pulmonary infection: from the secondary analysis of a cluster-randomized controlled trial.” Respiratory medicine (2026). PMID: 41570945 ↗
L2RCTCited in: Definitive Therapy & Source Control of the Inciting Insult, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[372]
Jamali Z, Molaei-Farsangi MH, Ahmadipour H et al.. “Comparison of the effect of surfactant with and without budesonide on the outcomes of respiratory distress syndrome (RDS) in premature infants: a randomized control trial.” BMC pregnancy and childbirth (2025). PMID: 41469593 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult
[373]
Farzanegan B, Shafigh N, Hasheminik M et al.. “The combined effect of statin and vitamin C in patients with pulmonary septic shock: a single-center, double-blind clinical trial.” BMC infectious diseases (2025). PMID: 41136950 ↗
L1RCTCited in: Definitive Therapy & Source Control of the Inciting Insult
[374]
Kollef MH, Shorr AF, Bassetti M et al.. “Timing of antibiotic therapy in the ICU.” Critical care (London, England) (2021). PMID: 34654462 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy & Source Control of the Inciting Insult
[375]
Zaragoza R, Vidal-Cortés P, Aguilar G et al.. “Update of the treatment of nosocomial pneumonia in the ICU.” Critical care (London, England) (2020). PMID: 32600375 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy & Source Control of the Inciting Insult, Complications & Iatrogenesis
[376]
Dellinger RP, Carlet JM, Masur H et al.. “Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.” Critical care medicine (2004). PMID: 15090974 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[377]
Fan E, Cheek F, Chlan L et al.. “An official American Thoracic Society Clinical Practice guideline: the diagnosis of intensive care unit-acquired weakness in adults.” American journal of respiratory and critical care medicine (2014). PMID: 25496103 ↗
L1GUIDELINECited in: History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[378]
Callum J, Skubas NJ, Bathla A et al.. “Use of Intravenous Albumin: A Guideline From the International Collaboration for Transfusion Medicine Guidelines.” Chest (2024). PMID: 38447639 ↗
L1GUIDELINECited in: History and Evolution of Treatment, Complications & Iatrogenesis
[379]
Wang J, Tong Z, Wang X et al.. “Time Course of Morbidity and Mortality Across Echocardiographic Phenotypes in Patients With Sepsis: A Systematic Review and Meta-Analysis.” Critical care medicine (2025). PMID: 40853197 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[380]
Shakoory B, Carcillo JA, Chatham WW et al.. “Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.” Critical care medicine (2016). PMID: 26584195 ↗
L2RCTCited in: History and Evolution of Treatment
[381]
Hernández G, Paredes I, Moran F et al.. “Effect of postextubation noninvasive ventilation with active humidification vs high-flow nasal cannula on reintubation in patients at very high risk for extubation failure: a randomized trial.” Intensive care medicine (2022). PMID: 36400984 ↗
L1RCTCited in: History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[382]
Hagel S, Bach F, Brenner T et al.. “Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial.” Intensive care medicine (2022). PMID: 35106617 ↗
L1RCTCited in: History and Evolution of Treatment
[383]
Kyriazopoulou E, Liaskou-Antoniou L, Adamis G et al.. “Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis. A Randomized Trial.” American journal of respiratory and critical care medicine (2021). PMID: 32757963 ↗
L1RCTCited in: History and Evolution of Treatment
[384]
Bedawi EO, Stavroulias D, Hedley E et al.. “Early Video-assisted Thoracoscopic Surgery or Intrapleural Enzyme Therapy in Pleural Infection: A Feasibility Randomized Controlled Trial. The Third Multicenter Intrapleural Sepsis Trial-MIST-3.” American journal of respiratory and critical care medicine (2023). PMID: 37820359 ↗
L1RCTCited in: History and Evolution of Treatment
[385]
Simonneau G, Barst RJ, Galie N et al.. “Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.” American journal of respiratory and critical care medicine (2002). PMID: 11897647 ↗
L1RCTCited in: History and Evolution of Treatment
[386]
Leaf DE, Raed A, Donnino MW et al.. “Randomized controlled trial of calcitriol in severe sepsis.” American journal of respiratory and critical care medicine (2014). PMID: 25029202 ↗
L1RCTCited in: History and Evolution of Treatment
[387]
Simou E, Leonardi-Bee J, Britton J. “The Effect of Alcohol Consumption on the Risk of ARDS: A Systematic Review and Meta-Analysis.” Chest (2017). PMID: 29288645 ↗
L2SR_OBSCited in: History and Evolution of Treatment
[388]
Schinkel M, Paranjape K, Kundert J et al.. “Towards Understanding the Effective Use of Antibiotics for Sepsis.” Chest (2021). PMID: 33905680 ↗
L2RCTCited in: History and Evolution of Treatment
[389]
Wunderink R, Leeper K, Schein R et al.. “Filgrastim in patients with pneumonia and severe sepsis or septic shock.” Chest (2001). PMID: 11171733 ↗
L1RCTCited in: History and Evolution of Treatment
[390]
Gupta S, Rau RE, Kairalla JA et al.. “Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.” The New England journal of medicine (2024). PMID: 39651791 ↗
L1RCTCited in: History and Evolution of Treatment
[391]
Dankiewicz J, Cronberg T, Lilja G et al.. “Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest.” The New England journal of medicine (2021). PMID: 34133859 ↗
L1RCTCited in: History and Evolution of Treatment
[392]
Rivers E, Nguyen B, Havstad S et al.. “Early goal-directed therapy in the treatment of severe sepsis and septic shock.” The New England journal of medicine (2001). PMID: 11794169 ↗
L1RCTCited in: History and Evolution of Treatment
[393]
Caironi P, Tognoni G, Masson S et al.. “Albumin replacement in patients with severe sepsis or septic shock.” The New England journal of medicine (2014). PMID: 24635772 ↗
L1RCTCited in: History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[394]
Vermorken JB, Mesia R, Rivera F et al.. “Platinum-based chemotherapy plus cetuximab in head and neck cancer.” The New England journal of medicine (2008). PMID: 18784101 ↗
L1RCTCited in: History and Evolution of Treatment
[395]
Guillevin L, Pagnoux C, Karras A et al.. “Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.” The New England journal of medicine (2014). PMID: 25372085 ↗
L1RCTCited in: History and Evolution of Treatment
[396]
Rauen T, Eitner F, Fitzner C et al.. “Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.” The New England journal of medicine (2015). PMID: 26630142 ↗
L1RCTCited in: History and Evolution of Treatment
[397]
Lee ZY, Ortiz-Reyes L, Lew CCH et al.. “Intravenous vitamin C monotherapy in critically ill patients: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.” Annals of intensive care (2023). PMID: 36882644 ↗
L1SR_MA_RCTCited in: History and Evolution of Treatment
[398]
Kamdar M, Solomon SR, Arnason J et al.. “Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.” Lancet (London, England) (2022). PMID: 35717989 ↗
L1RCTCited in: History and Evolution of Treatment
[399]
. “Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial.” Lancet (London, England) (2020). PMID: 32050090 ↗
L1RCTCited in: History and Evolution of Treatment
[400]
Tewari KS, Sill MW, Penson RT et al.. “Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).” Lancet (London, England) (2017). PMID: 28756902 ↗
L1RCTCited in: History and Evolution of Treatment
[401]
Attal M, Richardson PG, Rajkumar SV et al.. “Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.” Lancet (London, England) (2019). PMID: 31735560 ↗
L1RCTCited in: History and Evolution of Treatment
[402]
Morris JM, Roberts CL, Bowen JR et al.. “Immediate delivery compared with expectant management after preterm pre-labour rupture of the membranes close to term (PPROMT trial): a randomised controlled trial.” Lancet (London, England) (2015). PMID: 26564381 ↗
L1RCTCited in: History and Evolution of Treatment, Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[403]
Kehoe S, Hook J, Nankivell M et al.. “Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.” Lancet (London, England) (2015). PMID: 26002111 ↗
L1RCTCited in: History and Evolution of Treatment
[404]
Baud O, Maury L, Lebail F et al.. “Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial.” Lancet (London, England) (2016). PMID: 26916176 ↗
L1RCTCited in: History and Evolution of Treatment
[405]
Halliday BP, Wassall R, Lota AS et al.. “Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial.” Lancet (London, England) (2018). PMID: 30429050 ↗
L1RCTCited in: History and Evolution of Treatment
[406]
Chapman KR, Burdon JG, Piitulainen E et al.. “Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2015). PMID: 26026936 ↗
L1RCTCited in: History and Evolution of Treatment
[407]
Gardosi J, Ewington LJ, Booth K et al.. “Induction of labour versus standard care to prevent shoulder dystocia in fetuses suspected to be large for gestational age in the UK (the Big Baby trial): a multicentre, open-label, randomised controlled trial.” Lancet (London, England) (2025). PMID: 40319899 ↗
L1RCTCited in: History and Evolution of Treatment
[408]
. “Fracture fixation in the operative management of hip fractures (FAITH): an international, multicentre, randomised controlled trial.” Lancet (London, England) (2017). PMID: 28262269 ↗
L1RCTCited in: History and Evolution of Treatment
[409]
Ridker PM, MacFadyen JG, Thuren T et al.. “Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2017). PMID: 28855077 ↗
L1RCTCited in: History and Evolution of Treatment
[410]
Giamarellos-Bourboulis EJ, Kotsaki A, Kotsamidi I et al.. “Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial.” JAMA (2026). PMID: 41359996 ↗
L1RCTCited in: History and Evolution of Treatment, Complications & Iatrogenesis
[411]
Brown PA, Ji L, Xu X et al.. “Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.” JAMA (2021). PMID: 33651090 ↗
L1RCTCited in: History and Evolution of Treatment
[412]
Bracken MB, Shepard MJ, Holford TR et al.. “Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study.” JAMA (1997). PMID: 9168289 ↗
L1RCTCited in: History and Evolution of Treatment
[413]
Vincent JL, Francois B, Zabolotskikh I et al.. “Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial.” JAMA (2019). PMID: 31104069 ↗
L1RCTCited in: History and Evolution of Treatment
[414]
Turner MO, Lee VT, FitzGerald JM. “Melioidosis in a diabetic sailor.” Chest (1994). PMID: 7521816 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment
[415]
Roux D, Benichou N, Hajage D et al.. “Impact of renal replacement therapy strategy on beta-lactam plasma concentrations: the BETAKIKI study-an ancillary study of a randomized controlled trial.” Annals of intensive care (2023). PMID: 36840825 ↗
L2RCTCited in: History and Evolution of Treatment
[416]
Supinski GS, Schroder EA, Callahan LA. “Mitochondria and Critical Illness.” Chest (2019). PMID: 31494084 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[417]
Vallabhajosyula S, Kumar M, Pandompatam G et al.. “Prognostic impact of isolated right ventricular dysfunction in sepsis and septic shock: an 8-year historical cohort study.” Annals of intensive care (2017). PMID: 28884343 ↗
L3COHORTCited in: History and Evolution of Treatment
[418]
Liu W, Shao R, Zhang S et al.. “Characteristics, predictors and outcomes of new-onset QT prolongation in sepsis: a multicenter retrospective study.” Critical care (London, England) (2024). PMID: 38594724 ↗
L3COHORTCited in: History and Evolution of Treatment
[419]
Horn D, Ehret D, Gautham KS et al.. “Sunlight for the prevention and treatment of hyperbilirubinemia in term and late preterm neonates.” The Cochrane database of systematic reviews (2021). PMID: 34228352 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[420]
Crider K, Williams J, Qi YP et al.. “Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.” The Cochrane database of systematic reviews (2022). PMID: 36321557 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[421]
La Mantia L, Milanese C, Mascoli N et al.. “Cyclophosphamide for multiple sclerosis.” The Cochrane database of systematic reviews (2002). PMID: 12519578 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[422]
La Mantia L, Milanese C, Mascoli N et al.. “Cyclophosphamide for multiple sclerosis.” The Cochrane database of systematic reviews (2007). PMID: 17253481 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[423]
Smaill FM. “WITHDRAWN. Intrapartum antibiotics for Group B streptococcal colonisation.” The Cochrane database of systematic reviews (2010). PMID: 20091501 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[424]
Kylat RI, Ohlsson A. “Recombinant human activated protein C for severe sepsis in neonates.” The Cochrane database of systematic reviews (2012). PMID: 22513930 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[425]
Shann F, D'Souza RM, D'Souza R. “WITHDRAWN: Antibiotics for preventing pneumonia in children with measles.” The Cochrane database of systematic reviews (2007). PMID: 17636676 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[426]
Lister P, Iles R, Shaw BNj et al.. “WITHDRAWN. Inhaled steroids for neonatal chronic lung disease.” The Cochrane database of systematic reviews (2010). PMID: 20091533 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[427]
Schwenger EM, Tejani AM, Loewen PS. “Probiotics for preventing urinary tract infections in adults and children.” The Cochrane database of systematic reviews (2015). PMID: 26695595 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[428]
Thinkhamrop J, Hofmeyr GJ, Adetoro O et al.. “Antibiotic prophylaxis during the second and third trimester to reduce adverse pregnancy outcomes and morbidity.” The Cochrane database of systematic reviews (2015). PMID: 26092137 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[429]
Thinkhamrop J, Hofmeyr GJ, Adetoro O et al.. “Antibiotic prophylaxis during the second and third trimester to reduce adverse pregnancy outcomes and morbidity.” The Cochrane database of systematic reviews (2015). PMID: 25621770 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[430]
Qin C, Lin S, Pang L et al.. “Risk factors for sepsis: a systematic review and meta-analysis.” Frontiers in public health (2026). PMID: 42433399 ↗
L2SR_OBSCited in: History and Evolution of Treatment
[431]
Ibarz M, Haas LEM, Ceccato A et al.. “The critically ill older patient with sepsis: a narrative review.” Annals of intensive care (2024). PMID: 38200360 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[432]
Byrne L, Van Haren F. “Fluid resuscitation in human sepsis: Time to rewrite history?” Annals of intensive care (2017). PMID: 28050897 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[433]
Benghanem S, Stiel L, Jouan Y et al.. “Remote ischemic conditioning in intensive care: From bench to bedside.” Annals of intensive care (2026). PMID: 41788501 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[434]
Zhang G, Wu X, Liu S et al.. “Clinical subphenotypes and molecular endotypes in sepsis: toward an integrated and dynamic framework.” Annals of intensive care (2026). PMID: 42005529 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[435]
Hu D, Sheeja Prabhakaran H, Zhang YY et al.. “Mitochondrial dysfunction in sepsis: mechanisms and therapeutic perspectives.” Critical care (London, England) (2024). PMID: 39227925 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[436]
Ronco C, Bellomo R. “Hemoperfusion: technical aspects and state of the art.” Critical care (London, England) (2022). PMID: 35549999 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[437]
Bottari G, Ranieri VM, Ince C et al.. “Use of extracorporeal blood purification therapies in sepsis: the current paradigm, available evidence, and future perspectives.” Critical care (London, England) (2024). PMID: 39722012 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[438]
Bomrah S, Uddin M, Upadhyay U et al.. “A scoping review of machine learning for sepsis prediction- feature engineering strategies and model performance: a step towards explainability.” Critical care (London, England) (2024). PMID: 38802973 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[439]
Giordano FA, Ganslandt O, Münter MW et al.. “Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial.” The Lancet. Oncology (2026). PMID: 42372746 ↗
L1RCTCited in: History and Evolution of Treatment
[440]
Zhou K, Ou C, Li X et al.. “Comparative predictive value of nine inflammation-derived haematological indices for 28-day mortality in patients with sepsis: a multicentre retrospective cohort study.” Frontiers in medicine (2026). PMID: 42404557 ↗
L2COHORTCited in: History and Evolution of Treatment
[441]
Anton GI, Radu R, Ceban E et al.. “Efficacy and Safety of Meropenem in Pregnant Women with Upper Urinary Tract Infections: A Retrospective Cohort Study in Romania.” Antibiotics (Basel, Switzerland) (2026). PMID: 42353734 ↗
L2COHORTCited in: History and Evolution of Treatment
[442]
Zhou L, Li S, Ding Q et al.. “A comparison of pediatric sepsis definitions based on systemic inflammatory response syndrome and Phoenix criteria: a single-center PICU retrospective study.” Italian journal of pediatrics (2026). PMID: 42321878 ↗
L2COHORTCited in: History and Evolution of Treatment
[443]
Rivet V, Joseph A, Arrestier R et al.. “Immunosuppressive therapy management during sepsis in kidney transplant recipients: a prospective multicenter study.” Annals of intensive care (2025). PMID: 40784979 ↗
L2OTHERCited in: History and Evolution of Treatment
[444]
Gonzalez FA, Bacariza J, Varudo AR et al.. “Sepsis-induced myocardial dysfunction diagnosed with strain versus non-strain echocardiography parameters: incidence, evolution and association with prognosis.” Annals of intensive care (2025). PMID: 40999250 ↗
L2OTHERCited in: History and Evolution of Treatment
[445]
Toffart AC, Meert AP, Wallet F et al.. “ICU admission for solid cancer patients treated with immune checkpoint inhibitors.” Annals of intensive care (2023). PMID: 37072645 ↗
L2OTHERCited in: History and Evolution of Treatment
[446]
Helms J, Merdji H, Loewert S et al.. “Disseminated intravascular coagulation is strongly associated with severe acute kidney injury in patients with septic shock.” Annals of intensive care (2023). PMID: 38038826 ↗
L2OTHERCited in: History and Evolution of Treatment
[447]
Peschanski N, Chenevier-Gobeaux C, Mzabi L et al.. “Prognostic value of PCT in septic emergency patients.” Annals of intensive care (2016). PMID: 27207179 ↗
L2OTHERCited in: History and Evolution of Treatment
[448]
Schinas G, Voutsinas PM, Stefanou D et al.. “Infectious Complications of Antibody-Drug Conjugates: A Review of Safety Data from FDA-Approved Agents.” Current oncology reports (2026). PMID: 42430103 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[449]
Meng L, Liu Y, Wang N et al.. “Gut barrier-microbiota crosstalk in sepsis: from pathogenesis to potential therapies.” Frontiers in immunology (2026). PMID: 42396442 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[450]
Kumar A, Kumar A, Tyagi A et al.. “A review of bloodstream infections-pathogens, pathogenesis, diagnostic strategies, treatment methods-challenges and future aspects.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 42387129 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[451]
Zhang Q, Tan Y, Tao J et al.. “Epigenetics-mediated pathological alterations and their diagnostic and therapeutic potential in sepsis-associated acute kidney injury.” Clinical epigenetics (2026). PMID: 42374498 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[452]
Brierley J, Carcillo JA, Choong K et al.. “Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine.” Critical care medicine (2009). PMID: 19325359 ↗
L1GUIDELINECited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[453]
Joannidis M, Druml W, Forni LG et al.. “Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM.” Intensive care medicine (2010). PMID: 19921152 ↗
L1GUIDELINECited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[454]
Angriman F, Muttalib F, Lamontagne F et al.. “IV Vitamin C in Adults With Sepsis: A Bayesian Reanalysis of a Randomized Controlled Trial.” Critical care medicine (2023). PMID: 37026849 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[455]
Drewry AM, Mohr NM, Ablordeppey EA et al.. “Therapeutic Hyperthermia Is Associated With Improved Survival in Afebrile Critically Ill Patients With Sepsis: A Pilot Randomized Trial.” Critical care medicine (2022). PMID: 35120040 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[456]
Werdan K, Pilz G, Bujdoso O et al.. “Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study.” Critical care medicine (2007). PMID: 18074471 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[457]
Masse MH, Richard MA, D'Aragon F et al.. “Early Evidence of Sepsis-Associated Hyperperfusion-A Study of Cerebral Blood Flow Measured With MRI Arterial Spin Labeling in Critically Ill Septic Patients and Control Subjects.” Critical care medicine (2018). PMID: 29629988 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[458]
Pontes-Arruda A, Aragão AM, Albuquerque JD. “Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock.” Critical care medicine (2006). PMID: 16850002 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[459]
Kinasewitz GT, Privalle CT, Imm A et al.. “Multicenter, randomized, placebo-controlled study of the nitric oxide scavenger pyridoxalated hemoglobin polyoxyethylene in distributive shock.” Critical care medicine (2008). PMID: 18552688 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[460]
Pappalardo F, Crivellari M, Di Prima AL et al.. “Protein C zymogen in severe sepsis: a double-blinded, placebo-controlled, randomized study.” Intensive care medicine (2016). PMID: 27344436 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[461]
Radrizzani D, Bertolini G, Facchini R et al.. “Early enteral immunonutrition vs. parenteral nutrition in critically ill patients without severe sepsis: a randomized clinical trial.” Intensive care medicine (2006). PMID: 16788808 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[462]
Young P, Mackle D, Bellomo R et al.. “Conservative oxygen therapy for mechanically ventilated adults with sepsis: a post hoc analysis of data from the intensive care unit randomized trial comparing two approaches to oxygen therapy (ICU-ROX).” Intensive care medicine (2019). PMID: 31748836 ↗
L2RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[463]
Karnad DR, Bhadade R, Verma PK et al.. “Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study.” Intensive care medicine (2014). PMID: 24737258 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[464]
Jack T, Boehne M, Brent BE et al.. “In-line filtration reduces severe complications and length of stay on pediatric intensive care unit: a prospective, randomized, controlled trial.” Intensive care medicine (2012). PMID: 22527062 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[465]
Meisel C, Schefold JC, Pschowski R et al.. “Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.” American journal of respiratory and critical care medicine (2009). PMID: 19590022 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[466]
Kellum JA, Chawla LS, Keener C et al.. “The Effects of Alternative Resuscitation Strategies on Acute Kidney Injury in Patients with Septic Shock.” American journal of respiratory and critical care medicine (2016). PMID: 26398704 ↗
L2RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[467]
Walkey AJ, Wiener RS. “Macrolide antibiotics and survival in patients with acute lung injury.” Chest (2011). PMID: 22116799 ↗
L2RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[468]
Gyamfi-Bannerman C, Thom EA, Blackwell SC et al.. “Antenatal Betamethasone for Women at Risk for Late Preterm Delivery.” The New England journal of medicine (2016). PMID: 26842679 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[469]
Levy B, Girerd N, Amour J et al.. “Effect of Moderate Hypothermia vs Normothermia on 30-Day Mortality in Patients With Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation: A Randomized Clinical Trial.” JAMA (2022). PMID: 35103766 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[470]
Limaye AP, Stapleton RD, Peng L et al.. “Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical Illness: A Randomized Clinical Trial.” JAMA (2017). PMID: 28829877 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Prevention, Screening and Post-ICU Surveillance
[471]
Ohta Y, Miyamoto K, Kawazoe Y et al.. “Effect of dexmedetomidine on inflammation in patients with sepsis requiring mechanical ventilation: a sub-analysis of a multicenter randomized clinical trial.” Critical care (London, England) (2020). PMID: 32778146 ↗
L2RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[472]
Zampieri FG, Azevedo LCP, Neto AS et al.. “Effects of dapagliflozin on urinary output, fluid balance, and biochemistry in critically ill patients: a post-hoc secondary analysis of the DEFENDER trial.” Critical care (London, England) (2025). PMID: 40646628 ↗
L2RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[473]
Tadié JM, Locher C, Maamar A et al.. “Enteral citrulline supplementation versus placebo on SOFA score on day 7 in mechanically ventilated critically ill patients: the IMMUNOCITRE randomized clinical trial.” Critical care (London, England) (2023). PMID: 37784110 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[474]
Adlbrecht C, Wurm R, Depuydt P et al.. “Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial.” Critical care (London, England) (2020). PMID: 32131866 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[475]
Pickkers P, Heemskerk S, Schouten J et al.. “Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial.” Critical care (London, England) (2012). PMID: 22269279 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[476]
De Pascale G, Posteraro B, D'Arrigo S et al.. “(1,3)-β-D-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial.” Critical care (London, England) (2020). PMID: 32891170 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[477]
Parsons EC, Hough CL, Seymour CW et al.. “Red blood cell transfusion and outcomes in patients with acute lung injury, sepsis and shock.” Critical care (London, England) (2011). PMID: 21936902 ↗
L2RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[478]
Chung KK, Coates EC, Smith DJ et al.. “High-volume hemofiltration in adult burn patients with septic shock and acute kidney injury: a multicenter randomized controlled trial.” Critical care (London, England) (2017). PMID: 29178943 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[479]
Duprey MS, van den Boogaard M, van der Hoeven JG et al.. “Association between incident delirium and 28- and 90-day mortality in critically ill adults: a secondary analysis.” Critical care (London, England) (2020). PMID: 32312288 ↗
L2RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[480]
Helmy MA, Mostafa MS, Saber AT et al.. “Preemptive noradrenaline infusion: a game-changer against post-induction hypotension in surgical sepsis: a randomized double blind trial.” BMC anesthesiology (2026). PMID: 41965525 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[481]
Elmesiry AM, Elsheikh MR, Elshimy KM et al.. “Role of vitamin C infusion in postoperative mechanically ventilated neonates with sepsis: a randomized controlled trial.” European journal of pediatrics (2025). PMID: 41315087 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[482]
Safabakhsh M, Shab-Bidar S, Rohani P et al.. “Effect of probiotics on intestinal permeability in critically ill children with sepsis: preliminary results from a double-blind, placebo-controlled trial.” European journal of nutrition (2025). PMID: 40986080 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[483]
Wardill HR, van Groningen LFJ, Dorraki M et al.. “Enteral versus parenteral nutrition in auto-HCT: a randomized controlled trial on clinical outcomes and gut microbiome dynamics.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2025). PMID: 40971058 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets
[484]
Khodair HA, Elmahdy HS, Zidan LK et al.. “Assessment of the role of probiotics in prevention of ventilator-associated pneumonia in neonates.” European journal of pediatrics (2025). PMID: 40906025 ↗
L1RCTCited in: Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets, Complications & Iatrogenesis
[485]
Keh D, Trips E, Marx G et al.. “Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical Trial.” JAMA (2016). PMID: 27695824 ↗
L1RCTCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[486]
Pfister D, Siegemund M, Dell-Kuster S et al.. “Cerebral perfusion in sepsis-associated delirium.” Critical care (London, England) (2008). PMID: 18457586 ↗
L2TRIAL_NONRANDOMCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[487]
Marra A, Pandharipande PP, Girard TD et al.. “Co-Occurrence of Post-Intensive Care Syndrome Problems Among 406 Survivors of Critical Illness.” Critical care medicine (2018). PMID: 29787415 ↗
L2OTHERCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS), Special Populations, Prevention, Screening and Post-ICU Surveillance
[488]
Khan BA, Perkins AJ, Prasad NK et al.. “Biomarkers of Delirium Duration and Delirium Severity in the ICU.” Critical care medicine (2020). PMID: 31770149 ↗
L2OTHERCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[489]
Toth KM, Aghababa Z, Kennedy JN et al.. “Optimizing Agreement Between Bedside Nurse-Documented and Trained Researcher Delirium Assessments in the ICU.” Critical care medicine (2025). PMID: 40970763 ↗
L2OTHERCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[490]
Liu K, Nakashima T, Goto T et al.. “Phenotypes of Functional Decline or Recovery in Sepsis ICU Survivors: Insights From a 1-Year Follow-Up Multicenter Cohort Analysis.” Critical care medicine (2025). PMID: 39992173 ↗
L2OTHERCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS), Prevention, Screening and Post-ICU Surveillance
[491]
Duprey MS, Devlin JW, van der Hoeven JG et al.. “Association Between Incident Delirium Treatment With Haloperidol and Mortality in Critically Ill Adults.” Critical care medicine (2021). PMID: 33861548 ↗
L2OTHERCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[492]
Girard TD, Jackson JC, Pandharipande PP et al.. “Delirium as a predictor of long-term cognitive impairment in survivors of critical illness.” Critical care medicine (2010). PMID: 20473145 ↗
L2OTHERCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[493]
Hughes CG, Pandharipande PP, Thompson JL et al.. “Endothelial Activation and Blood-Brain Barrier Injury as Risk Factors for Delirium in Critically Ill Patients.” Critical care medicine (2016). PMID: 27088157 ↗
L2OTHERCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[494]
Morandi A, Rogers BP, Gunther ML et al.. “The relationship between delirium duration, white matter integrity, and cognitive impairment in intensive care unit survivors as determined by diffusion tensor imaging: the VISIONS prospective cohort magnetic resonance imaging study*.” Critical care medicine (2012). PMID: 22584766 ↗
L2OTHERCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[495]
Stollings JL, Kotfis K, Chanques G et al.. “Delirium in critical illness: clinical manifestations, outcomes, and management.” Intensive care medicine (2021). PMID: 34401939 ↗
L5REVIEW_NARRATIVECited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[496]
Brummel NE, Hughes CG, McNeil JB et al.. “Systemic inflammation and delirium during critical illness.” Intensive care medicine (2024). PMID: 38647548 ↗
L2OTHERCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[497]
Thompson K, Taylor C, Jan S et al.. “Health-related outcomes of critically ill patients with and without sepsis.” Intensive care medicine (2018). PMID: 29951846 ↗
L2OTHERCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS), Prevention, Screening and Post-ICU Surveillance
[498]
Brunello AG, Haenggi M, Wigger O et al.. “Usefulness of a clinical diagnosis of ICU-acquired paresis to predict outcome in patients with SIRS and acute respiratory failure.” Intensive care medicine (2009). PMID: 19760204 ↗
L2OTHERCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[499]
Wintermann GB, Petrowski K, Weidner K et al.. “Impact of post-traumatic stress symptoms on the health-related quality of life in a cohort study with chronically critically ill patients and their partners: age matters.” Critical care (London, England) (2019). PMID: 30736830 ↗
L2COHORTCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS), Prevention, Screening and Post-ICU Surveillance
[500]
Siew ED, Fissell WH, Tripp CM et al.. “Acute Kidney Injury as a Risk Factor for Delirium and Coma during Critical Illness.” American journal of respiratory and critical care medicine (2017). PMID: 27854517 ↗
L2OTHERCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[501]
Heybati K, Zhou F, Ali S et al.. “Outcomes of dexmedetomidine versus propofol sedation in critically ill adults requiring mechanical ventilation: a systematic review and meta-analysis of randomised controlled trials.” British journal of anaesthesia (2022). PMID: 35961815 ↗
L1SR_MA_RCTCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[502]
Morandi A, Hughes CG, Girard TD et al.. “Statins and brain dysfunction: a hypothesis to reduce the burden of cognitive impairment in patients who are critically ill.” Chest (2011). PMID: 21896517 ↗
L5OTHERCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[503]
Patidar AK, Khanna P, Kashyap L et al.. “Utilization of NIRS Monitor to Compare the Regional Cerebral Oxygen Saturation Between Dexmedetomidine and Propofol Sedation in Mechanically Ventilated Critically ill Patients with Sepsis- A Prospective Randomized Control Trial.” Journal of intensive care medicine (2024). PMID: 39370896 ↗
L1RCTCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[504]
Patel S, Stollings JL, Casey JD et al.. “Identifying Predictors of Extubation on the day of Passing an SBT in Critically ill Adults.” Journal of intensive care medicine (2023). PMID: 36648173 ↗
L2TRIAL_NONRANDOMCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[505]
Liu K, Kotani T, Nakamura K et al.. “Effects of evidence-based ICU care on long-term outcomes of patients with sepsis or septic shock (ILOSS): protocol for a multicentre prospective observational cohort study in Japan.” BMJ open (2022). PMID: 35351710 ↗
L5TRIAL_NONRANDOMCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[506]
Chi R, Perkins AJ, Khalifeh Y et al.. “Serum Albumin Level at Intensive Care Unit Admission and Delirium Duration and Severity in Critically Ill Adults.” American journal of critical care : an official publication, American Association of Critical-Care Nurses (2024). PMID: 39482092 ↗
L2RCTCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[507]
Zhao Y, Jiang J, Pu J et al.. “Association between the monocyte-to-lymphocyte ratio and 28-day all-cause mortality in sepsis-associated delirium patients: a retrospective study and machine learning.” BMC infectious diseases (2026). PMID: 41965559 ↗
L2COHORTCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[508]
Smith R, Harrison F, Bastarache J et al.. “Potential therapeutic benefit of exogenous ketone ester administration in delirium: a narrative review.” Critical care (London, England) (2025). PMID: 41057929 ↗
L5REVIEW_NARRATIVECited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[509]
Fleischmann-Struzek C, Joost FEA, Pletz MW et al.. “How are Long-Covid, Post-Sepsis-Syndrome and Post-Intensive-Care-Syndrome related? A conceptional approach based on the current research literature.” Critical care (London, England) (2024). PMID: 39210399 ↗
L5REVIEW_NARRATIVECited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS), Prevention, Screening and Post-ICU Surveillance
[510]
Puthucheary ZA, Gensichen JS, Cakiroglu AS et al.. “Implications for post critical illness trial design: sub-phenotyping trajectories of functional recovery among sepsis survivors.” Critical care (London, England) (2020). PMID: 32977833 ↗
L2OTHERCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS), Prevention, Screening and Post-ICU Surveillance
[511]
Salluh JI, Soares M, Teles JM et al.. “Delirium epidemiology in critical care (DECCA): an international study.” Critical care (London, England) (2010). PMID: 21092264 ↗
L4OTHERCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[512]
Ritter C, Tomasi CD, Dal-Pizzol F et al.. “Inflammation biomarkers and delirium in critically ill patients.” Critical care (London, England) (2014). PMID: 24886875 ↗
L2OTHERCited in: De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)
[513]
Alhazzani W, Jacobi J, Sindi A et al.. “The effect of selenium therapy on mortality in patients with sepsis syndrome: a systematic review and meta-analysis of randomized controlled trials.” Critical care medicine (2013). PMID: 23587641 ↗
L1SR_MA_RCTCited in: Complications & Iatrogenesis
[514]
Chang P, Liao Y, Guan J et al.. “Combined Treatment With Hydrocortisone, Vitamin C, and Thiamine for Sepsis and Septic Shock: A Randomized Controlled Trial.” Chest (2020). PMID: 32243943 ↗
L1RCTCited in: Complications & Iatrogenesis
[515]
Manzoni P, Rinaldi M, Cattani S et al.. “Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial.” JAMA (2009). PMID: 19809023 ↗
L1RCTCited in: Complications & Iatrogenesis
[516]
Shah AD, MacCallum NS, Harris S et al.. “Descriptors of Sepsis Using the Sepsis-3 Criteria: A Cohort Study in Critical Care Units Within the U.K. National Institute for Health Research Critical Care Health Informatics Collaborative.” Critical care medicine (2021). PMID: 34259454 ↗
L2COHORTCited in: Complications & Iatrogenesis
[517]
Peronnet E, Venet F, Maucort-Boulch D et al.. “Association between mRNA expression of CD74 and IL10 and risk of ICU-acquired infections: a multicenter cohort study.” Intensive care medicine (2017). PMID: 28477143 ↗
L2COHORTCited in: Complications & Iatrogenesis
[518]
Ramanathan K, Yeo N, Alexander P et al.. “Role of extracorporeal membrane oxygenation in children with sepsis: a systematic review and meta-analysis.” Critical care (London, England) (2020). PMID: 33287861 ↗
L1SR_OBSCited in: Complications & Iatrogenesis
[519]
Griffiths RD, Hall JB. “Intensive care unit-acquired weakness.” Critical care medicine (2010). PMID: 20048676 ↗
L5REVIEW_NARRATIVECited in: Complications & Iatrogenesis
[520]
Latronico N, Shehu I, Guarneri B. “Use of electrophysiologic testing.” Critical care medicine (2009). PMID: 20046116 ↗
L5REVIEW_NARRATIVECited in: Complications & Iatrogenesis, Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[521]
Beltrán-García J, Osca-Verdegal R, Pallardó FV et al.. “Sepsis and Coronavirus Disease 2019: Common Features and Anti-Inflammatory Therapeutic Approaches.” Critical care medicine (2020). PMID: 32826431 ↗
L5OTHERCited in: Complications & Iatrogenesis
[522]
Rosen MJ, Narasimhan M. “Critical care of immunocompromised patients: human immunodeficiency virus.” Critical care medicine (2006). PMID: 16917430 ↗
L5REVIEW_NARRATIVECited in: Complications & Iatrogenesis
[523]
Carlton EF, Kohne JG, Shankar-Hari M et al.. “Readmission Diagnoses After Pediatric Severe Sepsis Hospitalization.” Critical care medicine (2019). PMID: 30676337 ↗
L2OTHERCited in: Complications & Iatrogenesis
[524]
Monneret G, Lafon T, Gossez M et al.. “Monocyte HLA-DR expression in septic shock patients: insights from a 20-year real-world cohort of 1023 cases.” Intensive care medicine (2025). PMID: 40986015 ↗
L2OTHERCited in: Complications & Iatrogenesis
[525]
Vaidie J, Demiselle J, Gabriel A et al.. “Effect of temporary suspension of chronic immunosuppressive drugs on day-90 mortality and ICU-acquired infections among critically Ill patients with solid organ transplant: a retrospective multicenter study.” Intensive care medicine (2025). PMID: 40668232 ↗
L2OTHERCited in: Complications & Iatrogenesis
[526]
Kao KC, Hu HC, Hsieh MJ et al.. “Comparison of community-acquired, hospital-acquired, and intensive care unit-acquired acute respiratory distress syndrome: a prospective observational cohort study.” Critical care (London, England) (2015). PMID: 26530427 ↗
L2COHORTCited in: Complications & Iatrogenesis
[527]
van Vught LA, Wiewel MA, Hoogendijk AJ et al.. “The Host Response in Patients with Sepsis Developing Intensive Care Unit-acquired Secondary Infections.” American journal of respiratory and critical care medicine (2017). PMID: 28107024 ↗
L2OTHERCited in: Complications & Iatrogenesis
[528]
Planquette B, Timsit JF, Misset BY et al.. “Pseudomonas aeruginosa ventilator-associated pneumonia. predictive factors of treatment failure.” American journal of respiratory and critical care medicine (2013). PMID: 23641973 ↗
L2OTHERCited in: Complications & Iatrogenesis
[529]
Stravitz RT. “Critical management decisions in patients with acute liver failure.” Chest (2008). PMID: 18988787 ↗
L5REVIEW_NARRATIVECited in: Complications & Iatrogenesis
[530]
Afessa B, Shorr AF, Anzueto AR et al.. “Association between a silver-coated endotracheal tube and reduced mortality in patients with ventilator-associated pneumonia.” Chest (2009). PMID: 20038737 ↗
L2OTHERCited in: Complications & Iatrogenesis
[531]
Jia X, Malhotra A, Saeed M et al.. “Risk factors for ARDS in patients receiving mechanical ventilation for > 48 h.” Chest (2008). PMID: 18263691 ↗
L2OTHERCited in: Complications & Iatrogenesis
[532]
Stoll BJ, Hansen NI, Bell EF et al.. “Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012.” JAMA (2015). PMID: 26348753 ↗
L2OTHERCited in: Complications & Iatrogenesis
[533]
Albin O, Nadimidla S, Saravolatz L et al.. “Ventilator-associated pneumonia biomarker evaluation (VIBE) study: protocol for a prospective, observational, case-cohort study.” BMJ open (2025). PMID: 40987742 ↗
L5TRIAL_NONRANDOMCited in: Complications & Iatrogenesis
[534]
Taha M, Mostafa MM, Helmy F et al.. “Does oral care with mother's colostrum reduce the risk of late-onset sepsis in preterm infants? A randomized clinical trial.” Journal of neonatal-perinatal medicine (2025). PMID: 39973530 ↗
L1RCTCited in: Complications & Iatrogenesis
[535]
Kefale AB, Munea AM, Getahun KA et al.. “Quality of neonatal intensive care in Africa: a systematic review and meta-analysis.” BMC health services research (2026). PMID: 41821020 ↗
L1SR_OBSCited in: Complications & Iatrogenesis
[536]
Tungushpayev M, Suleimenova D, Sarria-Santamerra A et al.. “The value of machine and deep learning in management of critically ill patients: An umbrella review.” International journal of medical informatics (2025). PMID: 40795609 ↗
L1SR_OBSCited in: Complications & Iatrogenesis
[537]
Esteves AM, Bernardoni B, Brown S et al.. “Major publications in the critical care pharmacotherapy literature: 2024.” Journal of critical care (2025). PMID: 40675118 ↗
L1SR_OBSCited in: Complications & Iatrogenesis, Prevention, Screening and Post-ICU Surveillance
[538]
Green A, Patel S, Crabtree P et al.. “The association of sepsis bundle compliance with mortality in patients with ICU-acquired sepsis: a cohort study.” BMC infectious diseases (2025). PMID: 40394519 ↗
L2COHORTCited in: Complications & Iatrogenesis
[539]
Annane D, Bellissant E, Bollaert PE et al.. “Corticosteroids for treating sepsis.” The Cochrane database of systematic reviews (2015). PMID: 26633262 ↗
L1SR_OBSCited in: Complications & Iatrogenesis
[540]
Lewis SR, Pritchard MW, Schofield-Robinson OJ et al.. “Melatonin for the promotion of sleep in adults in the intensive care unit.” The Cochrane database of systematic reviews (2018). PMID: 29746721 ↗
L1SR_OBSCited in: Complications & Iatrogenesis
[541]
Bernard De Lajartre O, Massart N, Reizine F et al.. “ICU-acquired infection in neutropenic patients.” Critical care (London, England) (2026). PMID: 41845489 ↗
L2OTHERCited in: Complications & Iatrogenesis
[542]
Satoh K, Tsujimoto Y, Kasugai D et al.. “Clinical features and treatments of VEXAS syndrome in critical care: a scoping review.” Critical care (London, England) (2025). PMID: 40247386 ↗
L5REVIEW_NARRATIVECited in: Complications & Iatrogenesis
[543]
Leone M, Bechis C, Baumstarck K et al.. “De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial.” Intensive care medicine (2014). PMID: 25091790 ↗
L1RCTCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[544]
Estenssoro E, Kanoore Edul VS, Loudet CI et al.. “Predictive Validity of Sepsis-3 Definitions and Sepsis Outcomes in Critically Ill Patients: A Cohort Study in 49 ICUs in Argentina.” Critical care medicine (2018). PMID: 29742584 ↗
L2COHORTCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[545]
Barbier F, Roux A, Canet E et al.. “Temporal trends in critical events complicating HIV infection: 1999-2010 multicentre cohort study in France.” Intensive care medicine (2014). PMID: 25236542 ↗
L2COHORTCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[546]
Demoule A, Jung B, Prodanovic H et al.. “Diaphragm dysfunction on admission to the intensive care unit. Prevalence, risk factors, and prognostic impact-a prospective study.” American journal of respiratory and critical care medicine (2013). PMID: 23641946 ↗
L2COHORTCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[547]
Lukaszewicz AC, Grienay M, Resche-Rigon M et al.. “Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction.” Critical care medicine (2009). PMID: 19707128 ↗
L2CASE_REPORTCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[548]
AlRawahi AN, AlHinai FA, Doig CJ et al.. “The prognostic value of serum procalcitonin measurements in critically injured patients: a systematic review.” Critical care (London, England) (2019). PMID: 31796098 ↗
L1SR_OBSCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[549]
Chotalia M, Ali M, Hebballi R et al.. “Hyperdynamic Left Ventricular Ejection Fraction in ICU Patients With Sepsis.” Critical care medicine (2021). PMID: 34605779 ↗
L2OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[550]
Dong X, Liu Q, Zheng Q et al.. “Alterations of B Cells in Immunosuppressive Phase of Septic Shock Patients.” Critical care medicine (2020). PMID: 32304414 ↗
L2OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[551]
Tacke F, Nuraldeen R, Koch A et al.. “Iron Parameters Determine the Prognosis of Critically Ill Patients.” Critical care medicine (2016). PMID: 26934143 ↗
L2OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[552]
Vignon P, Charron C, Legras A et al.. “Left ventricular diastolic dysfunction is prevalent but not associated with mortality in patients with septic shock.” Intensive care medicine (2025). PMID: 39774865 ↗
L2OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[553]
Piton G, Manzon C, Cypriani B et al.. “Acute intestinal failure in critically ill patients: is plasma citrulline the right marker?” Intensive care medicine (2011). PMID: 21400011 ↗
L5REVIEW_NARRATIVECited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[554]
Soares M, Salluh JI, Toscano L et al.. “Outcomes and prognostic factors in patients with head and neck cancer and severe acute illnesses.” Intensive care medicine (2007). PMID: 17619854 ↗
L2OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[555]
Mehta RL, Bouchard J, Soroko SB et al.. “Sepsis as a cause and consequence of acute kidney injury: Program to Improve Care in Acute Renal Disease.” Intensive care medicine (2010). PMID: 21152901 ↗
L2OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[556]
Vandijck DM, Benoit DD, Depuydt PO et al.. “Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies.” Intensive care medicine (2008). PMID: 18214437 ↗
L2OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[557]
Balch JA, Chen UI, Liesenfeld O et al.. “Defining critical illness using immunological endotypes in patients with and without sepsis: a cohort study.” Critical care (London, England) (2023). PMID: 37474944 ↗
L2COHORTCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[558]
Gao X, Liu Y, Xu F et al.. “Assessment of Apoptosis Inhibitor of Macrophage/CD5L as a Biomarker to Predict Mortality in the Critically Ill With Sepsis.” Chest (2019). PMID: 31154043 ↗
L2OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[559]
Soares M, Darmon M, Salluh JIF et al.. “Prognosis of lung cancer patients with life-threatening complications.” Chest (2007). PMID: 17356101 ↗
L2OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[560]
Baldwin MR, Narain WR, Wunsch H et al.. “A prognostic model for 6-month mortality in elderly survivors of critical illness.” Chest (2013). PMID: 23632902 ↗
L2OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[561]
Ho KM, Chavan S, Pilcher D. “Omission of early thromboprophylaxis and mortality in critically ill patients: a multicenter registry study.” Chest (2011). PMID: 21940768 ↗
L2OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation), Prevention, Screening and Post-ICU Surveillance
[562]
Lu X, Shi Y, Chen L et al.. “Recombinant human interleukin-7 for patients with infection-associated lymphopenia: a systematic review and meta-analysis.” Respiratory medicine (2026). PMID: 42055480 ↗
L1SR_OBSCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[563]
Fu Y, Wang T, Lu R et al.. “Red blood cell transfusion in neurocritical patients: an updated systematic review and meta-analysis.” BMC anesthesiology (2026). PMID: 41918075 ↗
L1SR_OBSCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[564]
Xu P, Lou J, Kong H et al.. “Dynamic biomarker profiling and phenotyping in burn sepsis: a retrospective cohort study using growth mixture modeling.” Frontiers in cellular and infection microbiology (2026). PMID: 42079744 ↗
L2COHORTCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[565]
Zhu Y, Li Z, Zhou T et al.. “Association between red blood cell distribution width-platelet ratio and mortality in patients with sepsis-induced coagulopathy from the MIMIC-IV database: a retrospective cohort study.” BMC infectious diseases (2026). PMID: 42032529 ↗
L2COHORTCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[566]
Guan C, Gong A, Zhao Y et al.. “Interpretable machine learning model for new-onset atrial fibrillation prediction in critically ill patients: a multi-center study.” Critical care (London, England) (2024). PMID: 39473013 ↗
L2OTHERCited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation), Special Populations
[567]
Ohbe H, Satoh K, Totoki T et al.. “Definitions, epidemiology, and outcomes of persistent/chronic critical illness: a scoping review for translation to clinical practice.” Critical care (London, England) (2024). PMID: 39731183 ↗
L5REVIEW_NARRATIVECited in: Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)
[568]
Burry LD, Bell CM, Hill A et al.. “New and Persistent Sedative Prescriptions Among Older Adults Following a Critical Illness: A Population-Based Cohort Study.” Chest (2023). PMID: 36610663 ↗
L2COHORTCited in: Special Populations
[569]
Vincent JL, Sakr Y, Sprung CL et al.. “Sepsis in European intensive care units: results of the SOAP study.” Critical care medicine (2006). PMID: 16424713 ↗
L2OTHERCited in: Special Populations
[570]
Bellomo R, Kellum JA, Ronco C et al.. “Acute kidney injury in sepsis.” Intensive care medicine (2017). PMID: 28364303 ↗
L5REVIEW_NARRATIVECited in: Special Populations
[571]
White KC, Serpa-Neto A, Hurford R et al.. “Sepsis-associated acute kidney injury in the intensive care unit: incidence, patient characteristics, timing, trajectory, treatment, and associated outcomes. A multicenter, observational study.” Intensive care medicine (2023). PMID: 37432520 ↗
L2OTHERCited in: Special Populations
[572]
Weber-Carstens S, Schneider J, Wollersheim T et al.. “Critical illness myopathy and GLUT4: significance of insulin and muscle contraction.” American journal of respiratory and critical care medicine (2012). PMID: 23239154 ↗
L2OTHERCited in: Special Populations
[573]
Cobert J, Jeon SY, Boscardin J et al.. “Resilience, Survival, and Functional Independence in Older Adults Facing Critical Illness.” Chest (2024). PMID: 38871280 ↗
L2OTHERCited in: Special Populations
[574]
King MA, Matos RI, Hamele MT et al.. “PICU in the MICU: How Adult ICUs Can Support Pediatric Care in Public Health Emergencies.” Chest (2022). PMID: 35007553 ↗
L5REVIEW_NARRATIVECited in: Special Populations
[575]
Yuan S, Dou L, Tan Y et al.. “Association between the PaO2/FiO2-to-PaCO2 ratio and mortality in patients with sepsis: a retrospective study with dual-cohort validation.” Respiratory medicine (2026). PMID: 42270049 ↗
L2COHORTCited in: Special Populations
[576]
Schade Skov C, Brabrand M, de Groot B et al.. “Socioeconomic disparities and mortality among acute patients with sepsis: a retrospective Danish cohort study.” BMJ open (2026). PMID: 42103377 ↗
L3COHORTCited in: Special Populations
[577]
Siriwachirachai T, Sangkomkamhang US, Lumbiganon P et al.. “Antibiotics for meconium-stained amniotic fluid in labour for preventing maternal and neonatal infections.” The Cochrane database of systematic reviews (2010). PMID: 21154384 ↗
L1SR_OBSCited in: Special Populations
[578]
Mutter TC, Ruth CA, Dart AB. “Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function.” The Cochrane database of systematic reviews (2013). PMID: 23881659 ↗
L1SR_OBSCited in: Special Populations
[579]
Bond DM, Middleton P, Levett KM et al.. “Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome.” The Cochrane database of systematic reviews (2017). PMID: 28257562 ↗
L1SR_OBSCited in: Special Populations
[580]
Sotiriadis A, Makrydimas G, Papatheodorou S et al.. “Corticosteroids for preventing neonatal respiratory morbidity after elective caesarean section at term.” The Cochrane database of systematic reviews (2018). PMID: 30075059 ↗
L1SR_OBSCited in: Special Populations
[581]
Sotiriadis A, Makrydimas G, Papatheodorou S et al.. “Corticosteroids for preventing neonatal respiratory morbidity after elective caesarean section at term.” The Cochrane database of systematic reviews (2009). PMID: 19821379 ↗
L1SR_OBSCited in: Special Populations
[582]
Siriwachirachai T, Sangkomkamhang US, Lumbiganon P et al.. “Antibiotics for meconium-stained amniotic fluid in labour for preventing maternal and neonatal infections.” The Cochrane database of systematic reviews (2014). PMID: 25374369 ↗
L1SR_OBSCited in: Special Populations
[583]
van den Boogaard M, Schoonhoven L, van Achterberg T et al.. “Haloperidol prophylaxis in critically ill patients with a high risk for delirium.” Critical care (London, England) (2013). PMID: 23327295 ↗
L4TRIAL_NONRANDOMCited in: Prevention, Screening and Post-ICU Surveillance
[584]
Spyropoulos AC, Goldin M, Giannis D et al.. “Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.” JAMA internal medicine (2021). PMID: 34617959 ↗
L1RCTCited in: Prevention, Screening and Post-ICU Surveillance
[585]
Kosilek RP, Schmidt K, Baumeister SE et al.. “Frequency and risk factors of post-intensive care syndrome components in a multicenter randomized controlled trial of German sepsis survivors.” Journal of critical care (2021). PMID: 34280656 ↗
L2RCTCited in: Prevention, Screening and Post-ICU Surveillance
[586]
van der Staaij H, Prosepe I, Caram-Deelder C et al.. “Individualized Prediction of Platelet Transfusion Outcomes in Preterm Infants With Severe Thrombocytopenia.” JAMA (2025). PMID: 40952748 ↗
L2OTHERCited in: Prevention, Screening and Post-ICU Surveillance
[587]
Monti G, Konkayev A, Carta S et al.. “High dose esomeprazole as an anti-inflammatory agent in sepsis: Protocol for a randomized controlled trial.” Contemporary clinical trials (2023). PMID: 37625587 ↗
L5TRIAL_NONRANDOMCited in: Prevention, Screening and Post-ICU Surveillance
[588]
Havlicek EE, Goldman ZA, Faustino EVS et al.. “Hospital-acquired venous thromboembolism during invasive mechanical ventilation in children: a single-center, retrospective cohort study.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37423387 ↗
L3COHORTCited in: Prevention, Screening and Post-ICU Surveillance
[589]
Bourdiol A, Legros V, Vardon-Bounes F et al.. “Prevalence and risk factors of significant persistent pain symptoms after critical care illness: a prospective multicentric study.” Critical care (London, England) (2023). PMID: 37226261 ↗
L2OTHERCited in: Prevention, Screening and Post-ICU Surveillance
[590]
Soussi S, Sharma D, Jüni P et al.. “Identifying clinical subtypes in sepsis-survivors with different one-year outcomes: a secondary latent class analysis of the FROG-ICU cohort.” Critical care (London, England) (2022). PMID: 35449071 ↗
L2OTHERCited in: Prevention, Screening and Post-ICU Surveillance

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition, Classification & Shock-Physiology Spine

Sepsis and Septic Shock Definitions

Classification of Shock Types

Clinical Significance

Pathophysiology & Mechanism

Endothelial Activation and Microcirculatory Failure

Coagulopathy and Complement Dysregulation

Mitochondrial Dysfunction and Cytopathic Hypoxia

Immune Paralysis and Persistent Inflammation

Epidemiology, Etiology & Risk Factors

Demographic and Geographic Distribution

Risk Factors

Special Populations

Clinical Presentation

Presenting Symptoms and Time Course

Vital Signs and Hemodynamic Examination

Physical Examination by System

Phenotypic Variants by Infection Source

Red Flags

Atypical Presentations

Diagnosis & Workup (Hemodynamic & Bedside-First)

Clinical Diagnosis (Sepsis-3 Criteria)

Laboratory Studies

Imaging

Diagnostic Algorithm (Time-Critical)

Severity Scoring & Risk Stratification (ICU Scores)

Delta SOFA and Trajectory

SOFA-2 Update

Additional Prognostic Scores and Molecular Phenotypes

Acute Resuscitation & Time-Critical Management

Step 1: Initial Fluid Resuscitation

Step 2: Vasopressor Initiation

Step 3: Monitoring and Titration

Step 4: Adjunctive Therapies in Refractory Shock

Controversies and Guideline Disagreement

Definitive Therapy & Source Control of the Inciting Insult

Step 1: Source Control

Step 2: Antimicrobial Therapy - Timing

Step 3: Antimicrobial Selection - Empiric Regimen

Step 4: De-escalation and Duration of Therapy

Step 5: Antifungal Therapy

Step 6: Optimizing Antimicrobial Delivery

What NOT to Do

History and Evolution of Treatment

Early Goal-Directed Therapy and Resuscitation

Fluid Resuscitation: From Crystalloid vs. Colloid to Balanced vs. Saline and Restrictive vs. Liberal

Vasopressor Therapy

Adjunctive Therapies: Corticosteroids, Activated Protein C, Vitamin C, and Others

Antimicrobial Strategies

What Was Abandoned

Organ Support: Ventilatory, Hemodynamic, Renal & Extracorporeal Targets

Ventilatory Targets

Hemodynamic Targets

Renal Support

Extracorporeal Support

Sedation and Analgesia

Nutrition

De-escalation, Ventilator Liberation, Sedation-Delirium Control & Early Rehabilitation (ABCDEF Bundle & PICS)

Spontaneous Awakening and Breathing Trials

Sedation and Delirium Control

Early Mobilization and ICU‑Acquired Weakness

Post‑Intensive Care Syndrome (PICS)

Complications and Iatrogenesis

ICU-Acquired Weakness and Respiratory Monitoring

Autonomic and Gastrointestinal Complications

Venous Thromboembolism Prophylaxis

Pain Management and Sedation

Hospital-Acquired Infections

Rehabilitation and Mobilization

Prognostication, Goals of Care & End-of-Life (incl. Brain-Death Determination & Organ Donation)

Overall Mortality and Recovery

Prognostic Factors

Sedation and

Autonomic and Complications

Pain and Sedation